<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006899.pub3" GROUP_ID="WOUNDS" ID="262406082412095754" MERGED_FROM="" MODIFIED="2016-05-24 11:01:02 +0100" MODIFIED_BY="Gill Rizzello" REVIEW_NO="127" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2016-05-24 11:00:55 +0100" MODIFIED_BY="Gill Rizzello">
<TITLE MODIFIED="2011-11-01 16:51:33 +0000" MODIFIED_BY="[Empty name]">Autologous platelet-rich plasma for treating chronic wounds</TITLE>
<CONTACT MODIFIED="2016-05-24 11:00:55 +0100" MODIFIED_BY="Gill Rizzello"><PERSON ID="15772" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria José</FIRST_NAME><LAST_NAME>Martinez-Zapata</LAST_NAME><POSITION>Clinical Researcher</POSITION><EMAIL_1>mmartinezz@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 08</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 09</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-05-24 11:00:55 +0100" MODIFIED_BY="Gill Rizzello"><PERSON ID="15772" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria José</FIRST_NAME><LAST_NAME>Martinez-Zapata</LAST_NAME><POSITION>Clinical Researcher</POSITION><EMAIL_1>mmartinezz@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 08</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 09</FAX_1></ADDRESS></PERSON><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="VE">Venezuela</COUNTRY></ADDRESS></PERSON><PERSON ID="12177" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ivan</FIRST_NAME><LAST_NAME>Solà</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>isola@santpau.cat</EMAIL_1><EMAIL_2>ensayos@cochrane.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 537 814</PHONE_1><FAX_1>+34 935 537 809</FAX_1></ADDRESS></PERSON><PERSON ID="3640449D82E26AA200D5E26B848B55A4" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>José Angel</FIRST_NAME><LAST_NAME>Expósito</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>joseangelexposito@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Agency for Health Quality and Assessment of Catalonia (AQuAS)</ORGANISATION><ADDRESS_1>Roc Boronat, 81-95</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08805</ZIP><REGION>Catalonia</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 513 496</PHONE_1><PHONE_2>+34 935 510 000</PHONE_2></ADDRESS></PERSON><PERSON ID="36462B1C82E26AA200D5E26B3C36D939" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ignasi</FIRST_NAME><LAST_NAME>Bolíbar</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Staff</POSITION><EMAIL_1>Ibolibar@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Epidemiología Clínica y Salud Pública</DEPARTMENT><ORGANISATION>Hospital de la Santa Creu i Sant Pau</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 171</ADDRESS_1><ADDRESS_2>Edifici Casa de Convalescència</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08041</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 932 919 527</PHONE_1><PHONE_2>+34 932 919 526</PHONE_2><FAX_1>+34 932 919 525</FAX_1></ADDRESS></PERSON><PERSON ID="36539EF582E26AA200D5E26BFF39F587" ROLE="AUTHOR"><FIRST_NAME>Luciano</FIRST_NAME><LAST_NAME>Rodríguez</LAST_NAME><POSITION>Quality Manager</POSITION><EMAIL_1>lrodriguez@bst.cat</EMAIL_1><ADDRESS><DEPARTMENT>Tissue Bank</DEPARTMENT><ORGANISATION>Banc de Sang i Teixits</ORGANISATION><ADDRESS_1>Passeig Taulat 106-116</ADDRESS_1><CITY>Barcelona</CITY><ZIP>080035</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34935573500</PHONE_1></ADDRESS></PERSON><PERSON ID="3CC5B71D82E26AA201071537AC8946A4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joan</FIRST_NAME><LAST_NAME>Garcia</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>Joangarcia@bst.cat</EMAIL_1><ADDRESS><DEPARTMENT>Centre de Teixits i Teràpia Cellular</DEPARTMENT><ORGANISATION>Departament de Salut. Generalitat de Catalunya</ORGANISATION><ADDRESS_1>Autovia de Castelldedels, Km 2.7</ADDRESS_1><ADDRESS_2>L'Hospitalet de LLobregat</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08907</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 2607826</PHONE_1><FAX_1>+34 93 2607776</FAX_1></ADDRESS></PERSON><PERSON ID="z1311191547358902490458175115716" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><LAST_NAME>Zaror</LAST_NAME><EMAIL_1>carlos.zaror@ufrontera.cl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatric Dentistry and Orthodontic</DEPARTMENT><ORGANISATION>Faculty of Dentistry, Universidad de la Frontera</ORGANISATION><CITY>Temuco</CITY><COUNTRY CODE="CL">Chile</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-05-20 23:23:29 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="16" MONTH="6" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="6" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="10" YEAR="2012"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-05-23 09:55:52 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-05-23 09:55:52 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>First update. New search.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-05-19 01:01:23 +0100" MODIFIED_BY="Clare Dooley">
<DATE DAY="3" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>This is the first update of this review. A new search resulted in the inclusion of one additional study; the conclusions of the review have been changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-05-19 01:00:59 +0100" MODIFIED_BY="Clare Dooley">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-05-19 01:00:59 +0100" MODIFIED_BY="Clare Dooley">
<DATE DAY="2" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR">
<DATE DAY="10" MONTH="10" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-05-20 23:04:36 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-06-29 08:21:06 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-06-29 08:21:06 +0100" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Center (Barcelona). CIBER de Epidemiología y Salud Pública (CIBERESP)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-05-20 23:04:36 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-10-03 14:20:57 +0100" MODIFIED_BY="[Empty name]">
<NAME>PI0590173</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Spanish Agency of Health Technology Assessment. Institute of Health Carlos III </P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-05-20 23:04:36 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Wounds. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS) or the Department of Health</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2015-10-03 14:20:49 +0100" MODIFIED_BY="[Empty name]">
<NAME>CONICYT</NAME>
<COUNTRY CODE="CL">Chile</COUNTRY>
<DESCRIPTION>
<UL>
<LI>Higher educational program. Government of Chile, Project number 80140042. 2014-15</LI>
</UL>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-01-06 10:50:28 +0000" MODIFIED_BY="[Empty name]">
<NAME>Instituto de Salud Carlos III</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Dr. Mª José Martinez Zapata is funded by a Miguel Servet research contract from the Instituto de Salud Carlos III (CP15/00116).</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-05-24 09:11:11 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-05-23 09:58:01 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-10-09 17:29:47 +0100" MODIFIED_BY="[Empty name]">Autologous platelet-rich plasma (PRP) for chronic wounds</TITLE>
<SUMMARY_BODY MODIFIED="2016-05-23 09:58:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>What is autologous platelet-rich plasma and is it useful for treating chronic wounds?</P>
<P>
<B>Background</B>
</P>
<P>Chronic wounds (or ulcers) are breaks in the skin that do not heal, or require a long time to heal, and frequently recur. Chronic wounds include pressure ulcers, venous leg ulcers, arterial ulcers, neurotrophic ulcers, and foot ulcers in people with diabetes. Autologous platelet-rich plasma (PRP) is a potential wound healing treatment because it has components such as fibrin (a substance produced in the liver that makes the blood clot) and high concentrations of growth factors that are thought to help healing. We reviewed the evidence on the effect of autologous PRP on wound healing in people aged 18 years or older with chronic wounds from any cause (such as pressure ulcers, arterial ulcers, venous ulcers). We also included patients with wounds of mixed aetiology e.g. mixed arterial-venous ulcers.</P>
<P>
<B>What we found</B>
</P>
<P>We included 10 randomised clinical trials, with a total of 442 participants (mean age 61 years and 42% women). Four included studies recruited people with a range of chronic wounds; three studies enrolled people with venous leg ulcers; and the other three studies included people with diabetes who had foot ulcers. The median length of treatment was 12 weeks. All but three trials reported the sources of funding. Four of the studies received financial support from companies manufacturing PRP devices.</P>
<P>The results were non-conclusive as to whether autologous PRP improves the healing of chronic wounds generally compared with standard treatment. Autologous PRP may increase the healing of foot ulcers in people with diabetes compared with standard care, but it is unclear if autologous PRP has an effect on other types of chronic wound. Three studies reported wound complications such as infection or dermatitis, but results showed no difference in the risk of adverse events in people treated with PRP or standard care. These findings are based on low quality evidence due to the small number of studies and patients included, and their poor methodological quality.</P>
<P>This Plain Language Summary is up to date as of 16 June 2015.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-05-24 09:07:17 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-08-25 14:01:47 +0100" MODIFIED_BY="[Empty name]">
<P>Autologous platelet-rich plasma (PRP) is a treatment that contains fibrin and high concentrations of growth factors with the potential to improve the healing of chronic wounds. This is the first update of a review first published in 2012.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-09 17:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>To determine whether autologous PRP promotes the healing of chronic wounds.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-05-24 09:07:17 +0100" MODIFIED_BY="[Empty name]">
<P>In June 2015, for this first update, we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library): Ovid MEDLINE; Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. We also searched for ongoing and unpublished clinical trials in the WHO International Clinical Trials Registry Platform (ICTRP) (searched January 2015). We did not impose any restrictions with respect to language, date of publication, or study setting.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-05-20 22:39:26 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) that compared autologous PRP with placebo or alternative treatments for any type of chronic wound in adults. We did not apply any date or language restrictions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-05-23 09:57:04 +0100" MODIFIED_BY="[Empty name]">
<P>We used standard Cochrane methodology, including two reviewers independently selecting studies for inclusion, extracting data, and assessing risk of bias.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-05-23 09:57:06 +0100" MODIFIED_BY="[Empty name]">
<P>The search identified one new RCT, making a total of 10 included RCTs (442 participants, 42% women). The median number of participants per RCT was 29 (range 10 to 117). Four RCTs recruited people with a range of chronic wounds; three RCTs recruited people with venous leg ulcers, and three RCTs considered foot ulcers in people with diabetes. The median length of treatment was 12 weeks (range 8 to 40 weeks).</P>
<P>It is unclear whether autologous PRP improves the healing of chronic wounds generally compared with standard treatment (with or without placebo) (risk ratio (RR) 1.19, 95% confidence interval (CI) 0.95 to 1.50; I<SUP>2 </SUP>= 27%, low quality evidence, 8 RCTs, 391 participants). Autologous PRP may increase the healing of foot ulcers in people with diabetes compared with standard care (with or without placebo) (RR 1.22, 95% CI 1.01 to 1.49; I<SUP>2 </SUP>= 0%, low quality evidence, 2 RCTs, 189 participants). It is unclear if autologous PRP affects the healing of venous leg ulcers (RR 1.02, 95% CI 0.81 to 1.27; I<SUP>2 </SUP>= 0% ). It is unclear if there is a difference in the risk of adverse events in people treated with PRP or standard care (RR 1.05, 95% CI 0.29 to 3.88; I<SUP>2 </SUP>= 0%, low quality evidence from 3 trials, 102 participants).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-05-20 22:40:29 +0100" MODIFIED_BY="[Empty name]">
<P>PRP may improve the healing of foot ulcers associated with diabetes, but this conclusion is based on low quality evidence from two small RCTs. It is unclear whether PRP influences the healing of other chronic wounds. The overall quality of evidence of autologous PRP for treating chronic wounds is low. There are very few RCTs evaluating PRP, they are underpowered to detect treatment effects, if they exist, and are generally at high or unclear risk of bias. Well designed and adequately powered clinical trials are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-05-24 09:11:11 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-05-23 10:01:57 +0100" MODIFIED_BY="[Empty name]">
<P>See Glossary of terms for additional explanation of terms (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<CONDITION MODIFIED="2016-05-23 09:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>Chronic wounds are breaks in the skin that do not heal, or require a long time to heal, and frequently recur. Chronic wounds include pressure ulcers, venous leg ulcers, arterial ulcers, neurotrophic ulcers, and foot ulcers in people with diabetes.</P>
<P>The normal process of wound healing includes three phases: inflammation, tissue formation, and tissue remodelling. When the normal healing process is disrupted, a wound can become chronic in nature. Risk factors that commonly contribute to poor wound healing are: 1) local causes, such as wound infection, tissue hypoxia, repeated trauma, and presence of debris or necrotic tissue; 2) systemic diseases, such as diabetes mellitus, immunodeficiency, or malnutrition; and 3) certain medications, such as corticosteroids (<LINK REF="REF-de-la-Torre-2015" TYPE="REFERENCE">de la Torre 2015</LINK>).</P>
<P>Venous ulcers develop when the leg veins become damaged due to injury or disease, causing them to malfunction. Venous ulceration typically develops on either side of the lower leg between the ankle and calf. Venous ulcers have been estimated to affect up to 1% of the population in developed countries (<LINK REF="REF-Ebbeskog-1996" TYPE="REFERENCE">Ebbeskog 1996</LINK>). The prevalence rates of open ulcers in different studies ranges from 0.12% to 1.1% of the general population, whereas the prevalence rate of open or healed ulcers was reported to be 1.8% (<LINK REF="REF-Graham-2003" TYPE="REFERENCE">Graham 2003</LINK>). A study in the UK showed a prevalence of 0.45 per 1000 (<LINK REF="REF-Moffat-2004" TYPE="REFERENCE">Moffat 2004</LINK>).</P>
<P>A pressure ulcer is an area of tissue breakdown caused by pressure, shear or friction, or a combination of these between a bony prominence and an external surface (<LINK REF="REF-Grey-2006" TYPE="REFERENCE">Grey 2006</LINK>). Lack of movement causes compression of the tissues at the point where body and support surface meet. This compression causes impaired blood supply leading to tissue hypoxia and malnutrition. Anatomical sites commonly affected include the skin overlying the sacrum and hips (67%), but other locations commonly affected include heels, ankles, the occipital area, ears, and elbows. Pressure ulcers are relatively common. One epidemiological review reported that the prevalence of pressure ulcers in the UK ranges from 4.4% in a community unit to 37% in palliative care (<LINK REF="REF-Kaltenthaler-2001" TYPE="REFERENCE">Kaltenthaler 2001</LINK>). Prevalence in North America is similar and ranges from 4.7% in hospital patients to 33% in people in the community with spinal cord injuries (<LINK REF="REF-Kaltenthaler-2001" TYPE="REFERENCE">Kaltenthaler 2001</LINK>). Susceptibility is highest in people with neurological or cardiovascular disorders, dehydration, malnutrition, or hypotension, and in those who have undergone prolonged anaesthesia or surgery. Two-thirds of pressure ulcers occur in people older than 70 years (<LINK REF="REF-Barbenel-1977" TYPE="REFERENCE">Barbenel 1977</LINK>).  </P>
<P>Arterial (or ischaemic) ulcers are less common than venous ulcers and account for about 20% of leg ulcers. Atherosclerosis and diabetes are the commonest causes, but thrombotic episodes secondary to vasculitis (thromboangitis), and sickle cell disease can also result in arterial ulcers. Arterial ulceration typically develops on the dorsum of the foot or toes. Pain, with exercise or at night, is one characteristic of arterial ulcers and it is often aggravated by leg elevation.</P>
<P>Neurotrophic ulcers are usually caused by peripheral neuropathy, leading to loss of cutaneous sensitivity. These are often seen over pressure points of the metatarsophalangeal joint.</P>
<P>Diabetes is one frequent pathological condition that can result in an ulcer, with neuropathy and vascular disease being important contributory factors. These factors may lead to a loss of cutaneous sensibility and ischaemia, resulting in the amputation of the toe, foot, or leg (<LINK REF="REF-Gonzalez-2000" TYPE="REFERENCE">Gonzalez 2000</LINK>). Approximately 15% to 25% of people with diabetes will develop at least one foot ulcer during their lifetime (<LINK REF="REF-Reiber-1996" TYPE="REFERENCE">Reiber 1996</LINK>; <LINK REF="REF-Lavery-2003" TYPE="REFERENCE">Lavery 2003</LINK>; <LINK REF="REF-Singh-2005" TYPE="REFERENCE">Singh 2005</LINK>). The annual population-based incidence ranges from 1% to 4% and the prevalence is 4% to 10% (<LINK REF="REF-Reiber-2001" TYPE="REFERENCE">Reiber 2001</LINK>; <LINK REF="REF-Lavery-2003" TYPE="REFERENCE">Lavery 2003</LINK>).</P>
<P>A study from the USA reported that the Medicaid fee-for-service system incurred a total cost of approximately USD 11.6 million for the treatment of skin ulcers between 1994 and 1998 (<LINK REF="REF-Kumar-2004" TYPE="REFERENCE">Kumar 2004</LINK>). Patients with pressure ulcers were older, were more likely to have had surgery, and stayed in hospital longer. Furthermore, pressure ulcers were the most frequent, and also the most costly type of ulcer (<LINK REF="REF-Kumar-2004" TYPE="REFERENCE">Kumar 2004</LINK>). Another study of home care in Canada presented a similar prevalence of chronic wounds (<LINK REF="REF-Rodrigues-2006" TYPE="REFERENCE">Rodrigues 2006</LINK>), and again pressure ulcers were the most common aetiology (37%). A costing study estimated that the cost of pressure ulcers in the UK was 4% of the total National Health Service expenditure for the financial year 1999 to 2000 (<LINK REF="REF-Bennett-2004" TYPE="REFERENCE">Bennett 2004</LINK>).</P>
<P>Medical management of chronic wounds should, whenever possible, involve treatment of the primary cause. This may be glycaemic control for people with diabetes, or vascular surgery for people with chronic venous disease or ischaemic vascular disease (<LINK REF="REF-de-la-Torre-2015" TYPE="REFERENCE">de la Torre 2015</LINK>). Other measures thought to be important include the removal of necrotic or infected tissue (<LINK REF="REF-Edwards-2002" TYPE="REFERENCE">Edwards 2002</LINK>), off-loading (<LINK REF="REF-Spencer-2000" TYPE="REFERENCE">Spencer 2000</LINK>), compression therapy (<LINK REF="REF-O_x0027_Meara-2009a" TYPE="REFERENCE">O'Meara 2009a</LINK>; <LINK REF="REF-O_x0027_Meara-2009b" TYPE="REFERENCE">O'Meara 2009b</LINK>), maintenance of a moist wound environment, management of wound infection (<LINK REF="REF-FDA-2005" TYPE="REFERENCE">FDA 2005</LINK>), wound cleansing (<LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>), and diet (<LINK REF="REF-Langer-2003" TYPE="REFERENCE">Langer 2003</LINK>; <LINK REF="REF-FDA-2005" TYPE="REFERENCE">FDA 2005</LINK>). Despite treatment, many chronic wounds fail to heal, persist for months or years, and/or recur after healing (<LINK REF="REF-Rodrigues-2006" TYPE="REFERENCE">Rodrigues 2006</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-05-23 10:01:57 +0100" MODIFIED_BY="[Empty name]">
<P>Autologous platelet-rich plasma (PRP) has been under development as a theory since the 1990s (<LINK REF="REF-Anitua-2004" TYPE="REFERENCE">Anitua 2004</LINK>), and is increasingly used clinically to treat cutaneous chronic wounds (<LINK REF="REF-Knighton-1988" TYPE="REFERENCE">Knighton 1988</LINK>; <LINK REF="REF-Crovetti-2005" TYPE="REFERENCE">Crovetti 2005</LINK>). There are several techniques used to obtain autologous PRP, although some are not standardised or approved. The most common technique is to obtain a sample of blood from the patients themselves (autologous); this blood is then centrifuged to separate the platelets from red and white blood cells. These platelets rich in growth factors are highly concentrated and suspended in a small volume of plasma. Because most individuals have a baseline blood platelet count of 200,000 (±75,000)/µL, a PRP platelet count of 1 million/µL has been postulated as the ideal therapeutic dose of PRP (<LINK REF="REF-Marx-2004" TYPE="REFERENCE">Marx 2004</LINK>).</P>
<P>There are two methods to liberate growth factors from the platelets. The first is to add thrombin or calcium which activates the platelets and release the growth factors (platelet releasate). The second approach is to bring about physical lyses of the platelets (lysate) by freezing (<LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>), or by using other methods such as sonication, or to disrupt cell membranes and release cellular content with ultrasounds (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>). The final product is applied locally to the wound as a gel or a solution.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-05-21 15:45:41 +0100" MODIFIED_BY="[Empty name]">
<P>PRP contains high concentrations of growth factors which are thought to facilitate healing (<LINK REF="REF-Marlovits-2004" TYPE="REFERENCE">Marlovits 2004</LINK>). When these growth factors are released from the platelets they trigger a tissue regeneration process (<LINK REF="REF-Knighton-1988" TYPE="REFERENCE">Knighton 1988</LINK>; <LINK REF="REF-Robinson-1993" TYPE="REFERENCE">Robinson 1993</LINK>). One recent study demonstrated that multiple growth factors are increased in the granulation tissue of refractory diabetic dermal ulcers after being treated with PRP (<LINK REF="REF-Yuan-2009" TYPE="REFERENCE">Yuan 2009</LINK>). PRP, contains intra- and extra-platelet components other than growth factors and these can also contribute to the regeneration of tissue. Fibrinogen, for example, creates the fibrin network necessary for cellular implantation and later multiplication (<LINK REF="REF-Munirah-2007" TYPE="REFERENCE">Munirah 2007</LINK>). Autologous PRP has the advantage of low or null risk of infection or immune reactions.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-05-20 22:41:51 +0100" MODIFIED_BY="[Empty name]">
<P>An earlier systematic review about the efficacy of autologous PRP in tissue regeneration forms the basis of this review on chronic wounds (<LINK REF="REF-Martinez_x002d_Zapata-2009" TYPE="REFERENCE">Martinez-Zapata 2009</LINK>). The use of autologous PRP is increasing in the clinical setting due to the healthcare and social relevance of chronic wounds and the limited results with current treatments. Clinical trials that evaluate the efficacy of autologous PRP are ongoing, and it is timely to synthesise and evaluate current evidence on this subject.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-01-08 18:03:56 +0000" MODIFIED_BY="[Empty name]">
<P>To determine whether autologous PRP promotes the healing of chronic wounds.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-05-24 09:11:11 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-05-20 22:42:13 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-08-23 14:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) that compared autologous PRP with alternative treatments or placebo for chronic wounds.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-05-20 22:42:02 +0100" MODIFIED_BY="[Empty name]">
<P>We considered trials that included people aged 18 years or older with chronic wounds from any cause (such as pressure ulcers, arterial ulcers, venous ulcers). We also included patients with wounds of mixed aetiology e.g. mixed arterial-venous ulcers.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-10-12 11:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>Studies that compared autologous PRP (any method of collection and formulation) with placebo or alternative topical therapies such as standard care or protease-modulating matrix (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).<BR/>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-05-20 22:42:13 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-05-20 22:42:13 +0100" MODIFIED_BY="[Empty name]">
<P>Proportion of chronic wounds completely healed (defined as 100% epithelialisation or skin closure without drainage).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-05-20 04:14:08 +0100" MODIFIED_BY="Clare Dooley">
<OL>
<LI>Total area epithelialised at the end of the intervention (measured in cm<SUP>2</SUP>).</LI>
<LI>Percentage of wound area healed.</LI>
<LI>Time to complete wound healing.</LI>
<LI>Wound pain (measured by any validated scale).</LI>
<LI>Wound complications: infection, necrosis.</LI>
<LI>Quality of life (measured by any validated scale).</LI>
<LI>Adverse events</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-05-24 09:11:11 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-05-24 09:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>For this first update, we searched the following electronic databases to find reports of relevant RCTs:</P>
<UL>
<LI>The Cochrane Wounds Specialised Register (searched 16 June 2015);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2015, Issue 5);</LI>
<LI>Ovid MEDLINE (1946 to 15 June 2015);</LI>
<LI>Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations) (searched 15 June 2015);</LI>
<LI>Ovid EMBASE (1974 to 15 June 2015);</LI>
<LI>EBSCO CINAHL (1982 to 16 June 2015).</LI>
</UL>
<P>The search strategies used for Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid EMBASE, and EBSCO CINAHL can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>, and <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> respectively. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision) (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We combined the Ovid EMBASE and EBSCO CINAHL searches with the randomised controlled trials filters developed by the Scottish Intercollegiate Guidelines Network (<LINK REF="REF-SIGN-2015" TYPE="REFERENCE">SIGN 2015</LINK>). We did not impose any restrictions with respect to language or date of publication.</P>
<P>We also searched the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) (searched 30 January 2015), to identify ongoing and unpublished studies.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-05-23 15:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>We checked the reference lists of all relevant publications retrieved by the database searches to identify further studies. We also contacted trial authors for additional information.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-05-23 10:04:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-05-21 15:56:12 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (CZ and MMZ) independently assessed each study identified by the search to check its eligibility. There was agreement between the review authors and it was therefore not necessary to consult a third review author to obtain consensus. Those references which appeared to meet the inclusion criteria were retrieved in full and further assessed independently by the same two review authors (CZ and MMZ).</P>
<P>We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>), and '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-05-20 22:42:42 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted details of studies and recorded them using a data extraction sheet. If data were missing from reports, or clarification was needed, we made attempts to contact the trial authors to obtain missing information. We included data from studies published in duplicate only once. Two review authors (CZ and MMZ) independently extracted the data. Any discrepancy was resolved by discussion.</P>
<P>We extracted the following data for each included trial.</P>
<UL>
<LI>Trial characteristics (design, setting, location of care, country, source of funding, if the clinical trial reported the calculation of the sample size, and whether an intention-to-treat analysis was performed on the data reported in the published trial).</LI>
<LI>Participants by treatment group (number, age, sex, type of wound, wound size, length of follow-up).</LI>
<LI>Intervention (concurrent interventions, duration of treatment).</LI>
<LI>Comparison condition.</LI>
<LI>Outcome measures.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-05-20 22:42:53 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (MMZ, and CZ) independently assessed the risk of bias of the eligible trials. There was agreement between the review authors and it was not necessary to consult a third review author (IS) to obtain consensus.</P>
<P>We based our 'Risk of bias' assessment on the guidance in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We examined the adequacy of the method used to generate the allocation sequence, the method of allocation concealment and the level of blinding (clinician, participant or outcome assessor). We further examined the presence of incomplete outcome data, and selective reporting (see 'Risk of bias' tables in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>We classified each trial at high, unclear, or low risk of bias. We described the reason for each judgment from details provided in the trial reports or from data sought and provided by trial authors. We considered a trial to be at low risk of bias when it concealed allocation and blinded participants and outcome assessors, if it reported complete outcome data, and where we did not suspect selective outcome reporting (we assessed prespecification of outcomes from methods sections of trial publications). If one or more of these key domains were not met, we considered the trial to be at high risk of bias. If one or more of these key domains were unclear, we considered the trial as 'unclear' with respect to risk of bias (see table 8.7a of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>)).<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-05-23 10:04:14 +0100" MODIFIED_BY="[Empty name]">
<P>For binary outcome measures (proportion of wounds completely healed, adverse events), we calculated the risk ratio (RR). For continuous outcomes (total area healed, wound pain, and quality of life), we recorded either mean change from baseline for each group or mean post-treatment or intervention values and their standard deviation (SD) for each group. We pooled the estimate of treatment effect using the generic inverse method and calculated mean differences (MDs). For all measures, we calculated the 95% confidence interval (95% CI). For time to healing we planned a time to event analysis of survival.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-09-06 19:38:11 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was either the participant or the ulcer randomised. We collected and analysed a single measurement for each outcome from each participant or ulcer.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-09-06 15:25:33 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted study authors in an effort to obtain additional information where data were missing or unclear. In order to undertake an intention-to-treat analysis, when it was possible, we sought data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow-up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-05-20 22:43:18 +0100" MODIFIED_BY="[Empty name]">
<P>We quantified the impact of statistical heterogeneity using the I<SUP>2</SUP> statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). Where statistical heterogeneity was high (I<SUP>2 </SUP>&gt; 75%) or where there was clinical heterogeneity, we investigated possible causes by exploring the impact of participants' characteristics (e.g. wound aetiology) and the method used to liberate the growth factors. We would not pool studies which had high statistical heterogeneity (I<SUP>2 </SUP>&gt; 75%). For levels of I<SUP>2</SUP> less than 50% we applied a fixed-effect model; for levels of I<SUP>2</SUP> over 50% but less than 75% we used a random-effects model.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-03-03 13:46:21 +0000" MODIFIED_BY="[Empty name]">
<P>We did not assess whether the review was subject to publication bias by using a funnel plot because there were fewer than 10 included studies in our analysis of the main outcome (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-05-20 22:43:43 +0100" MODIFIED_BY="[Empty name]">
<P>We determined the pooled effect estimate for each outcome through a meta-analysis of the individual effect measures of the studies by means of a random-effects model when there was clinical heterogeneity (studies with wound ulcers of different aetiologies) (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
<P>When there was neither clinical nor statistical heterogeneity, we used a fixed-effect model (I<SUP>2</SUP> less than 50%). We included studies that presented results of multiple ulcers on a participant in the analysis, calculating the effective sample size, as per the guidance in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>). In addition, the intracluster correlation coefficient considered was 0.05 based on published data (<LINK REF="REF-Scriven-1998" TYPE="REFERENCE">Scriven 1998</LINK>; <LINK REF="REF-Vas-2008" TYPE="REFERENCE">Vas 2008</LINK>).</P>
<P>We used the statistical package Review Manager 5, provided by Cochrane (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-05-20 22:44:01 +0100" MODIFIED_BY="[Empty name]">
<P>Potential sources of clinical heterogeneity are:</P>
<OL>
<LI>wound aetiology (pressure ulcers, diabetes, ischaemia, and venous disease). When the clinical trial included ulcers of different aetiologies, we classified the trial as being of 'mixed chronic wounds';</LI>
<LI>methods to liberate growth factors from the platelets: lysate and releasate.</LI>
</OL>
<P>For these reasons, we stratified study data by type of chronic wound. Additionally, we performed a prespecified subgroup analysis by the methods used to liberate growth factors from the platelets.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-05-23 09:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>We prespecified a sensitivity analysis to investigate the effect of excluding studies with high risk of bias (as defined earlier, namely, if one or more of the key domains of concealed allocation, blinded participants, blinded outcome assessors, complete outcome data, and selective reporting were at high risk of bias). We also conducted a sensitivity analysis to examine the effect of excluding from the meta-analysis studies which either had a total attrition greater than 30%, or differences in attrition between the groups exceeding 10%; we did not prespecify this sensitivity analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>We prepared a 'Summary of findings' table, including assessment of the overall quality of the evidence for the main outcomes using the approach of the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE Working Group) (<LINK REF="REF-Langedam-2013" TYPE="REFERENCE">Langedam 2013</LINK>). This approach assesses the quality of the body of evidence per comparison and outcome, taking into account five factors: risk of bias across all studies; indirectness, interventions and outcomes; reporting the outcome; inconsistency amongst studies; imprecision; and publication bias.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-05-23 10:19:38 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-05-23 10:19:38 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-05-23 10:19:38 +0100" MODIFIED_BY="[Empty name]">
<P>The search identified 297 citations. After considering titles and abstracts, we retrieved 66 potentially relevant studies in full-text. We included 10 studies in qualitative synthesis (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>, <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>) and nine in quantitative synthesis (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>, <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>). We also identified nine clinical trials that are ongoing (<LINK REF="STD-NCT00658983" TYPE="STUDY">NCT00658983</LINK>; <LINK REF="STD-ChiCTR_x002d_TRC_x002d_00000325" TYPE="STUDY">ChiCTR-TRC-00000325</LINK>; <LINK REF="STD-NCT02213952" TYPE="STUDY">NCT02213952</LINK>; <LINK REF="STD-IRCT2014060415574N3" TYPE="STUDY">IRCT2014060415574N3</LINK>; <LINK REF="STD-ISRCTN84928077" TYPE="STUDY">ISRCTN84928077</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000004840" TYPE="STUDY">JPRN-UMIN000004840</LINK>; <LINK REF="STD-NCT02209662" TYPE="STUDY">NCT02209662</LINK>; <LINK REF="STD-NCT02307448" TYPE="STUDY">NCT02307448</LINK>; <LINK REF="STD-NCT02312518" TYPE="STUDY">NCT02312518</LINK>). A further two studies are awaiting assessment (<LINK REF="STD-Obolenskiy-2014" TYPE="STUDY">Obolenskiy 2014</LINK>; <LINK REF="STD-Serra-2014" TYPE="STUDY">Serra 2014</LINK>). We excluded the remaining 45 studies, of which 11 are ongoing (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>We contacted some authors in an effort to obtain additional information (<LINK REF="STD-Tarpila-1998" TYPE="STUDY">Tarpila 1998</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Saad-Setta-2011" TYPE="STUDY">Saad Setta 2011</LINK>; <LINK REF="STD-NCT00215735" TYPE="STUDY">NCT00215735</LINK>). Only one trial author responded and answered our questions (<LINK REF="STD-Tarpila-1998" TYPE="STUDY">Tarpila 1998</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-05-20 22:46:31 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted descriptive data from the ten included trials. Overall, data on 442 participants were included in the review, 228 participants received platelet-rich plasma (PRP) and 214 received a control treatment. Forty-two per cent of participants were female and 58% were male; the mean age was 61 years. The median number of participants included per clinical trial was 29 (range 10 to 117).</P>
<P>Four trials treated people with wounds due to different aetiologies ('mixed wounds') (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>). Two of these included ulcers of more than one aetiology (venous diseases, diabetic disease, occlusive peripheral vascular diseases, vasculitis and/or pressure ulcers) (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>), another included different ulcers in the trial, but each participant had ulcers due to only one cause (<LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>), and one study included both variations (<LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>). Three trials treated venous leg ulcers (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>), and three trials treated foot ulcers in people with diabetes (<LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>). The median wound duration at baseline was 49 weeks, with a range from 19 in <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK> to 280 weeks in <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>. The median wound size at baseline was 11.2 cm<SUP>2</SUP>, ranging from 3.2 cm<SUP>2 </SUP>in <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>) to 149 cm<SUP>2</SUP> in <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK> (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>The methods used to obtain autologous PRP varied between studies, but all used the participants&#8217; own blood and centrifuged this to obtain a concentrate of platelets. The procedure to liberate growth factors from the platelets varied between studies. Four trials applied a platelet lysate (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>), four used platelet releasate (<LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>), and in two studies the method used was not clearly reported (<LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>).</P>
<P>The four studies that used platelet lysate kept it frozen in the days prior to use. The four studies that used platelet releasate prepared the autologous PRP a few hours before it was administered to the participant (<LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>). The median duration of treatment was 12 weeks, with a range from eight weeks in <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK> to 40 weeks in <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>.</P>
<P>Only three trials specified that they had calculated the required sample size (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>). Two studies presented the data from more than one ulcer per patient (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>). One trial did not report a standard deviation and we therefore excluded it from the pooled analyses (<LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>).</P>
<P>There was imbalance between groups at baseline in seven trials (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). In the <LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK> study, the experimental group had a longer wound duration than the control group (119 weeks versus 47 weeks). In the <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK> study, the placebo group presented with a larger wound area than the experimental group (29 cm<SUP>2</SUP> versus 13 cm<SUP>2</SUP>), the PRP group had more wounds (17 versus 9) and wound duration was longer (6.2 months versus 4.3 months) than in the placebo group. <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK> reported that participants in the control group were older than those in the experimental group (61 versus 45 years old) and the duration of the ulcer also was longer (110 days versus 68 days) in the control group. In <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>, the experimental group was older than the control group. In the <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>, <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>, and <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK> studies, the wound area was significantly different between groups at baseline (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>In the <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK> study, only 40 of 72 patients were evaluated due to the high percentage of protocol violations and failure to complete treatment. <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK> experienced difficulty in recruiting patients and the trial authors were unable to achieve the necessary sample size: only 26 of the 80 patients needed were included.</P>
<P>All but three trials reported the sources of funding (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>). Four of the studies received financial support from companies manufacturing PRP devices (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-05-23 10:07:52 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 45 studies for the following reasons (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>):</P>
<UL>
<LI>Twenty-two studies were not randomised (<LINK REF="STD-Knighton-1986" TYPE="STUDY">Knighton 1986</LINK>; <LINK REF="STD-Atri-1990" TYPE="STUDY">Atri 1990</LINK>; <LINK REF="STD-K_x00f6_veker-1992" TYPE="STUDY">Köveker 1992</LINK>; <LINK REF="STD-Tarpila-1998" TYPE="STUDY">Tarpila 1998</LINK>; <LINK REF="STD-Reutter-1999" TYPE="STUDY">Reutter 1999</LINK>; <LINK REF="STD-Aminian-2000" TYPE="STUDY">Aminian 2000</LINK>; <LINK REF="STD-Margolis-2001" TYPE="STUDY">Margolis 2001</LINK>; <LINK REF="STD-Mazzuco-2004" TYPE="STUDY">Mazzuco 2004</LINK>; <LINK REF="STD-Saldamalacchia-2004" TYPE="STUDY">Saldamalacchia 2004</LINK>; <LINK REF="STD-S_x00e1_nchez-2007" TYPE="STUDY">Sánchez 2007</LINK>; <LINK REF="STD-Aminian-2011" TYPE="STUDY">Aminian 2011</LINK>; <LINK REF="STD-Carter-2011" TYPE="STUDY">Carter 2011</LINK>; <LINK REF="STD-Jorgensen-2011" TYPE="STUDY">Jorgensen 2011</LINK>; <LINK REF="STD-Saad-Setta-2011" TYPE="STUDY">Saad Setta 2011</LINK>; <LINK REF="STD-Enriquez_x002d_Vega-2012" TYPE="STUDY">Enriquez-Vega 2012</LINK>; <LINK REF="STD-NCT00762138" TYPE="STUDY">NCT00762138</LINK>; <LINK REF="STD-NCT01553955" TYPE="STUDY">NCT01553955</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000009860" TYPE="STUDY">JPRN-UMIN000009860</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000015689" TYPE="STUDY">JPRN-UMIN000015689</LINK>; <LINK REF="STD-NCT02088268" TYPE="STUDY">NCT02088268</LINK>; <LINK REF="STD-NCT02071979" TYPE="STUDY">NCT02071979</LINK>; <LINK REF="STD-Morimoto-2015" TYPE="STUDY">Morimoto 2015</LINK>).</LI>
<LI>Five studies considered acute wounds (<LINK REF="STD-Danielsen-2008" TYPE="STUDY">Danielsen 2008</LINK>; <LINK REF="STD-Hao-2010" TYPE="STUDY">Hao 2010</LINK>; <LINK REF="STD-Cervelli-2012" TYPE="STUDY">Cervelli 2012</LINK>; <LINK REF="STD-NCT00856934" TYPE="STUDY">NCT00856934</LINK>; <LINK REF="STD-NCT01639144" TYPE="STUDY">NCT01639144</LINK>).</LI>
<LI>Fifteen studies did not assess autologous PRP (<LINK REF="STD-Steed-1992" TYPE="STUDY">Steed 1992</LINK>; <LINK REF="STD-Holloway-1993" TYPE="STUDY">Holloway 1993</LINK>; <LINK REF="STD-Steed-1993" TYPE="STUDY">Steed 1993</LINK>; <LINK REF="STD-Steinbaum-1994" TYPE="STUDY">Steinbaum 1994</LINK>; <LINK REF="STD-Steed--1996" TYPE="STUDY">Steed 1996</LINK>; <LINK REF="STD-Crovetti-2004" TYPE="STUDY">Crovetti 2004</LINK>; <LINK REF="STD-Afshari-2005" TYPE="STUDY">Afshari 2005</LINK>; <LINK REF="STD-Niezgoda-2005" TYPE="STUDY">Niezgoda 2005</LINK>; <LINK REF="STD-Ma-2007" TYPE="STUDY">Ma 2007</LINK>; <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>; <LINK REF="STD-Scevola-2010" TYPE="STUDY">Scevola 2010</LINK>; <LINK REF="STD-Jaiswal-2010" TYPE="STUDY">Jaiswal 2010</LINK>; <LINK REF="STD-Greppi-2011" TYPE="STUDY">Greppi 2011</LINK>; <LINK REF="STD-Soula-2012" TYPE="STUDY">Soula 2012</LINK>; <LINK REF="STD-Khandelwal-2013" TYPE="STUDY">Khandelwal 2013</LINK>).</LI>
<LI>Two studies were stopped early, one in venous leg ulcers (<LINK REF="STD-NCT00273234" TYPE="STUDY">NCT00273234</LINK>), and one in diabetic foot ulcers (<LINK REF="STD-NCT00338702" TYPE="STUDY">NCT00338702</LINK>). The reasons given were lack of financial support in both studies, and the former also had enrolment difficulties due to the stringent patient inclusion criteria.</LI>
<LI>One study was terminated with inconclusive results and was not published (<LINK REF="STD-NCT00215735" TYPE="STUDY">NCT00215735</LINK>). We requested more information from the investigators but we have not received a response.</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-05-23 09:58:26 +0100" MODIFIED_BY="[Empty name]">
<P>Only one study presented low risk of bias across all domains (<LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>). Three studies were at high risk of bias for at least one domain, with the remainder being at overall unclear risk of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2016-05-23 09:58:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Adequacy of the method used to generate the allocation sequence</HEADING>
<P>Of the ten included studies, only five adequately reported the method used to generate the randomisation sequence (<LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>). The other studies mentioned that the clinical trial was randomised but did not report further details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment</HEADING>
<P>Four of the ten studies adequately reported allocation concealment (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>), but in the remaining six studies this was not specified (<LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2016-05-23 09:58:26 +0100" MODIFIED_BY="[Empty name]">
<P>Five studies blinded the participants, this was either specifically reported or the control treatment was identical in appearance to the autologous PRP, and we judged that the participants were properly blinded because of this similarity (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>).</P>
<P>Four studies blinded the caregivers (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>), and seven studies blinded the outcome assessors (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>).</P>
<P>
<LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK> was an open trial and <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK> did not mention whether the control group was identical to the experimental group.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-05-20 22:47:36 +0100" MODIFIED_BY="[Empty name]">
<P>All trials reported if there were any participants lost to follow-up with the exception of <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>. In general terms, the included trials had dropout percentages lower than 30%, with the exception of <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK> and <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>, with 40% and 44%, respectively. Three studies had no participants lost to follow-up (<LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>). Losses to follow-up were similar between the experimental and control groups in all trials except in the studies by <LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK> and <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK> which had an imbalance in patient loss after randomisation. The losses to follow-up in <LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK> were three (18.7%) patients in the experimental group and five (31.2%) patients in the control group. The losses to follow-up in the <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK> study were 21 (52.5%) patients in the experimental group and 11 (34.4%) patients in the control group.</P>
<P>Three trials performed intention-to-treat analyses (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>). Additionally, <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK> performed a per protocol analysis for secondary outcomes because there was a high percentage of protocol violations and failure to complete the treatment.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-05-20 22:47:51 +0100" MODIFIED_BY="[Empty name]">
<P>One clinical trial presented selective reporting (<LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>). The non-reported results in question referred to the percentage of change in wound area at end-of-study visit from baseline, the percentage of change in wound volume at end-of-study visit from baseline, and volume closure rate per day at end-of-study visit. We did not seek trial protocols but recognise this is something we should consider for the future.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-05-21 16:45:40 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Autologous platelet-rich plasma (PRP) compared with standard care (with or without placebo)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome  </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of chronic wounds completely healed</HEADING>
<P>Eight RCTs (391 participants) compared PRP with standard care (with or without placebo), and reported data for the outcome of complete wound healing. Two studies involved 189 participants with diabetic foot ulcers (<LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>), two recruited 101 participants with venous leg ulcers (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>), and four studies involved 101 participants with mixed chronic wounds (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>). Overall, it is unclear whether the addition of autologous PRP to standard treatment affects the risk of chronic wound healing compared with standard treatment alone (low quality evidence, downgraded twice for risk of bias) (RR 1.19, 95% CI 0.95 to 1.50; I<SUP>2 </SUP>= 27%).</P>
<P>Looking separately at the two studies in people with diabetic foot ulcers (189 participants), there is some low quality evidence (downgraded twice for risk of bias) that autologous PRP may increase the risk of complete healing in people with diabetic foot ulcers (RR 1.22, 95% CI 1.01 to 1.49). However, both these studies used a different method of harvesting the PRP from all but one of the other studies. It is unclear whether PRP affects the healing of venous leg ulcers (RR 1.02, 95% CI 0.81 to 1.27; I<SUP>2 </SUP>= 0%, low quality evidence), or mixed chronic wounds (RR 1.85, 95% CI 0.76 to 4.51; I<SUP>2 </SUP>= 42%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). In each case, we downgraded the quality of the evidence for imprecision (the confidence interval was wide) and risk of bias (usually incomplete outcome data, selective reporting, or the randomisation process was unclear) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>We conducted a subgroup analysis to investigate whether different methods of liberating growth factors from the platelets resulted in different clinical effects, however, this comparison was confounded by wound type (most of the trials using PRP releasate involve people with diabetic foot ulcers). The studies which used PRP releasate had a pooled RR of complete healing of 1.23, 95% CI 1.01 to 1.49; I<SUP>2 </SUP>= 0% (<LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>), and those for PRP lysate had a pooled RR of 1.45, 95% CI 0.67 to 3.13 (I<SUP>2 </SUP>= 70%) (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Consequently it is unclear whether the method of harvesting PRP influences any clinical effect.</P>
<P>We did not perform the prespecified sensitivity analysis because the quality of evidence was low, principally due to risk of bias of studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes  </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Total area epithelialised</HEADING>
<P>Three trials of mixed chronic wounds (66 participants) reported data for this outcome (<LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>). There was no clear evidence of a difference between the groups (pooled MD -2.78 cm<SUP>2</SUP>, 95% CI -8.67 to 3.11; I<SUP>2 </SUP>= 47%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of wound area healed</HEADING>
<P>One trial reported the average reduction in ulcer size after two days of treatment (5.42 cm<SUP>2</SUP> in the experimental group and 0.8 cm<SUP>2</SUP> in the control group). However, the standard deviations of these measures were not reported and we could not analyse the results (<LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>).</P>
<P>Two small trials of mixed chronic wounds (47 participants) reported data on percentage of wound area healed and we pooled these data (<LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>). Although a greater area was healed with PRP than control (MD 51.78%, 95% CI 32.70 to 70.86; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), these data are at high risk of bias: <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK> due to unblinded outcome assessment and attrition, and <LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK> due to attrition; and this must be taken into consideration when interpreting the finding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time to complete wound healing</HEADING>
<P>Two RCTs reported data on this outcome (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>). Neither trial reported sufficient information to replicate the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Wound pain</HEADING>
<P>Not reported in any trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Wound complications</HEADING>
<P>Three trials (117 participants) reported wound complications such as infection (<LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>), or dermatitis (<LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>). Overall it was not clear whether there was a difference in rates of wound complication between PRP and standard care. Two small trials (30 participants) reported data for wound infection (<LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>), and there was no clear difference (RR 0.80, 95% CI 0.14 to 4.73; I<SUP>2 </SUP>= 0%). <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK> and <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK> (87 participants) reported dermatitis, and there was no clear difference (RR 1.31, 95% CI 0.18 to 9.69; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>Not reported in any trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Six out of nine trials reported information on adverse events (<LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>), but only three trials presented them (<LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>). Overall, 5/56 participants (8.9%) in the PRP group experienced an adverse event compared with 4/46 (8.6%) in the control group. It is unclear whether there was a difference in the risk of adverse events between PRP and standard care (very low quality evidence) (RR 1.05, 95% CI 0.29 to 3.88; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We downgraded the quality of evidence for risk of bias and imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). <LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>, <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>, and <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK> did not report data on adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Autologous PRP plus protease-modulating matrix compared with protease-modulating matrix alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes  </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of chronic wounds completely healed</HEADING>
<P>We identified one trial with three treatment groups that compared protease-modulating matrix alone, PRP alone, and PRP and protease-modulating matrix in combination (total of 51 participants, 17 in each group) in people with diabetes and a foot ulcer (<LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>). We only extracted data for the comparison of protease-modulating matrix with and without PRP as the only systematic difference between groups was the presence/absence of PRP. There was no difference in the risk of complete ulcer healing with and without PRP in this context (2 participants in each group completely healed; RR 1.00, 95% CI 0.16 to 6.30). There was very low quality evidence for this outcome (downgraded for risk of (attrition) bias and imprecision) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes  </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Wound pain or quality of life</HEADING>
<P>Not reported in <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Not reported in <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-05-23 10:47:21 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-05-23 10:47:21 +0100" MODIFIED_BY="[Empty name]">
<P>Our aim was to evaluate the effectiveness and safety of autologous platelet-rich plasma (PRP) in healing chronic wounds. This is the first update of a review published in 2012 (<LINK REF="REF-Martinez_x002d_Zapata-2012" TYPE="REFERENCE">Martinez-Zapata 2012</LINK>), and we have included one new randomised controlled trial (RCT) and nine ongoing RCTs, bringing the total number of included studies to 10.</P>
<P>We observed substantial variations within trials regarding eligible participants, wound aetiologies, and other design and conduct features. Four trials treated people with mixed aetiology chronic wounds (there were participants with wounds caused by more than one aetiology and participants who had wounds of several aetiologies in the same trial) (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>); three treated people with venous leg ulcers (<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>), and three treated people with diabetes and foot ulcers (<LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>). Nine out of 10 studies compared PRP plus standard care with standard care alone (with or without placebo). One study in people with diabetes evaluated PRP in the context of protease-modulating matrix (<LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>).</P>
<P>The process used to 'harvest' autologous PRP varied between studies, however, it was impossible to draw conclusions about any differences in the effects of PRP harvested in different ways since these studies were also different in the types of patients included.</P>
<P>We analysed the overall effect of PRP on complete wound healing with data from eight RCTs and there was uncertainty as to whether PRP affects the risk of complete healing (low quality evidence). Although there is a possible beneficial effect of PRP on complete wound healing when the studies confined to diabetic foot ulcers are examined, this is low quality evidence and these studies also harvested the PRP in a way that was different to most of the other studies (PRP releasate rather than lysate). There were no data reported on quality of life.</P>
<P>There is great uncertainty in terms of whether there are differential effects of PRP and standard care in terms of safety (adverse events). Pooling the data from three trials showed no clear evidence of a difference, however, this comparison is very underpowered.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-05-20 22:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>There is increasing interest in using autologous PRP, as evidenced by the large number of ongoing trials that we have identified in this review. Autologous PRP is used because it contains growth factors which are thought to aid wound repair, however, the current evidence is very sparse and of low quality, therefore, we do not know whether PRP speeds wound healing in people with chronic wounds such as foot ulcers in people with diabetes and venous leg ulcers.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-05-20 22:51:30 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence concerning the efficacy of autologous PRP in chronic wounds is low or very low quality; typically due to various risks of bias and imprecision (due to small sample sizes and lack of statistical power).</P>
<P>Most studies were very small, did not report an a priori sample size calculation, and would have been underpowered to detect anything but very large treatment effects. In the <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK> study a target sample size was calculated but there were difficulties in achieving full recruitment, and the final sample size was smaller than that planned. The lack of statistical power limits the adequate evaluation of autologous PRP efficacy. In seven of the included studies there was an apparent imbalance at baseline for important characteristics, probably chance imbalances due to small sample sizes (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>; <LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>; <LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>).</P>
<P>Most studies were at high or unclear risk of bias due to poor reporting (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>These limitations (inadequate simple size, unclear randomisation sequence, and allocation concealment) could explain that in seven trials there was an imbalance between groups of baseline characteristics.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-03-02 09:17:11 +0000" MODIFIED_BY="[Empty name]">
<P>Our assessment of risk of bias was hampered by the poor reporting of the included studies. We requested information from six authors (<LINK REF="STD-Tarpila-1998" TYPE="STUDY">Tarpila 1998</LINK>; <LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>; <LINK REF="STD-NCT00215735" TYPE="STUDY">NCT00215735</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>; <LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>; <LINK REF="STD-Saad-Setta-2011" TYPE="STUDY">Saad Setta 2011</LINK>), but we only received one response (<LINK REF="STD-Tarpila-1998" TYPE="STUDY">Tarpila 1998</LINK>). </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-05-20 23:14:17 +0100" MODIFIED_BY="[Empty name]">
<P>We previously published a systematic review concerning the effectiveness of autologous PRP for tissue regeneration (search date February 2006), which included seven RCTs of chronic wounds (<LINK REF="REF-Martinez_x002d_Zapata-2009" TYPE="REFERENCE">Martinez-Zapata 2009</LINK>). Our overall conclusion is unchanged, namely that we are unclear whether PRP influences the healing rate of chronic wounds.</P>
<P>There are three other published systematic reviews that assess efficacy of PRP in wound care (<LINK REF="REF-Lacci-2010" TYPE="REFERENCE">Lacci 2010</LINK>; <LINK REF="REF-Mao-2010" TYPE="REFERENCE">Mao 2010</LINK>; <LINK REF="REF-Villela-2010" TYPE="REFERENCE">Villela 2010</LINK>). The reviews by <LINK REF="REF-Lacci-2010" TYPE="REFERENCE">Lacci 2010</LINK> and <LINK REF="REF-Mao-2010" TYPE="REFERENCE">Mao 2010</LINK> were narrative reviews (no meta-analysis) and concluded that more rigorous trials were needed before the clinical use of PRP could be recommended. The review by <LINK REF="REF-Villela-2010" TYPE="REFERENCE">Villela 2010</LINK> focused on PRP for diabetic foot ulcers and had more liberal inclusion criteria (any clinical trial design and homologous or autologous PRP). The meta-analysis combined the results of four RCTs. Two studies assessed homologous PRP (<LINK REF="STD-Steed-1992" TYPE="STUDY">Steed 1992</LINK>; <LINK REF="STD-Holloway-1993" TYPE="STUDY">Holloway 1993</LINK>), and the other two studies, autologous PRP (<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>; <LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>). The meta-analysis indicated that PRP significantly improved the healing of diabetic foot ulcers, however, this finding was heavily influenced by the <LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK> trial which arguably should have been excluded because the participants had ulcers of different aetiologies.</P>
<P>This current review is an update of a previously published version (<LINK REF="REF-Martinez_x002d_Zapata-2012" TYPE="REFERENCE">Martinez-Zapata 2012</LINK>), and offers a more rigorous 'Risk of bias' assessment, a more recent search, and an evaluation of the quality of evidence. We found some low quality evidence of a possible effect of autologous PRP on the healing of diabetic foot ulcers.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-05-20 22:51:48 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-05-20 22:51:48 +0100" MODIFIED_BY="[Empty name]">
<P>It is unclear whether autologous platelet-rich plasma (PRP) influences the healing of chronic wounds, as the existing evidence is sparse and of low or very low quality.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-05-20 22:51:48 +0100" MODIFIED_BY="[Empty name]">
<P>Well designed, adequately powered RCTs are needed to determine whether using PRP confers any benefit in terms of more rapid or increased wound healing. Nine trials assessing the efficacy of autologous PRP in chronic wounds are ongoing and their results will provide further, valuable evidence (<LINK REF="STD-NCT00658983" TYPE="STUDY">NCT00658983</LINK>; <LINK REF="STD-ChiCTR_x002d_TRC_x002d_00000325" TYPE="STUDY">ChiCTR-TRC-00000325</LINK>; <LINK REF="STD-NCT02213952" TYPE="STUDY">NCT02213952</LINK>; <LINK REF="STD-IRCT2014060415574N3" TYPE="STUDY">IRCT2014060415574N3</LINK>; <LINK REF="STD-ISRCTN84928077" TYPE="STUDY">ISRCTN84928077</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000004840" TYPE="STUDY">JPRN-UMIN000004840</LINK>; <LINK REF="STD-NCT02209662" TYPE="STUDY">NCT02209662</LINK>; <LINK REF="STD-NCT02307448" TYPE="STUDY">NCT02307448</LINK>; <LINK REF="STD-NCT02312518" TYPE="STUDY">NCT02312518</LINK>).  </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-05-23 10:44:13 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to acknowledge the contribution of peer referees (David Armstrong, Robert Ashford, Rachel Richardson) and editors of Cochrane Wounds (David Margolis, Andrea Nelson, Gill Worthy) for their comments on the protocol and review. Thanks also to copy-editors Heather Maxwell and Clare Dooley and to Carolyn Newey for help in editing the first version of the manuscript.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-05-23 10:34:11 +0100" MODIFIED_BY="[Empty name]">
<P>Maria José Martinez-Zapata: None.</P>
<P>Arturo J Martí-Carvajal: Arturo J Martí-Carvajal was employed in by Eli Lilley in 2004 and Merck in 2007 to run workshops on the critical appraisal of clinical trials. This activity was not related to his work with Cochrane or any Cochrane review. </P>
<P>Ivan Solà: None.</P>
<P>José Angel Expósito: None.</P>
<P>Ignasi Bolíbar: None.</P>
<P>Luciano Rodríguez: None.</P>
<P>Joan Garcia: None.</P>
<P>Carlos Zaro: None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-05-23 10:45:15 +0100" MODIFIED_BY="[Empty name]">
<P>Maria Jose Martinez-Zapata: Conceived, designed and co-ordinated the review. Selected the studies, extracted data and checked the quality of data extraction, undertook quality assessment, analysed or interpreted data, checked quality assessment, performed part of data analysis or interpretation, and performed statistical analysis. Completed the first draft, performed previous work that was the foundation of the current review, performed part of writing or editing, made an intellectual contribution to, and advised on the review, secured funding, and wrote to study author/experts/companies. Approved final review prior to submission and acted as guarantor of the review.</P>
<P>Arturo Marti-Carvajal: Designed the review, extracted data, checked the quality of data extraction, undertook quality assessment, analysed or interpreted data, checked quality assessment, performed part of data analysis or interpretation, checked the quality of statistical analysis, and performed part of writing or editing of the review. Made an intellectual contribution, performed previous work that was the foundation of the current review, wrote to study author/experts/companies, advised on, and approved the final review prior to submission.</P>
<P>Carlos Zaror selected the studies, extracted data, and undertook quality assessment in the current update.</P>
<P>Jose-Angel Exposito: Performed part of writing or editing, advised on part of the review, and approved the final review prior to submission.</P>
<P>Ivan Sola: Advised on part of the review and approved final review prior to submission.</P>
<P>Luciano Rodriguez: Performed part of writing or editing, advised on part of the review, and approved the final review prior to submission.<BR/>
<BR/>Joan Garcia: Performed part of writing or editing, advised on part of the review, and approved the final review prior to submission.</P>
<P>Ignasi Bolibar: Advised on part of the review and approved final review prior to submission.</P>
<SUBSECTION>
<HEADING LEVEL="2">Contributions of editorial base</HEADING>
<P>For the first version of this review:</P>
<P>Nicky Cullum: Edited the review, advised on methodology, interpretation, and review content. Approved the final review prior to publication.</P>
<P>Sally Bell-Syer: Co-ordinated the editorial process. Advised on methodology, interpretation, and content. Edited and copy-edited the review.</P>
<P>Ruth Foxlee: Designed the search strategy, ran the searches, and edited the search methods section.</P>
<P>For this update:</P>
<P>Nicky Cullum: Edited the review, advised on methodology, interpretation, and review content. Approved the final review prior to publication.</P>
<P>Gill Rizzello: Co-ordinated the editorial process. Edited the review.</P>
<P>Rocio Rodriguez-Lopez: Ran the searches.</P>
<P>Reetu Child: Checked the search strategies and methods section.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-05-21 16:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>In the protocol, we stated that we would consider risk of bias based on sequence generation, allocation concealment, blinding (participants, clinicians, outcome assessors), and withdrawals. However, in the review we have reflected the current guidance in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> and have added 'incomplete outcome data' and 'selective reporting' to reflect this (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<P>We included the percentage of wound area healed, a secondary outcome that we did not prespecify in the protocol, as we judged it to be clinically important.</P>
<P>We excluded the secondary outcome percentage of change in healed wound width, length or depth. The reason of this exclusion has been to avoid multiple testing of healing outcomes.</P>
<P>In addition to the searches planned in the protocol, we also searched for ongoing studies in the database, International Clinical Trials Registry Platform (ICTRP): <A HREF="http://www.who.int/ictrp/network/en/">http://www.who.int/ictrp/network/en/</A>, that includes clinicaltrial.gov and other clinical trial registry databases.</P>
<P>In this up-to-date review we have added the quality of evidence and a 'Summary of findings' table with GRADE ratings.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-05-24 11:01:02 +0100" MODIFIED_BY="Gill Rizzello">
<STUDIES MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anitua-2008" MODIFIED="2016-05-20 04:51:43 +0100" MODIFIED_BY="Clare Dooley" NAME="Anitua 2008" YEAR="2004">
<REFERENCE MODIFIED="2016-05-20 04:51:43 +0100" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="OTHER">
<AU>Aguirre JJ, Francisco S, Cabezas A, Calleja A, Ayerdi E, Pena MA, et al</AU>
<TI>Randomized open-label controlled pilot trial to evaluate the effectiveness of PRGF in the treatment of chronic cutaneous ulcers: results at 4 weeks of follow-up.</TI>
<TO>Ensayo clínico piloto, aleatorizado, en grupos paralelos, ciego y controlado con tratamiento convencional para evaluar la eficacia de plasma rico en factores de crecimiento en el tratamiento de las úlceras cutáneas: resultados a las 4 semanas de seguimiento</TO>
<SO>XIX Congreso de la Sociedad Española de Farmacología Clínica</SO>
<YR>2004</YR>
<PG>Abstract 19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712769"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-02 09:11:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, et al</AU>
<TI>Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers</TI>
<SO>Journal of Biomedical Materials Research - Part B Applied Biomaterials</SO>
<YR>2008</YR>
<VL>84</VL>
<NO>2</NO>
<PG>415-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712770"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712768"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Driver-2006" MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" NAME="Driver 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Driver VR, Hanft J, Fylling CP, Beriou JM; Autologel Diabetic Foot Ulcer Study Group</AU>
<TI>A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers</TI>
<SO>Ostomy/Wound Management</SO>
<YR>2006</YR>
<VL>52</VL>
<NO>6</NO>
<PG>68-87</PG>
<IDENTIFIERS MODIFIED="2011-05-10 17:35:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712772"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712771"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakagia-2007" MODIFIED="2016-05-20 23:18:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kakagia 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-05-20 23:18:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakagia D, Kazakos K, Xarchas K, Karanikas M, Georgiadis G, Tripsiannis G, et al</AU>
<TI>Synergistic action of protease-modulating matrix and autologous growth factors in healing diabetic foot ulcers. A prospective randomized trial</TI>
<SO>Journal of Diabetes and its Complications</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>6</NO>
<PG>387-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712774"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712773"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knighton-1990" MODIFIED="2012-01-11 16:16:34 +0000" MODIFIED_BY="[Empty name]" NAME="Knighton 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-01-11 16:16:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F</AU>
<TI>Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1990</YR>
<VL>170</VL>
<NO>1</NO>
<PG>56-60</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:30:46 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712776"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-28 21:56:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knighton DR, Doucette M, Fiegel VD, Ciresi K, Butler E, Austin L</AU>
<TI>The use of platelet derived wound healing formula in human clinical trials</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1988</YR>
<VL>266</VL>
<PG>319-29</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712775"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krupski-1991" MODIFIED="2011-10-29 22:31:08 +0100" MODIFIED_BY="[Empty name]" NAME="Krupski 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-10-29 22:31:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krupski WC, Reilly LM, Perez S, Moss KM, Crombleholme PA, Rapp JH</AU>
<TI>A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic nonhealing wounds: a preliminary report</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>4</NO>
<PG>526-32</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:31:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712779"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712778"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2012" MODIFIED="2016-03-02 09:15:34 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-03-02 09:15:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li L, Wang C, Wang Y, He LP, Yang YZ, Chen LH, et al</AU>
<TI>Impact of topical application of autologous platelet-rich gel on medical expenditure and length of stay in hospitals in diabetic patients with refractory cutaneous ulcers</TI>
<SO>Sichuan Da Xue Xue Bao Yi Xue Ban</SO>
<YR>2012</YR>
<VL>43</VL>
<NO>5</NO>
<PG>762-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712781"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712780"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Planinsek-Rucigaj-2007" MODIFIED="2016-03-02 09:24:43 +0000" MODIFIED_BY="[Empty name]" NAME="Planinsek Rucigaj 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-03-02 09:24:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Planinsek Rucigaj T, Lunder T</AU>
<TI>Stimulation of venous leg ulcers with thrombocytic growth factors: A randomised study</TI>
<SO>Proceedings of the 17th Conference of the European Wound Management Association</SO>
<YR>2007</YR>
<PG>Abstract 93</PG>
<ED>Dealey C</ED>
<PB>European Wound Healing Association</PB>
<CY>Glasgow, UK</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712783"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712782"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Senet-2003" MODIFIED="2011-10-29 22:31:20 +0100" MODIFIED_BY="[Empty name]" NAME="Senet 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-29 22:31:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Senet P, Bon FX, Benbunan M, Bussel A, Traineau R, Calvo F</AU>
<TI>Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1342-8</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:31:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712785"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712784"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stacey-2000" MODIFIED="2011-11-28 21:58:46 +0000" MODIFIED_BY="[Empty name]" NAME="Stacey 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-11-28 21:58:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stacey MC, Mata SD, Trengove NJ, Mather CA</AU>
<TI>Randomised double-blind placebo controlled trial of topical autologous platelet lysate in venous ulcer healing</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>3</NO>
<PG>296-301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712787"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712786"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weed-2004" MODIFIED="2016-03-02 09:32:14 +0000" MODIFIED_BY="[Empty name]" NAME="Weed 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-03-02 09:32:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weed B, Davis MDP, Felty CL, Liedl DA, Pineda AA, Moore SB, et al</AU>
<TI>Autologous platelet lysate product versus placebo in patients with chronic leg ulcerations: a pilot study using a randomized, double-blind, placebo-controlled trial</TI>
<SO>Wounds: A Compendium of Clinical Research and Practice</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>9</NO>
<PG>273-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712789"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712788"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Afshari-2005" MODIFIED="2016-03-02 09:32:30 +0000" MODIFIED_BY="[Empty name]" NAME="Afshari 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-03-02 09:32:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Afshari M, Larijani B, Fadayee M, Darvishzadeh F, Ghahary A, Pajoui M, et al</AU>
<TI>Efficacy of topical epidermal growth factor in healing diabetic foot ulcers</TI>
<SO>Therapy</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>5</NO>
<PG>759-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712791"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712790"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aminian-2000" MODIFIED="2016-03-02 09:32:47 +0000" MODIFIED_BY="[Empty name]" NAME="Aminian 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-03-02 09:32:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aminian B, Shams M, Soveyd M, Omrani GR</AU>
<TI>Topical autologous platelet-derived growth factors in the treatment of chronic diabetic ulcers</TI>
<SO>Archives of Iranian Medicine</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>2</NO>
<PG>55-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712793"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712792"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aminian-2011" MODIFIED="2016-05-20 22:57:10 +0100" MODIFIED_BY="[Empty name]" NAME="Aminian 2011" YEAR="">
<REFERENCE MODIFIED="2016-05-20 22:57:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Aminian B, Shams M, Karim-Aghaee B, Soveyd M, Omrani GR</AU>
<TI>Tha role of autologous derived growth factor in the management of decubitus ulcers</TI>
<SO>www.ams.ac.ir/AIM/9922/aminian9922.html</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712795"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712794"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atri-1990" MODIFIED="2011-10-29 22:31:40 +0100" MODIFIED_BY="[Empty name]" NAME="Atri 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-10-29 22:31:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atri SC, Misra J, Bisht D, Misra K</AU>
<TI>Use of homologous platelet factors in achieves total healing of recalcitrant skin ulcers</TI>
<SO>Surgery</SO>
<YR>1990</YR>
<VL>108</VL>
<NO>3</NO>
<PG>508-12</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:31:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712797"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712796"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2011" MODIFIED="2016-03-02 09:38:35 +0000" MODIFIED_BY="[Empty name]" NAME="Carter 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-03-02 09:38:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter MJ, Fylling CP, Li WW, de Leon J, Driver VR, Serena TE, et al</AU>
<TI>Analysis of run-in and treatment data in a wound outcomes registry: Clinical impact of topical platelet-rich plasma gel on healing trajectory</TI>
<SO>International Wound Journal </SO>
<YR>2011</YR>
<VL>8 </VL>
<NO>6 </NO>
<PG>638-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712799"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712798"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cervelli-2012" MODIFIED="2016-03-02 09:38:55 +0000" MODIFIED_BY="[Empty name]" NAME="Cervelli 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-03-02 09:38:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cervelli V, Nicoli F, Spallone D, Verardi S, Sorge R, Nicoli M, et al</AU>
<TI>Treatment of traumatic scars using fat grafts mixed with platelet-rich plasma, and resurfacing of skin with the 1540 nm nonablative laser</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2012  </YR>
<VL>37 </VL>
<NO>1 </NO>
<PG>55-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712801"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712800"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2010" MODIFIED="2016-03-02 09:39:36 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-03-02 09:39:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen TM, Tsai J-C, Burnouf T</AU>
<TI>A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers</TI>
<SO>Dermatologic Surgery</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>4</NO>
<PG>453-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712803"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712802"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crovetti-2004" MODIFIED="2012-01-18 15:29:58 +0000" MODIFIED_BY="[Empty name]" NAME="Crovetti 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-18 15:29:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crovetti G, Martinelli G, Issi M, Barone M, Guizzardi M, Campanati B, et al</AU>
<TI>Platelet gel for healing cutaneous chronic wounds</TI>
<SO>Transfusion and Apheresis Science</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>145&#8211;51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712805"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712804"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danielsen-2008" MODIFIED="2016-05-21 17:01:39 +0100" MODIFIED_BY="[Empty name]" NAME="Danielsen 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-03-02 09:39:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Danielsen P, Jorgensen B, Karlsmark T, Jorgensen LN, Agren MS</AU>
<TI>Effect of topical autologous platelet-rich fibrin versus no intervention on epithelialization of donor sites and meshed split-thickness skin autografts: a randomized clinical trial</TI>
<SO>Plastic and Reconstructive Surgery</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>5</NO>
<PG>1431-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712807"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-21 17:01:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Danielsen P, Jorgensen B, Karlsmark T, Jorgensen LN, Agren MS</AU>
<TI>Effects of locally applied autologous platelet-rich fibrin on split thickness skin graft donor sites</TI>
<SO>Proceedings of the 16th Conference of the European Wound Management Association; Prague, Czech Republic; 18-20 May, 2006. Poster 083</SO>
<CY>Prague</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712808"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712806"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enriquez_x002d_Vega-2012" MODIFIED="2012-09-07 09:39:40 +0100" MODIFIED_BY="[Empty name]" NAME="Enriquez-Vega 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-09-07 09:39:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enriquez-Vega ME, Bobadilla-Flores NO, Rodriguez-Jimenez OA, Guerra-Marquez A, Carrasco-Nava L, Varela-Silva J</AU>
<TI>Platelet rich plasma for the treatment of ischemic ulcers in diabetic patients</TI>
<SO>Revista Mexicana de Angiologia </SO>
<YR>2012</YR>
<VL>40</VL>
<NO>2</NO>
<PG>51-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712810"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712809"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greppi-2011" MODIFIED="2016-03-02 09:45:28 +0000" MODIFIED_BY="[Empty name]" NAME="Greppi 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-03-02 09:45:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greppi N, Mazzucco L, Galetti G, Bona F, Petrillo E, Smacchia C, et al</AU>
<TI>Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients</TI>
<SO>Biologicals</SO>
<YR>2011</YR>
<VL>39 </VL>
<NO>2</NO>
<PG>73-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712812"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712811"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hao-2010" MODIFIED="2016-03-02 09:46:22 +0000" MODIFIED_BY="[Empty name]" NAME="Hao 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-03-02 09:46:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hao T, Zhu J, Hu W, Zhang H, Gao Z, Wen X, et al</AU>
<TI>Autogenous platelet-rich plasma gel with acellular xenogeneic dermal matrix for treatment of deep II degree burns</TI>
<SO>Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>6</NO>
<PG>647-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712814"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712813"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holloway-1993" MODIFIED="2012-01-18 15:30:29 +0000" MODIFIED_BY="[Empty name]" NAME="Holloway 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-18 15:30:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holloway GA, Steed DL, DeMarco MJ, Masumoto T, Moosa HH, Webster MW, et al</AU>
<TI>A randomized,controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, nonhealing diabetic wounds</TI>
<SO>Wounds</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>4</NO>
<PG>198&#8211;206</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712816"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712815"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaiswal-2010" MODIFIED="2016-03-02 09:46:49 +0000" MODIFIED_BY="[Empty name]" NAME="Jaiswal 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-03-02 09:46:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaiswal SS, Gambhir RPS, Agrawal A, Harish S</AU>
<TI>Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers</TI>
<SO>Indian Journal of Surgery</SO>
<YR>2010</YR>
<VL>72</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712818"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712817"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorgensen-2011" MODIFIED="2016-03-02 09:47:04 +0000" MODIFIED_BY="[Empty name]" NAME="Jorgensen 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-03-02 09:47:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorgensen B, Karlsmark T, Vogensen H, Haase L, Lundquist R</AU>
<TI>A pilot study to evaluate the safety and clinical performance of Leucopatch, an autologous, additive-free, platelet-rich fibrin for the treatment of recalcitrant chronic wounds</TI>
<SO>International Journal of Lower Extremity Wounds </SO>
<YR>2011</YR>
<VL>10</VL>
<NO>4</NO>
<PG>218-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712820"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712819"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JPRN_x002d_UMIN000009860" MODIFIED="2016-05-20 22:57:53 +0100" MODIFIED_BY="[Empty name]" NAME="JPRN-UMIN000009860" YEAR="2013">
<REFERENCE MODIFIED="2016-05-20 22:57:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-UMIN000009860</AU>
<TI>Treatment of cutaneous ulcer using platelet-rich plasma</TI>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000009860</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712822"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712821"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JPRN_x002d_UMIN000015689" MODIFIED="2016-05-20 22:58:04 +0100" MODIFIED_BY="[Empty name]" NAME="JPRN-UMIN000015689" YEAR="2014">
<REFERENCE MODIFIED="2016-05-20 22:58:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-UMIN000015689</AU>
<TI>An exploratory clinical trial using platelet-rich plasma in patients with chronic skin ulcers</TI>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000015689</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712824"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712823"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khandelwal-2013" MODIFIED="2016-05-20 22:58:21 +0100" MODIFIED_BY="[Empty name]" NAME="Khandelwal 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-20 22:58:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khandelwal S, Chaudhary P, Poddar DD, Saxena N, Singh RA, Biswal UC</AU>
<TI>Comparative study of different treatment options of grade III and IV diabetic foot ulcers to reduce the incidence of amputations</TI>
<SO>Clinical Practice</SO>
<YR>2013</YR>
<VL>3</VL>
<NO>1</NO>
<PG>e9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712826"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712825"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knighton-1986" MODIFIED="2012-09-07 09:42:22 +0100" MODIFIED_BY="[Empty name]" NAME="Knighton 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-09-07 09:42:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knighton DR, Fiegel VD, Austin LL, Butler EL</AU>
<TI>Classification and treatment of chronic non-healing wounds</TI>
<SO>Annals of Surgery</SO>
<YR>1986</YR>
<VL>204</VL>
<NO>3</NO>
<PG>322-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712828"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712827"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-K_x00f6_veker-1992" MODIFIED="2016-03-02 10:08:18 +0000" MODIFIED_BY="[Empty name]" NAME="Köveker 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-03-02 10:08:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Köveker G, Coerper S, Tolksdorf A, Becker HD</AU>
<TI>Clinical experience with platelet-derived wound healing factors (PDWHF) in venous leg ulcers</TI>
<SO>Proceedings of the 5th Annual Symposium on Advanced Wound Care; 1992, 23-25 April; New Orleans, Lousiana</SO>
<YR>1992</YR>
<PG>63</PG>
<IDENTIFIERS MODIFIED="2010-01-13 08:40:14 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712830"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712829"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2007" MODIFIED="2012-01-18 15:32:11 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-18 15:32:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma B, Cheng DS, Xia ZF, Ben DF, Lu W, Cao ZF, et al</AU>
<TI>Randomized, multicenter, double-blind, and placebo-controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial-thickness burns and skin graft donor site</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>6</NO>
<PG>795&#8211;9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712832"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712831"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Margolis-2001" MODIFIED="2011-10-29 22:32:02 +0100" MODIFIED_BY="[Empty name]" NAME="Margolis 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-10-29 22:32:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA</AU>
<TI>Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>3</NO>
<PG>483-8</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:32:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712834"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712833"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazzuco-2004" MODIFIED="2011-10-29 22:32:11 +0100" MODIFIED_BY="[Empty name]" NAME="Mazzuco 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-10-29 22:32:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazzucco L, Medici D, Serra M, Panizza R, Rivara G, Orecchia S</AU>
<TI>The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study</TI>
<SO>Transfusion</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>7</NO>
<PG>1013-8</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:32:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712836"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712835"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morimoto-2015" MODIFIED="2016-03-02 10:09:31 +0000" MODIFIED_BY="[Empty name]" NAME="Morimoto 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-03-02 10:09:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morimoto N, Kakudo N, Matsui M, Ogura T, Hara T, Suzuki K, et al</AU>
<TI>Exploratory clinical trial of combination wound therapy with a gelatin sheet and platelet-rich plasma in patients with chronic skin ulcers: study protocol</TI>
<SO>BMJ Open</SO>
<YR>2015</YR>
<VL>5</VL>
<NO>5</NO>
<PG>e007733</PG>
<IDENTIFIERS MODIFIED="2015-06-18 08:54:56 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712838"/><IDENTIFIER MODIFIED="2015-06-18 08:54:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmjopen-2015-007733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712837"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00215735" MODIFIED="2016-05-20 22:58:40 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00215735" YEAR="5735">
<REFERENCE MODIFIED="2016-05-20 22:58:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00215735</AU>
<TI>Effect of platelet concentrate in treatment of diabetic ulcers</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00215735</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS MODIFIED="2011-11-28 22:23:00 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712839"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00273234" MODIFIED="2016-05-20 22:58:56 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00273234" YEAR="2006">
<REFERENCE MODIFIED="2016-05-20 22:58:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00273234</AU>
<TI>Clinical effectiveness of topical autologous platelet gel for the treatment of venous ulcers</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00273234</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712842"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712841"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00338702" MODIFIED="2016-05-20 22:59:12 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00338702" YEAR="2006">
<REFERENCE MODIFIED="2016-05-20 22:59:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00338702</AU>
<TI>A randomized, controlled trial of autologous platelet gel treatment in diabetic foot ulcers</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00338702</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712844"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712843"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00762138" MODIFIED="2016-05-20 22:59:29 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00762138" YEAR="2010">
<REFERENCE MODIFIED="2016-05-20 22:59:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00762138</AU>
<TI>The AutoloGel&#8482; Post-Market Surveillance (TAPS) Program</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00762138</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712846"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712845"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00856934" MODIFIED="2016-05-20 22:59:36 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00856934" YEAR="2009">
<REFERENCE MODIFIED="2016-05-20 22:59:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00856934</AU>
<TI>Effect of platelet rich plasma and keratinocyte suspensions on wound healing</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00856934</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712848"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712847"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01553955" MODIFIED="2016-05-20 22:59:45 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01553955" YEAR="2012">
<REFERENCE MODIFIED="2016-05-20 22:59:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01553955</AU>
<TI>Efficacy of training in preparation of platelet rich plasma using a standard centrifuge and manual pipetting methods</TI>
<SO>clinicaltrials.gov/show/NCT01553955</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712850"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712849"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01639144" MODIFIED="2016-05-20 22:59:59 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01639144" YEAR="2012">
<REFERENCE MODIFIED="2016-05-20 22:59:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01639144</AU>
<TI>Use of platelet-rich plasma (PRP) and platelet-poor plasma (PPP) to prevent infection and delayed wound healing after elective foot and ankle surgery in healthy adults</TI>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT016391</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712852"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712851"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02071979" MODIFIED="2016-05-20 23:00:11 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02071979" YEAR="2014">
<REFERENCE MODIFIED="2016-05-20 23:00:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02071979</AU>
<TI>Registry trial of the effectiveness of platelet rich plasma for chronic non-healing wounds (CMS)</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT02071979?term=NCT02071979&amp;rank=1</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712854"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712853"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02088268" MODIFIED="2016-05-20 23:00:20 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02088268" YEAR="2014">
<REFERENCE MODIFIED="2016-05-20 23:00:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02088268</AU>
<TI>Treatment of PRP on diabetes wound</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT02088268?term=NCT02088268&amp;rank=1</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712856"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712855"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niezgoda-2005" MODIFIED="2012-09-07 09:43:17 +0100" MODIFIED_BY="[Empty name]" NAME="Niezgoda 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-09-07 09:43:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP</AU>
<TI>Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers</TI>
<SO>Advances in Skin and Wound Care</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>5</NO>
<PG>258-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712858"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712857"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reutter-1999" MODIFIED="2012-01-18 15:32:22 +0000" MODIFIED_BY="[Empty name]" NAME="Reutter 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-18 15:32:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reutter H, Bort S, Jung MF, Klyscz T, Schippert W, Zuder D, et al</AU>
<TI>Questionable effectiveness of autologous platelet growth factors (PDWHF) in treatment of venous ulcers of the leg</TI>
<SO>Hautarzt</SO>
<YR>1999</YR>
<VL>50</VL>
<NO>12</NO>
<PG>859-65</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:32:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712860"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712859"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saad-Setta-2011" MODIFIED="2016-03-02 10:27:34 +0000" MODIFIED_BY="[Empty name]" NAME="Saad Setta 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-03-02 10:27:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I</AU>
<TI>Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study</TI>
<SO>International Wound Journal</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>3</NO>
<PG>307-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712862"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712861"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saldamalacchia-2004" MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" NAME="Saldamalacchia 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saldalamacchia G, Lapice E, Cuomo V, De Feo E, D'Agostino E, Rivellese AA, et al</AU>
<TI>A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers</TI>
<SO>Nutrition, Metabolism, and Cardiovascular Disease</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>6</NO>
<PG>395-6</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:32:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712864"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712863"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-S_x00e1_nchez-2007" MODIFIED="2016-03-02 10:28:00 +0000" MODIFIED_BY="[Empty name]" NAME="Sánchez 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-28 22:15:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sánchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I</AU>
<TI>Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices</TI>
<SO>American Journal of Sports Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>2</NO>
<PG>245-51</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:32:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712866"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712865"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scevola-2010" MODIFIED="2012-01-11 15:31:39 +0000" MODIFIED_BY="[Empty name]" NAME="Scevola 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-11 15:31:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scevola S, Nicoletti G, Brenta F, Isernia P, Maestri M, Faga A</AU>
<TI>Allogenic platelet gel in the treatment of pressure sores: A pilot study</TI>
<SO>International Wound Journal</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>3</NO>
<PG>184-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712868"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712867"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soula-2012" MODIFIED="2016-03-02 10:35:01 +0000" MODIFIED_BY="[Empty name]" NAME="Soula 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-03-02 10:35:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soula O, Seroussi C, Desort-Henin V, Correia J, Soula R, Soula G, et al</AU>
<TI>Phase I/II results of innovative PDGF-BB formulation with improved compliance at low-cost for the treatment of diabetic foot ulcer</TI>
<SO>EWMA Journal</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>2</NO>
<PG>91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712870"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712869"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steed-1992" MODIFIED="2011-10-29 22:32:53 +0100" MODIFIED_BY="[Empty name]" NAME="Steed 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-10-29 22:32:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW</AU>
<TI>Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1598-604</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:32:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712872"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712871"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steed-1993" MODIFIED="2016-03-02 10:35:19 +0000" MODIFIED_BY="[Empty name]" NAME="Steed 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-03-02 10:35:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steed DL</AU>
<TI>Growth factors in the treatment of diabetic foot ulcers</TI>
<SO>Wounds: A Compendium of Clinical Research and Practice</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>2</NO>
<PG>80-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712874"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712873"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steed--1996" MODIFIED="2016-03-02 10:35:42 +0000" MODIFIED_BY="[Empty name]" NAME="Steed  1996" YEAR="1996">
<REFERENCE MODIFIED="2016-03-02 10:35:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steed DL, Edington HD, Webster MW</AU>
<TI>Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>2</NO>
<PG>230-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712876"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712875"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinbaum-1994" MODIFIED="2011-10-29 23:30:13 +0100" MODIFIED_BY="[Empty name]" NAME="Steinbaum 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-10-29 23:30:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinbaum SS, Cucinell S, Hathaway TK</AU>
<TI>Effects of cryoprecipitate on the healing of chronic wounds</TI>
<SO>Military Medicine</SO>
<YR>1994</YR>
<VL>159</VL>
<NO>2</NO>
<PG>105-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712878"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712877"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarpila-1998" MODIFIED="2016-03-02 10:37:55 +0000" MODIFIED_BY="[Empty name]" NAME="Tarpila 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-03-02 10:37:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tarpila E, Jergovic D, Sjoberg F, Bjornsson A, Abildgard L, Rosseau A</AU>
<TI>Autologous platelet-derived wound healing factors in the treatment of leg ulcers with split-skin grafts</TI>
<SO>European Wound Management Association Conference 1998</SO>
<YR>1998</YR>
<PG>81-5</PG>
<PB>European Wound Management Association</PB>
<CY>Harrogate, UK</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712880"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712879"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-03-02 10:39:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Obolenskiy-2014" MODIFIED="2016-03-02 10:38:51 +0000" MODIFIED_BY="[Empty name]" NAME="Obolenskiy 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-03-02 10:38:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obolenskiy VN, Ermolova A, Laberko A, Semenova TV</AU>
<TI>Efficacy of platelet-rich plasma for the treatment of chronic wounds</TI>
<SO>European Wound Management Association Journal</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>1</NO>
<PG>37-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712882"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712881"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serra-2014" MODIFIED="2016-03-02 10:39:12 +0000" MODIFIED_BY="[Empty name]" NAME="Serra 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-03-02 10:39:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serra R, Grande R, Butrico L, Montemurro R, De Caridi G, Fugetto F, et al</AU>
<TI>Skin grafting and topical application of platelet gel in the treatment of vascular lower extremity ulcers</TI>
<SO>Acta Phlebologica</SO>
<YR>2014</YR>
<VL>15</VL>
<NO>3</NO>
<PG>129-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712884"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712883"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ChiCTR_x002d_TRC_x002d_00000325" MODIFIED="2016-05-20 23:00:33 +0100" MODIFIED_BY="[Empty name]" NAME="ChiCTR-TRC-00000325" YEAR="2009">
<REFERENCE MODIFIED="2016-05-20 23:00:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ChiCTR-TRC-00000325</AU>
<TI>A prospective, randomized, controlled trial of autologous platelet-rich plasma gel to treat refractory dermal ulcer</TI>
<SO>www.chictr.org/en/proj/show.aspx?proj=1072</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712886"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712885"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT2014060415574N3" MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" NAME="IRCT2014060415574N3" YEAR="2014">
<REFERENCE MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT2014060415574N3</AU>
<TI>Effect of platelet dressing on the healing of diabetic foot ulcers compared with routine dressing in patients with diabetic foot ulcers - Shahid Beheshti Hospital</TI>
<SO>www.irct.ir/searchresult.php?id=15574&amp;number=3</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712888"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712887"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN84928077" MODIFIED="2016-05-20 23:00:47 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN84928077" YEAR="2013">
<REFERENCE MODIFIED="2016-05-20 23:00:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN84928077</AU>
<TI>Randomised controlled trial of platelet rich plasma biotherapies in the management of adult patients with recalcitrant and slow healing wounds following major trauma</TI>
<SO>isrctn.com/ISRCTN84928077</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712890"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712889"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JPRN_x002d_UMIN000004840" MODIFIED="2016-05-20 23:00:57 +0100" MODIFIED_BY="[Empty name]" NAME="JPRN-UMIN000004840" YEAR="2011">
<REFERENCE MODIFIED="2016-05-20 23:00:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-UMIN000004840</AU>
<TI>Clinical study for the treatment of chronic wounds using Platelet-rich Plasma</TI>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004840</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712891"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00658983" MODIFIED="2016-05-20 23:01:05 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00658983" YEAR="2009">
<REFERENCE MODIFIED="2016-05-20 23:01:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00658983</AU>
<TI>Autologous platelet enriched gel versus metalloproteinase inhibitor in the healing of chronic lower leg ulcers</TI>
<SO>clinicaltrials.gov/show/NCT00658983</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712894"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712893"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02209662" MODIFIED="2016-05-20 23:01:15 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02209662" YEAR="2014">
<REFERENCE MODIFIED="2016-05-20 23:01:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02209662</AU>
<TI>Safety and efficacy study of APIC-PRP in non-healing diabetic foot ulcers</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT02209662?term=NCT02209662&amp;rank=1</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712896"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712895"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02213952" MODIFIED="2016-05-20 23:01:43 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02213952" YEAR="2014">
<REFERENCE MODIFIED="2016-05-20 23:01:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02213952</AU>
<TI>PRP ULCERAS: Clinical trial phase III (PRPULCERAS)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02213952</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712898"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-20 23:01:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>San Sebastian KM, Lobato I, Hernández I, Burgos-Alonso N, Gomez-Fernandez M, López J, et al</AU>
<TI>Efficacy and safety of autologous platelet rich plasma for the treatment of vascular ulcers in primary care: Phase III study</TI>
<SO>BMC Family Practice</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>211</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712899"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-03-02 10:44:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712897"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02307448" MODIFIED="2016-05-20 23:01:56 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02307448" YEAR="2014">
<REFERENCE MODIFIED="2016-05-20 23:01:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02307448</AU>
<TI>Effectiveness of autologous platelet rich plasma in the treatment of chronic non-healing wounds</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT02307448?term=NCT02307448&amp;rank=1</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712901"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712900"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02312518" MODIFIED="2016-05-20 23:02:07 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02312518" YEAR="2014">
<REFERENCE MODIFIED="2016-05-20 23:02:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02312518</AU>
<TI>Clinical trial of ECLIPSE PRP&#8482; Wound Biomatrix in chronic non-healing venous leg ulcers</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT02312518?term=NCT02312518&amp;rank=1</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2712903"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2712902"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-05-24 09:09:51 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-05-24 09:09:51 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Anitua-2004" MODIFIED="2011-10-29 22:33:41 +0100" MODIFIED_BY="[Empty name]" NAME="Anitua 2004" TYPE="JOURNAL_ARTICLE">
<AU>Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT</AU>
<TI>Autologous platelets as a source of proteins for healing and tissue regeneration</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>1</NO>
<PG>4-15</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:33:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Barbenel-1977" MODIFIED="2012-01-11 15:32:06 +0000" MODIFIED_BY="[Empty name]" NAME="Barbenel 1977" TYPE="JOURNAL_ARTICLE">
<AU>Barbenel JC, Jordan MM, Nicol SM, Clark MO</AU>
<TI>Incidence of pressure-sores in the Greater Glasgow Health Board area</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>2</VL>
<NO>8037</NO>
<PG>548-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2004" MODIFIED="2016-03-02 10:55:21 +0000" MODIFIED_BY="[Empty name]" NAME="Bennett 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bennett G, Dealey C, Posnett J</AU>
<TI>The cost of pressure ulcers in the UK</TI>
<SO>Age and Ageing</SO>
<YR>2004</YR>
<VL>33</VL>
<NO>3</NO>
<PG>230-5</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:33:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Crovetti-2005" MODIFIED="2012-01-18 15:51:51 +0000" MODIFIED_BY="[Empty name]" NAME="Crovetti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Crovetti G, Martinelli G, Issi M, Barone M, Guizzardi M, Campanati B, et al</AU>
<TI>Autologous platelet gel applications during cardiovascular surgery: effect on wound healing</TI>
<SO>Journal of Extra-Corporeal Technology</SO>
<YR>2005</YR>
<VL>37</VL>
<NO>2</NO>
<PG>148-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-la-Torre-2015" MODIFIED="2016-05-20 23:02:14 +0100" MODIFIED_BY="[Empty name]" NAME="de la Torre 2015" TYPE="OTHER">
<AU>de la Torre J</AU>
<TI>Chronic wounds</TI>
<SO>emedicine.medscape.com/article/1298452-overview#a1</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2015-03-25 15:38:47 +0000" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebbeskog-1996" MODIFIED="2011-10-29 22:34:05 +0100" MODIFIED_BY="[Empty name]" NAME="Ebbeskog 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ebbeskog B, Lindholm C, Ohman S</AU>
<TI>Leg and foot ulcer patients. Epidemiology and nursing care in an urban population in south Stockholm, Sweden</TI>
<SO>Scandinavian Journal of Primary Health Care</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>4</NO>
<PG>238-43</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:34:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2002" MODIFIED="2012-09-07 09:51:26 +0100" MODIFIED_BY="[Empty name]" NAME="Edwards 2002" TYPE="COCHRANE_REVIEW">
<AU>Edwards J, Stapley S</AU>
<TI>Debridement of diabetic foot ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-09-07 09:51:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-09-07 09:51:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003556.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2005" MODIFIED="2016-05-20 23:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="FDA 2005" TYPE="OTHER">
<AU>US Dept of Health and Human Services, Food and Drug Administration (FDA)</AU>
<TI>Guidance for industry: chronic cutaneous ulcer and burn wounds-developing products for treatment</TI>
<SO>www.fda.gov/cber/guidelines.htm</SO>
<YR>(accessed 2 March 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez-2000" MODIFIED="2011-10-29 22:34:20 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzalez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez ER, Oley MA</AU>
<TI>The management of lower-extremity diabetic ulcers</TI>
<SO>Managed Care Interface</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>11</NO>
<PG>80-7</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:34:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2003" MODIFIED="2016-03-02 10:56:54 +0000" MODIFIED_BY="[Empty name]" NAME="Graham 2003" TYPE="JOURNAL_ARTICLE">
<AU>Graham ID, Harrison MB, Nelson EA, Lorimer K, Fisher A</AU>
<TI>Prevalence of lower-limb ulceration: a systematic review of prevalence studies</TI>
<SO>Advances in Skin and Wound Care</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>6</NO>
<PG>305-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grey-2006" MODIFIED="2011-11-28 23:49:37 +0000" MODIFIED_BY="[Empty name]" NAME="Grey 2006" TYPE="JOURNAL_ARTICLE">
<AU>Grey JE, Harding KG, Enoch S</AU>
<TI>Pressure ulcers</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<NO>7539</NO>
<PG>472-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2012-08-23 09:48:33 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2012-04-12 00:21:57 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2016-05-20 23:02:30 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaltenthaler-2001" MODIFIED="2011-10-29 22:34:30 +0100" MODIFIED_BY="[Empty name]" NAME="Kaltenthaler 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kaltenhaler E, Whitfield, Walters SJ, Akehurst RL, Paisley S</AU>
<TI>UK, USA and Canada: how do their pressure ulcer prevalence and incidence data compare?</TI>
<SO>Journal of Wound Care</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>1</NO>
<PG>530-5</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:34:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Knighton-1988" MODIFIED="2011-10-29 22:34:42 +0100" MODIFIED_BY="[Empty name]" NAME="Knighton 1988" TYPE="JOURNAL_ARTICLE">
<AU>Knighton DR, Doucette M, Fiegel VD, Ciresi K, Butler E, Austin L</AU>
<TI>The use of platelet derived wound healing formula in human clinical trials</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1988</YR>
<VL>266</VL>
<PG>319-29</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:34:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2004" MODIFIED="2012-01-18 15:52:12 +0000" MODIFIED_BY="[Empty name]" NAME="Kumar 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kumar RN, Gupchup GV, Dodd MA, Shah B, Iskedjian M, Einarson TR, et al</AU>
<TI>Direct health care costs of 4 common skin ulcers in New Mexico Medicaid fee-for-service patients</TI>
<SO>Advances in Skin and Wound Care</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>3</NO>
<PG>143-9</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:34:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lacci-2010" MODIFIED="2012-02-16 09:30:10 +0000" MODIFIED_BY="[Empty name]" NAME="Lacci 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lacci KM, Dardik A</AU>
<TI>Platelet-rich plasma: support for its use in wound healing</TI>
<SO>Yale Journal of Biology and Medicine</SO>
<YR>2010</YR>
<VL>83</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langedam-2013" MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" NAME="Langedam 2013" TYPE="JOURNAL_ARTICLE">
<AU>Langendam MW, Aki EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ</AU>
<TI>Assessing and presenting summaries of evidence in Cochrane Reviews</TI>
<SO>Systematic Reviews</SO>
<YR>2013</YR>
<VL>2</VL>
<PG>81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langer-2003" MODIFIED="2011-11-20 14:52:34 +0000" MODIFIED_BY="[Empty name]" NAME="Langer 2003" TYPE="COCHRANE_REVIEW">
<AU>Langer G, Schloemer G, Knerr A, Kuss O, Behrens J</AU>
<TI>Nutritional interventions for preventing and treating pressure ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-11-20 14:52:34 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-11-20 14:52:34 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003216"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lavery-2003" MODIFIED="2011-10-29 22:35:45 +0100" MODIFIED_BY="[Empty name]" NAME="Lavery 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ</AU>
<TI>Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>5</NO>
<PG>1435-8</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:35:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2016-05-20 23:02:53 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mao-2010" MODIFIED="2012-01-11 15:32:33 +0000" MODIFIED_BY="[Empty name]" NAME="Mao 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mao CL, Rivet AJ, Sidora T, Pasko MT</AU>
<TI>Update on pressure ulcer management and deep tissue injury</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2010</YR>
<VL>44</VL>
<NO>2</NO>
<PG>325-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marlovits-2004" MODIFIED="2011-11-28 23:51:36 +0000" MODIFIED_BY="[Empty name]" NAME="Marlovits 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marlovits S, Mousavi M, Gäbler C, Erdös J, Vécsei V</AU>
<TI>A new simplified technique for producing platelet-rich plasma: A short technical note</TI>
<SO>European Spine Journal</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>102-6</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:35:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Martinez_x002d_Zapata-2009" MODIFIED="2016-03-02 10:58:32 +0000" MODIFIED_BY="[Empty name]" NAME="Martinez-Zapata 2009" TYPE="JOURNAL_ARTICLE">
<AU>Martínez-Zapata MJ, Martí-Carvajal A, Solà I, Bolibar I, Angel Expósito J, Rodriguez L, et al</AU>
<TI>Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review</TI>
<SO>Transfusion</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>1</NO>
<PG>44-56</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:36:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Marx-2004" MODIFIED="2016-03-02 10:58:51 +0000" MODIFIED_BY="[Empty name]" NAME="Marx 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marx RE</AU>
<TI>Platelet-rich plasma: evidence to support its use</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>4</NO>
<PG>489-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moffat-2004" MODIFIED="2012-09-06 19:38:11 +0100" MODIFIED_BY="[Empty name]" NAME="Moffat 2004" TYPE="JOURNAL_ARTICLE">
<AU>Moffat CJ, Franks PJ, Doherty DC, Martin R, Blewett R, Ross F</AU>
<TI>Prevalence of leg ulcers in a London population</TI>
<SO>QJM</SO>
<YR>2004</YR>
<VL>97</VL>
<NO>7</NO>
<PG>431-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2016-05-21 15:54:51 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG</AU>
<TI>PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</TI>
<SO>J Clin Epidemiol</SO>
<YR>2009</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1006-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2005" MODIFIED="2011-11-20 14:54:37 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2005" TYPE="COCHRANE_REVIEW">
<AU>Moore ZE, Cowman S</AU>
<TI>Wound cleansing for pressure ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-11-20 14:54:37 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-11-20 14:54:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004983.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Munirah-2007" MODIFIED="2016-03-02 10:59:08 +0000" MODIFIED_BY="[Empty name]" NAME="Munirah 2007" TYPE="JOURNAL_ARTICLE">
<AU>Munirah S, Samsudin OC, Chen HC, Sharifah Salmah SH, Aminuddin BS, Ruszymah BHI</AU>
<TI>Articular cartilage restoration in load-bearing osteochondral defects by implantation of autologous chondrocyte-fibrin constructs</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>2007</YR>
<VL>89</VL>
<NO>8</NO>
<PG>1099-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2009a" MODIFIED="2012-09-07 10:00:23 +0100" MODIFIED_BY="[Empty name]" NAME="O'Meara 2009a" TYPE="JOURNAL_ARTICLE">
<AU>O'Meara S, Tierney J, Cullum N, Bland JM, Franks PJ, Mole T, et al</AU>
<TI>Four layer bandage compared with short stretch bandage for venous leg ulcers: systematic review and meta-analysis of randomised controlled trials with data from individual patients</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>b1344</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:36:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2009b" MODIFIED="2012-09-07 10:05:50 +0100" MODIFIED_BY="[Empty name]" NAME="O'Meara 2009b" TYPE="COCHRANE_REVIEW">
<AU>O'Meara S, Cullum NA, Nelson EA</AU>
<TI>Compression for venous leg ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-09-07 10:05:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-09-07 10:05:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000265.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reiber-1996" MODIFIED="2011-11-28 23:53:44 +0000" MODIFIED_BY="[Empty name]" NAME="Reiber 1996" TYPE="JOURNAL_ARTICLE">
<AU>Reiber GE</AU>
<TI>The epidemiology of diabetic foot problems</TI>
<SO>Diabetic Medicine</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>6-11</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:37:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Reiber-2001" MODIFIED="2009-02-25 18:33:26 +0000" MODIFIED_BY="[Empty name]" NAME="Reiber 2001" TYPE="BOOK_SECTION">
<AU>Reiber GE</AU>
<TI>Epidemiology of foot ulcers and amputations in the diabetic foot</TI>
<SO>The Diabetic Foot</SO>
<YR>2001</YR>
<PG>13-32</PG>
<ED>Bowker JH, Pfeifer MA</ED>
<PB>Mosby</PB>
<CY>St Louis, Mo</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-05-23 10:49:17 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1993" MODIFIED="2011-10-29 23:23:43 +0100" MODIFIED_BY="[Empty name]" NAME="Robinson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Robinson CJ</AU>
<TI>Growth factors: therapeutic advances in wound healing</TI>
<SO>Annals of Medicine</SO>
<YR>1993</YR>
<VL>25</VL>
<PG>535-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodrigues-2006" MODIFIED="2012-09-07 09:57:30 +0100" MODIFIED_BY="[Empty name]" NAME="Rodrigues 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigues I, Mégie MF</AU>
<TI>Prevalence of chronic wounds in Quebec home care: an exploratory study</TI>
<SO>Ostomy/Wound Management</SO>
<YR>2006</YR>
<VL>52</VL>
<NO>5</NO>
<PG>46-8, 50, 52-7</PG>
<IDENTIFIERS MODIFIED="2011-10-29 22:37:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Scriven-1998" MODIFIED="2016-05-20 23:03:05 +0100" MODIFIED_BY="[Empty name]" NAME="Scriven 1998" TYPE="JOURNAL_ARTICLE">
<AU>Scriven JM, Taylor LE, Wood AJ, Bell PRF, Naylor AR, London NJM </AU>
<TI>A prospective randomised trial of four-layer versus short stretch compression bandages for the treatment of venous leg ulcers </TI>
<SO>Annals of the Royal College of Surgeons of England</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>3</NO>
<PG>215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2015" MODIFIED="2016-05-24 09:09:51 +0100" MODIFIED_BY="[Empty name]" NAME="SIGN 2015" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>Search filters</TI>
<SO>www.sign.ac.uk/methodology/filters.html#random</SO>
<YR>(accessed 23 May 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-2005" MODIFIED="2012-01-11 15:33:30 +0000" MODIFIED_BY="[Empty name]" NAME="Singh 2005" TYPE="JOURNAL_ARTICLE">
<AU>Singh N, Armstrong DG, Lipsky BA</AU>
<TI>Preventing foot ulcers in patients with diabetes</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>2</NO>
<PG>217-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spencer-2000" MODIFIED="2011-11-20 16:18:35 +0000" MODIFIED_BY="[Empty name]" NAME="Spencer 2000" TYPE="COCHRANE_REVIEW">
<AU>Spencer S</AU>
<TI>Pressure relieving interventions for preventing and treating diabetic foot ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-11-20 16:18:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-11-20 16:18:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002302"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2016-05-20 23:03:28 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting bias</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<CY>Available from www.cochrane-handbook.org</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vas-2008" MODIFIED="2016-03-02 11:05:56 +0000" MODIFIED_BY="[Empty name]" NAME="Vas 2008" TYPE="JOURNAL_ARTICLE">
<AU>Vas J, Modesto M, Mendez C, Perea-Milla E, Aguilar I, Carrasco-Lozano JM, et al</AU>
<TI>Effectiveness of acupuncture, special dressings and simple, low-adherence dressings for healing venous leg ulcers in primary healthcare: study protocol for a cluster-randomized open-labeled trial</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>29</PG>
<IDENTIFIERS MODIFIED="2012-08-23 10:00:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-08-23 10:00:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1472-6882-8-29"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Villela-2010" MODIFIED="2016-03-02 11:06:08 +0000" MODIFIED_BY="[Empty name]" NAME="Villela 2010" TYPE="JOURNAL_ARTICLE">
<AU>Villela DL, Santos VL</AU>
<TI>On the use of platelet-rich plasma for diabetic ulcer: a systematic review</TI>
<SO>Growth Factors </SO>
<YR>2010</YR>
<VL>28</VL>
<NO>2</NO>
<PG>111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yuan-2009" MODIFIED="2011-11-29 00:04:11 +0000" MODIFIED_BY="[Empty name]" NAME="Yuan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Yuan NB, Long Y, Zhang XX, Ran XW</AU>
<TI>Study on the mechanism of autologous platelet-rich gel to treat the refractory diabetic dermal</TI>
<SO>Sichuan Da Xue Xue Bao Yi Xue Ban</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>2</NO>
<PG>292-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-05-20 23:03:56 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Martinez_x002d_Zapata-2008" MODIFIED="2016-05-20 23:03:44 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez-Zapata 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Exposito JA, Bolivar I, Rodríguez L, et al</AU>
<TI>Autologous platelet-rich plasma for treating chronic wounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-05-20 02:49:40 +0100" MODIFIED_BY="Clare Dooley"><IDENTIFIER MODIFIED="2016-05-20 02:45:24 +0100" MODIFIED_BY="Clare Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD006899.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martinez_x002d_Zapata-2012" MODIFIED="2016-05-20 23:03:56 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez-Zapata 2012" TYPE="COCHRANE_REVIEW">
<AU>Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Expósito JA, Bolíbar I, Rodríguez L, et al</AU>
<TI>Autologous platelet-rich plasma for treating chronic wounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2016-05-20 02:49:16 +0100" MODIFIED_BY="Clare Dooley"><IDENTIFIER MODIFIED="2016-05-20 02:49:13 +0100" MODIFIED_BY="Clare Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD006899.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-05-23 10:47:53 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-05-20 23:16:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-05-20 01:38:33 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Anitua-2008">
<CHAR_METHODS MODIFIED="2016-05-19 02:02:46 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised open-label controlled pilot trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: Hospital</P>
<P>Country: Spain</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the patient</P>
<P>Follow-up: 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:04:51 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 15 (Group 1 experimental: 8 and Group 2 control: 7)<BR/>Number ulcers assessed: 15<BR/>Wound aetiology: mixed 10, venous ulcers 4, pressure ulcers and 1 other<BR/>Age (mean and SD): Group 1: 45 (20) Group 2: 61 (16)<BR/>Sex: 7 F/8 M<BR/>
<B>Inclusion criteria</B>: Adults of both sexes with chronic ( &gt; 4 weeks) skin ulcers of less than 12 cm in diameter or Wagner grade II/III<BR/>
<B>Exclusion criteria</B>: ulcer of arterial origin; infection; insulin-dependent diabetes mellitus; vasculitis; lupus; cryoglobulinemia; haematological abnormality; epilepsy; solid tumour; anticoagulants; immunosuppressant drugs; anaemia; pregnant women or inadequate birth control</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:10:55 +0100" MODIFIED_BY="Clare Dooley">
<P>At baseline all patients received conventional treatment (cleansing, debridement, and wet cure with physiological saline and sterile gauzes) After randomisation it was not reported if the participants randomised to the experimental group continued to receive the conventional treatment in addition to the weekly treatment of autologous PRGF</P>
<P>Experimental group: Autologous PRGF</P>
<P>
<BR/>Control group: Conventional treatment</P>
<P>
<BR/>Length of treatment: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-20 01:38:33 +0100" MODIFIED_BY="Clare Dooley">
<P>Mean percentage of surface healed*<BR/>Lesion area*<BR/>Adverse events<BR/>*Measures were made from photographic records using Mouseyes software</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:06:35 +0100" MODIFIED_BY="Clare Dooley">
<P>Funding: The Biotechnology Institute provided the PRGF System® device. Baseline characteristics were not similar between groups. Patients in the control group were older, had longer ulcer duration and larger wound sizes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-20 04:43:11 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Driver-2006">
<CHAR_METHODS MODIFIED="2016-05-20 04:43:11 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised double-blind placebo controlled trial</P>
<P>Number of participant centres: 14</P>
<P>Setting: wound care physicians&#8217; and podiatrists&#8217; offices, outpatient wound care centres, a university-based college of podiatric medicine clinic, Veteran&#8217;s Administration wound care clinics, and an Army hospital limb preservation programme</P>
<P>Country: USA</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the patient</P>
<P>Follow-up: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:11:22 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 72 (40 treatment arm and 32 control arm)</P>
<P>Wound aetiology: Diabetic foot ulcers</P>
<P>Age, mean (SD) years: 56.4 (10.2) treatment arm and 57.5 (9.1) control arm</P>
<P>Sex: 59 M/13 F</P>
<P>
<B>Inclusion criteria</B>: Adults of both sexes with diabetes mellitus 1 or 2, and a chronic skin ulcer with evolution of at least 4 weeks. Hb A1c &lt; 12; foot ulcer; wound area measurement between 0.5 cm<SUP>2</SUP> and 20 cm<SUP>2</SUP>, inclusive. Ulcer had to be clinically non-infected</P>
<P>
<B>Exclusion criteria</B>: Patient currently enrolled in another clinical trial. Non-diabetic ulcers. Ulcer had exposed tendons, ligaments, muscle, or bone. Gangrene or osteomyelitis. Acute Charcot foot. Patient currently receiving or having received radiation, chemotherapy, IV antibiotic/antimicrobial agents, or growth factor therapy. Serum albumin level &lt; 2.5 g/dL, Hb &lt; 10.5 mg/dL, or platelet count &lt; 100 x 10<SUP>9</SUP>/L. Renal dialysis, immune insufficiency, platelet disorders, eating/ nutritional, haematological, collagen vascular disease, rheumatic disease, or bleeding disorders. History of peripheral vascular repair. Surgical correction (other than debridement) required for ulcer to heal. Any situation that could interfere with compliance of the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:11:55 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: To obtain the PRP, 20 mL of blood was extracted from the patient. This blood was centrifuged to separate PRP and was administered as gel (AutoloGel®, Cytomedix, Inc, Rockville, Md) in the treatment group</P>
<P>Control group: Wounds in the control group were treated with a saline gel (placebo) (Normlgel®,Mölnlycke Health Care, Norcross, Ga).</P>
<P>In both groups the gel was covered with a contact layer dressing, followed by the non-absorbent side of a foam dressing, and finally, the absorbent side of a foam dressing. Frequency of administration: twice weekly at 3- or 4-day intervals. Length of treatment: 12 weeks or until the ulcer was healed. Follow-up post-treatment: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:16:46 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcome: Healing (100% epithelisation) at the end of study<BR/>Secondary outcomes: Time to healing; percent change in wound area at end-of-study visit from baseline; percent change in wound volume at end-of-study visit from baseline; area closure rate per day at end-of-study visit; volume closure rate per day at end-of-study visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:18:03 +0100" MODIFIED_BY="Clare Dooley">
<P>Funding: Not specified, but Cytomedix Inc participated and provided the machine used to centrifuge the blood for PRP preparation. Basal characteristics of the patients were similar between groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-20 23:16:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kakagia-2007">
<CHAR_METHODS MODIFIED="2016-05-19 02:19:45 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised controlled trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: Hospital</P>
<P>Country: Greece</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the patient</P>
<P>Follow-up: 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-20 23:16:22 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised (patients): 51</P>
<P>Wound aetiology: Diabetic</P>
<P>Age: 58-61 years</P>
<P>Sex: 29 F/22 M</P>
<P>
<B>Inclusion criteria</B>: Diabetic patients with skin wounds that had been present for at least 3 months, &gt; 2.5 cm<SUP>2 </SUP>of area after debridement.</P>
<P>
<B>Exclusion criteria</B>: Previous treatment with vacuum, hyperbaric oxygen immunosuppressive agents, radiation or growth factors; anaemia; cellulitis; venous  stasis; pulses &lt; 40; osteomyelitis; malignancy in the wound; difficult to follow-up</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:21:56 +0100" MODIFIED_BY="Clare Dooley">
<P>Group I: Protease-modulating matrix (Promogran<SUP>®</SUP>); Group II: PRP; Group III: protease-modulating matrix plus PRP. The PRP was prepared by the Gravitational Platelet Separation System. All ulcers were sharply debrided prior to the application of study treatment and covered by vapour permeable film (Tegaderm<SUP>®</SUP> 3M) after the application of study treatment. The ulcers were assessed weekly. Length of treatment: not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:22:15 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcomes: Percentage change in ulcer dimensions (length, width and depth) with respect to baseline<BR/>Secondary outcomes: Complete healing at 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-20 04:39:21 +0100" MODIFIED_BY="Clare Dooley">
<P>We extracted only the data for the groups receiving protease-modulating matrix alone (Group I) and protease-modulating matrix with PRP (Group III). The change in wound dimension data were wrongly analysed (they did not account for baseline values; baseline values of length, width and depth were not presented). Consequently we did not analyse these data</P>
<P>Funding was not specified. At baseline the comparison groups had similar characteristics</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 02:30:55 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Knighton-1990">
<CHAR_METHODS MODIFIED="2016-05-19 02:23:51 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised double-blind placebo controlled cross-over trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: Wound Healing Clínic, Department of Surgery</P>
<P>Country: USA</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the ulcer</P>
<P>Follow-up: 16 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:25:11 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 32 (16 in each group). Number of patients analysed: 13 in PRP group and 11 in control group</P>
<P>Number of patients by wound aetiology: 10 venous diseases, 9 diabetic, 4 occlusive peripheral vascular diseases, and 1 vasculitis. One ulcer in each group affected the bone</P>
<P>Number of ulcers assessed: 21 in the experimental group and 13 in the control group</P>
<P>Age (mean and SD): 64 (±8) years treatment group and 62 (±10) years control group</P>
<P>Sex: Both</P>
<P>
<B>Inclusion criteria</B>: Adults with a chronic skin leg ulcer, an evolution of at least 8 weeks and a normal platelet number count<BR/>
<B>Exclusion criteria</B>: Failure to follow-up the protocol, amputation of the extremity, and extensive surgical intervention needed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:25:36 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: Autologous platelet-derived wound healing formula added to mycrocrystalline collagen (Avitene®)</P>
<P>Control group: placebo (platelet buffer solution added to mycrocrystalline collagen)</P>
<P>All ulcers were sharply debrided prior to the application of study treatment. The patient applied the treatment and used a twice-daily wound dressing protocol. The experimental treatment or placebo was applied and covered by one layer petrolatum-impregnated gauze, followed by sized gauze sponges for 12 hours. Sulfadiazine was then applied for the next 12 hours. Length of treatment: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:26:03 +0100" MODIFIED_BY="Clare Dooley">
<P>Total epithelialisation of the wound. Time to 100% of epithelialisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:30:55 +0100" MODIFIED_BY="Clare Dooley">
<P>At baseline the experimental group had longer wound duration than the control group (119 weeks versus 47 weeks). The sample size was not specified in the paper. There was no mention of the effect of cluster when the unit of analysis was the ulcer and not the patient. Analysis was per protocol</P>
<P>This clinical trial was supported by a grant from the Veterans Administration and from Cura Tech Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 02:30:16 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Krupski-1991">
<CHAR_METHODS MODIFIED="2016-05-19 02:27:34 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised double-blind placebo controlled trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: San Francisco Department of Veterans Affairs Medical Center</P>
<P>Country: USA.</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the ulcer</P>
<P>Follow-up: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:28:37 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 18 (10 in experimental group and 8 in control group)</P>
<P>Number ulcers: 26</P>
<P>Wound aetiology: Mixed 78% diabetic, 72% occlusive peripheral vascular disease, and 28% venous disease. Age (mean and SD): 66 (± 5) years treatment group and 67 (± 4.5) years control group</P>
<P>Sex: Both<BR/>
<B>Inclusion criteria</B>: Adult men, with a chronic skin leg ulcer and an evolution of at least 8 weeks<BR/>
<B>Exclusion criteria</B>: Platelet count &lt; 100.000/mm<SUP>3</SUP>; tcPO<SUB>2 </SUB>&lt; 20 mmHg; infection; inability to remain non-weight-bearing; terminal disease; &gt; 100 cm<SUP>2 </SUP>of area wound or &gt; 50,000 mm<SUP>3</SUP> in volume wound; &gt; 3 chronic wounds; allergy; non-compliance with the protocol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:29:42 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: PRP topical solution</P>
<P>Control group: saline solution (placebo) every 12 hours</P>
<P>All ulcers were sharply debrided prior to the application of study treatment. The treatment was applied every 12 hours. The experimental treatment or placebo was applied and covered by a 4 x 4 gauze and a petrolatum-impregnated gauze, followed by a gauze wrap dressing Length of treatment: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:29:47 +0100" MODIFIED_BY="Clare Dooley">
<P>Total epithelialisation of the wound, total wound area, wound volume, rate of healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:30:16 +0100" MODIFIED_BY="Clare Dooley">
<P>The sample size was not specified in the paper. There was no mention of the effect of cluster when the unit of analysis was the ulcer and not the patient. Analysis was per protocol. At baseline, the wound area was larger in the placebo group than in the experimental group. The PRP group had a greater number (17 versus 9) of wounds and wound duration was longer (6.2 versus 4.3 month) than in the placebo group Supported by the Department of Veterans Affairs Research Service and a grant of Curative Technologies Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-20 00:24:30 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Li-2012">
<CHAR_METHODS MODIFIED="2016-05-19 02:32:34 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Prospective randomised controlled trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: Department of Diabetic Ulcers Centre in West China Hospital of Sichuan University</P>
<P>Country: China</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the ulcer</P>
<P>Follow-up: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:32:56 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 117 (59 in experimental group and 58 in control group)</P>
<P>Number ulcers: 117</P>
<P>Wound aetiology: diabetic ulcer</P>
<P>Age: not reported</P>
<P>Sex: Both (75 men/42 women)<BR/>
<B>Inclusion criteria</B>: Duration of ulcers before been admitted to hospital &gt; 2 weeks</P>
<P>After 2 weeks treatment in hospital, including blood sugar/blood pressure control; anticoagulation; anti-infection; standard usual care for ulcers (debridement, drainage, pressure reduce, dressing change), there is no improvement &#8211; defined as &#8220;non-healing diabetic ulcers&#8221;</P>
<P>Written consent from patients/patients family</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-20 00:24:30 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: Autologous platelet gel + usual care</P>
<P>Autologous platelet gel was prepared by applying two-level manual differential centrifugation and is mixed with thrombin-calcium at 10:1 ratio. Autologous platelet gel treatment every 2 weeks</P>
<P>Suile Wound Dressing changes every 3 days and photographed</P>
<P>Control group: Usual care (debridement; a Suile Wound Dressing (Hedonist Biochemical Technologies Co. Ltd, USA); a secondary dressing. The Suile Wound Dressing was changed every 3 days and photographed)</P>
<P>Length of treatment: 12 weeks or until ulcer healed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:34:18 +0100" MODIFIED_BY="Clare Dooley">
<P>Complete healing</P>
<P>Length of healing</P>
<P>Expenditure</P>
<P>Length of stay in the hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-26 15:20:05 +0000" MODIFIED_BY="[Empty name]">
<P>This paper is in Chinese</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 02:38:20 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<CHAR_METHODS MODIFIED="2016-05-19 02:35:26 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised controlled trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: Dermatology department</P>
<P>Country: Slovenia</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the patient</P>
<P>Follow-up: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:35:53 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 10 (5 patients in each group)</P>
<P>Number ulcers: 22</P>
<P>Wound aetiology: chronic venous insufficiency</P>
<P>Age: Not reported</P>
<P>Sex: Not reported<BR/>
<B>Inclusion criteria</B>: Patients with a venous leg ulcer<BR/>
<B>Exclusion criteria</B>: Acute wound infection and &gt; 30 cm<SUP>2</SUP> of ulcer area</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:37:53 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: Autologous platelet releasate obtained from 80 mL of the patient's own blood and prepared by the GPS<SUP> TM</SUP> System. The product was mixed with thrombin and 1M Cl<SUB>2</SUB>Ca. The PRP gel was applied to the ulcer that was covered with antibiotic and collagen dressing every 2 days</P>
<P>Control group: the ulcer was treated with antibiotic and collagen dressing with 1M Cl<SUB>2</SUB>Ca every 2 days</P>
<P>All patients received compression therapy with long-stretch therapy. Length of treatment: not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:38:11 +0100" MODIFIED_BY="Clare Dooley">
<P>Reduction in ulcer size</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:38:20 +0100" MODIFIED_BY="Clare Dooley">
<P>This is an abstract. There were no data with SD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-20 01:38:43 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Senet-2003">
<CHAR_METHODS MODIFIED="2016-05-19 02:38:47 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised double-blind placebo controlled trial</P>
<P>Number of participating  centres: 1</P>
<P>Setting: Hospital</P>
<P>Country: France</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the patient</P>
<P>Follow-up: 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-20 01:37:20 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 15 (8 in the experimental group and 7 in the control group)</P>
<P>Number ulcers: 1 per patient</P>
<P>Wound aetiology: Chronic venous leg ulcer</P>
<P>Age (mean): 72.3 years Sex: 6 F/7 M</P>
<P>
<B>Inclusion criteria</B>: Adults of both sexes with chronic skin venous leg ulcers of at least 2 months duration; ulcer size between 3 and 50 cm<SUP>2</SUP>; established venous disease; homolateral ankle-brachial index &gt; 0.8 or peripheral pulses present; normal platelet count, Hb &gt; 11g/dL and albumin &gt; 35 g/L <BR/>
<B>Exclusion criteria</B>: pregnancy; allergy to hydrocolloid dressing; systemic diseases; treatment with cytostatics or corticosteroids; ulcers with exposed tendons or bones; infected ulcers; poor compliance with compression therapy; positive serology to lues, Hepatitis B, Hepatitis C, HIV, Human T Lymphocyte virus I and II. Diabetes if the concentration of blood glucose was &gt; 2 g/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:39:55 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: topical use of frozen autologous platelet suspension in saline solution</P>
<P>Control group: saline solution (placebo)</P>
<P>Patients received standard topical and pressure treatment. The frequency of treatment was 3 times/week at hospital. Length of treatment: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-20 01:38:43 +0100" MODIFIED_BY="Clare Dooley">
<P>Ulcer healing, rate of ulcer healing and adverse effects. Other outcomes: local expression of the vascular endothelial growth factor; local expression of the keratocytes growth factor; local expression of the interleukin-8; local expression of the metalloproteinase-1 tissular inhibitor</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:40:11 +0100" MODIFIED_BY="Clare Dooley">
<P>Supported by the Institut National de la Santé et de la Reserche Medicale and Coloplast. Both groups were homogeneous at baseline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 02:41:36 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Stacey-2000">
<CHAR_METHODS MODIFIED="2016-05-19 02:40:43 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised double-blind placebo controlled trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: Departament of Surgery</P>
<P>Country: Australia</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the patient</P>
<P>Follow-up: 9 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:41:09 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 86 (42 in the experimental group and 44 in the control group)</P>
<P>Number ulcers: 1 per patient</P>
<P>Wound aetiology: Chronic venous leg ulcer</P>
<P>Age (median): 70 years Sex: 50 F/36 M</P>
<P>
<B>Inclusion criteria</B>: Adults of both sexes with demonstrated chronic venous ulcer<BR/>
<B>Exclusion criteria</B>: Any patient who did not meet the inclusion criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:41:27 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: growth factors obtained from autologous platelet lysate</P>
<P>Control group: placebo</P>
<P>Topical application 2 times a week associated with gauze and pressure dressing. Length of treatment: until ulcer healing or for a 9-month period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:41:30 +0100" MODIFIED_BY="Clare Dooley">
<P>Ulcer healing. Time to ulcer healing. Platelet growing factor and epidermic growing factor concentrations in the platelet lysate. Mitogenic ability of the platelet lysate in a fibroblast culture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:41:36 +0100" MODIFIED_BY="Clare Dooley">
<P>Both groups were homogeneous at baseline. The study was supported by The Medical Research Foundation of Western of Australia and Beiersdorf A.G. (Germany)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-20 04:40:05 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Weed-2004">
<CHAR_METHODS MODIFIED="2016-05-19 02:42:13 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised double-blind placebo controlled trial</P>
<P>Number of participant centres: 1</P>
<P>Setting: Dermatology department</P>
<P>Country: USA</P>
<P>Unit of randomisation: the patient</P>
<P>Unit of analysis: the patient</P>
<P>Follow-up: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:43:08 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 26 (15 experimental group and 11 control group)</P>
<P>Number of ulcers assessed: 1 per patient</P>
<P>Wound aetiology: Mixed 9; multifactorial 7; neurotrophic 5; venous ulcers 3; traumatic 1; idiopathic and 1 pressure ulcer</P>
<P>Age (mean and SD): 67.6 (11.9) years (experimental group) and 57.8 (18.2) years (placebo group)</P>
<P>Sex: 11 F/15 M</P>
<P>
<B>Inclusion criteria</B>: Adults of both sexes with a chronic skin leg ulcer and an evolution of at least 8 weeks. Arterial, venous, neuropathic or vascular (small-vessel) ulcers. Hb &gt; 9.0g/dL and a platelet count &gt; 100 x 10<SUP>9</SUP>/L</P>
<P>
<B>Exclusion criteria</B>: Angina pectoris; symptomatic hypotension; myocardial infarction; class III or IV congestive heart failure; clotting function disorders; or a platelet  count &lt; 100 x 10<SUP>9</SUP>/L; osteomyelitis; wounds caused by burns or irradiation; wounds &gt; 100 cm<SUP>2</SUP>; and pregnancy or lactation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-20 04:40:05 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: Autologous platelet lysate combined with collagen</P>
<P>Control group: Platelet-poor plasma combined with collagen (placebo group) for the first 12 weeks of therapy. After 12 weeks, there was a washout period of two weeks. During this washout period, patients applied only normal saline-moistened gauze twice-daily to their ulcerations.</P>
<P>Patients whose ulcers had not healed were then assigned to receive whichever treatment they had not received in the previous 12 weeks. Patients were instructed to apply the product in a thin layer over the entire surface of the wound. Xeroform gauze was applied in a double layer over the platelet product, and a sterile gauze dressing was placed over this. The entire wound site was covered with a gauze wrap</P>
<P>Length of treatment: Twice a day for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:43:50 +0100" MODIFIED_BY="Clare Dooley">
<P>Complete healing (100% epithelialisation). Rate of wound healing (ulcer surface depending on the duration of the treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 02:44:02 +0100" MODIFIED_BY="Clare Dooley">
<P>Funding was not specified. Originally, this study was designed to include a higher number of patients: "This study was originally designed to accrue 40 patients in each group; the actual number of patients enrolled in the study was small and the study was not powered to detect significance. The study had to be terminated prematurely because of the difficulty of enrolling patients." At baseline, the experimental group was older than the control group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>F: female<BR/>M: male<BR/>Hb: haemoglobin<BR/>IV: intravenous<BR/>PDWHF: platelet-derived wound healing formula<BR/>PRGF: plasma-rich growth factor<BR/>PRP: platelet-rich plasma<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-05-20 04:35:43 +0100" MODIFIED_BY="Clare Dooley" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:47:42 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Afshari-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:47:42 +0100" MODIFIED_BY="Clare Dooley">
<P>Randomised clinical trial that assessed recombinant epidermal growth factor compared with placebo in diabetic foot ulcers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:47:43 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Aminian-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:47:43 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised. Patient allocation was by alternation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:47:49 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Aminian-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:47:49 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised. Patient allocation was by alternation, except in cases of two or more ulcers, in which case allocation was by lot</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:47:51 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Atri-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:47:51 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised, sequential clinical trial (a three-month treatment period first, followed by a three-month period with experimental treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:47:58 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Carter-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:47:58 +0100" MODIFIED_BY="Clare Dooley">
<P>Observational study in chronic wounds</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:08 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Cervelli-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:08 +0100" MODIFIED_BY="Clare Dooley">
<P>PRP for cosmetic or functional improvement of traumatic scars (acute wounds)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:11 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Chen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:11 +0100" MODIFIED_BY="Clare Dooley">
<P>PRP used was allogeneic, not autologous. Not a randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:17 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Crovetti-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:17 +0100" MODIFIED_BY="Clare Dooley">
<P>Not a randomised clinical trial. Three of 24 patients received autologous PRP and the others homologous PRP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:21 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Danielsen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:21 +0100" MODIFIED_BY="Clare Dooley">
<P>The primary outcome was healing quality of the donor site in patients with a skin graft</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-20 04:35:43 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Enriquez_x002d_Vega-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-20 04:35:43 +0100" MODIFIED_BY="Clare Dooley">
<P>It is a before-after study to assess efficacy of a single dose of 20mL to 30 mL autologous platelet-rich plasma in ulcers of diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:44 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Greppi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:44 +0100" MODIFIED_BY="Clare Dooley">
<P>Allogeneic platelet gel in recalcitrant ulcers. Not controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:47 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Hao-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:47 +0100" MODIFIED_BY="Clare Dooley">
<P>This non-controlled study assessed the efficacy of PRP in healing deep II degree burns (acute wounds)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:56 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Holloway-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:56 +0100" MODIFIED_BY="Clare Dooley">
<P>This randomised clinical trial assessed an activated platelet supernatant, topical CT-102. PRP used was homologous, not autologous</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:48:58 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Jaiswal-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:48:58 +0100" MODIFIED_BY="Clare Dooley">
<P>PRP used was recombinant, not autologous</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:03 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Jorgensen-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:03 +0100" MODIFIED_BY="Clare Dooley">
<P>Uncontrolled pilot study in recalcitrant chronic wounds</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:14 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-JPRN_x002d_UMIN000009860">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:14 +0100" MODIFIED_BY="Clare Dooley">
<P>This is an ongoing non-randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:28 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-JPRN_x002d_UMIN000015689">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:28 +0100" MODIFIED_BY="Clare Dooley">
<P>This is an ongoing single-arm non-randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:34 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Khandelwal-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:34 +0100" MODIFIED_BY="Clare Dooley">
<P>This is a randomised three-arm study that assess recombinant PRP (rhPDGF)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:36 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Knighton-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:36 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:39 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-K_x00f6_veker-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:39 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised clinical trial; compared two platelet-derived wound healing factors (one was autologous and other was a commercial preparation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:42 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Ma-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:42 +0100" MODIFIED_BY="Clare Dooley">
<P>This clinical trial assessed a topical recombinant human acidic fibroblast growth factor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:45 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Margolis-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:45 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised. Retrospective case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:49:48 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Mazzuco-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:49:48 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised. Clinical trial controlled with a retrospective cohort of patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:50:24 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Morimoto-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:50:24 +0100" MODIFIED_BY="Clare Dooley">
<P>This is an open-label, non-randomised controlled, ongoing clinical trial. Both arms will include treatment with PRP. Patients will be randomised to the gelatin sheet or the hydrocolloid dressing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:50:45 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT00215735">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:50:45 +0100" MODIFIED_BY="Clare Dooley">
<P>This was a single, blind multicentric, randomised controlled trial that assessed the effect of platelet concentrate in the treatment of diabetic ulcers. This study was terminated; the results were inconclusive and not published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:50:53 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT00273234">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:50:53 +0100" MODIFIED_BY="Clare Dooley">
<P>This study was stopped prior to recruitment. The reasons were the lack of financial support and that study criteria severely limited enrolment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:50:55 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT00338702">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:50:55 +0100" MODIFIED_BY="Clare Dooley">
<P>This study was stopped prior to recruitment. Industry support and funding not forthcoming</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:15 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT00762138">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:15 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised. Prospective, open-label, patient registry. The primary objective is safety. The study will evaluate the incidence of hematologic and immunologic adverse events, including coagulopathies in patients with wounds to which AutoloGel TM® was applied. These adverse events can be associated with bovine thrombin when used in the preparation of PRP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:16 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT00856934">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:16 +0100" MODIFIED_BY="Clare Dooley">
<P>This study assessed the efficacy of PRP in healing a skin graft donor site acute wound</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:26 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT01553955">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:26 +0100" MODIFIED_BY="Clare Dooley">
<P>This is an ongoing non-randomised clinical trial, with a single group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:31 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT01639144">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:31 +0100" MODIFIED_BY="Clare Dooley">
<P>This is an ongoing randomised clinical trial in acute wounds</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:39 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT02071979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:39 +0100" MODIFIED_BY="Clare Dooley">
<P>This is an observational controlled study that will include 1500 patients with diabetic foot ulcers, venous ulcers, or pressure ulcers and will compare PRP with standard wound care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:40 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT02088268">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:40 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:41 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Niezgoda-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:41 +0100" MODIFIED_BY="Clare Dooley">
<P>It was about Regranex (Becaplermin), a synthetic product</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:43 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Reutter-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:43 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:51:58 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Saad-Setta-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:51:58 +0100" MODIFIED_BY="Clare Dooley">
<P>The method of randomisation was not correct: "This study was performed on 24 patients. They were systematically randomised into two groups. The odd-numbered patients had PRP (group I) and the even-numbered patients had PPP (group II)"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:02 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Saldamalacchia-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:02 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:03 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Scevola-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:03 +0100" MODIFIED_BY="Clare Dooley">
<P>PRP used was allogeneic, not autologous</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:09 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Soula-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:09 +0100" MODIFIED_BY="Clare Dooley">
<P>This is a phase I/II clinical trial to compare the efficacy and safety of BioChaperone PDGF-BB (a growth factor) versus becaplermin gel (synthetic product) administered once a day in patients with diabetic foot ulcer<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:12 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Steed--1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:12 +0100" MODIFIED_BY="Clare Dooley">
<P>PRP used was homologous, not autologous</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:13 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Steed-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:13 +0100" MODIFIED_BY="Clare Dooley">
<P>Randomised clinical trial. PRP used was homologous, not autologous</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:15 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Steed-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:15 +0100" MODIFIED_BY="Clare Dooley">
<P>PRP used was homologous, not autologous</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:17 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Steinbaum-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:17 +0100" MODIFIED_BY="Clare Dooley">
<P>The experimental group was treated with autologous fibronectin cryoprecipitate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:24 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-S_x00e1_nchez-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:24 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised. Case-control study. Application of autologous platelet-rich during Achilles tendon surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 02:52:27 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Tarpila-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 02:52:27 +0100" MODIFIED_BY="Clare Dooley">
<P>Not randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PRP: platelet-rich plasma</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-05-19 02:59:39 +0100" MODIFIED_BY="Clare Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-05-19 02:59:33 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Obolenskiy-2014">
<CHAR_METHODS MODIFIED="2015-06-18 09:27:03 +0100" MODIFIED_BY="[Empty name]">
<P>Design: Controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:59:33 +0100" MODIFIED_BY="Clare Dooley">
<P>Number included patients: 81 (Group 1 experimental: 44 and Group 2 control: 37)<BR/>Wound aetiology: chronic wounds of various aetiologies<BR/>Age (mean and SD): adults<BR/>
<B>Inclusion criteria</B>: Adults of both sexes with chronic wounds of various aetiologies<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:55:27 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental group: Autologous platelet gel</P>
<P>
<BR/>Control group: Conventional treatment<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:54:42 +0100" MODIFIED_BY="Clare Dooley">
<P>Time to complete wound re-epithelialisation</P>
<P>Mean inpatient hospital duration</P>
<P>Direct cost of treatments</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-18 09:22:05 +0100" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-05-19 02:59:39 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Serra-2014">
<CHAR_METHODS MODIFIED="2016-05-19 02:54:50 +0100" MODIFIED_BY="Clare Dooley">
<P>Design: Randomised controlled trial</P>
<P>Unit of randomisation: the patient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 02:59:39 +0100" MODIFIED_BY="Clare Dooley">
<P>Number randomised (patients): 162 (Group 1 experimental: 87 and Group 2 control: 75)<BR/>Wound aetiology: lower limbs ulcers (venous, arterial, diabetic)<BR/>Age (mean and SD): adults<BR/>Sex: 93 F/69 M<BR/>
<B>Inclusion criteria</B>: Adults of both sexes with chronic with lower limbs ulcers (venous, arterial, diabetic) with a duration of more than six weeks<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:55:22 +0100" MODIFIED_BY="Clare Dooley">
<P>All patients undergo autologous skin grafting procedure</P>
<P>Experimental group: Autologous platelet gel</P>
<P>
<BR/>Control group: Conventional treatment<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:55:32 +0100" MODIFIED_BY="Clare Dooley">
<P>Healing time after skin grafting procedure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-18 09:18:19 +0100" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-05-23 10:47:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-05-20 04:45:43 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-ChiCTR_x002d_TRC_x002d_00000325">
<CHAR_STUDY_NAME MODIFIED="2016-05-19 02:56:10 +0100" MODIFIED_BY="Clare Dooley">
<P>A prospective, randomised, controlled trial of autologous platelet-rich plasma gel to treat refractory dermal ulcer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-01-11 15:27:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-20 04:45:43 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: China. Number randomised (patients): 100</P>
<P>Wound aetiology: Mixed</P>
<P>Age: 18 years and older</P>
<P>Sex: male and female<BR/>
</P>
<P>
<B>Inclusion criteria</B>:18 years or older. Standard therapy of dermal ulcer for 2 to 6 weeks, was ineffective. ABI &lt; 0.6 or good blood supply to the ulcer. Fasting blood glucose &lt; 8 mmol/L. Postprandial blood glucose &lt; 11 mmol/L. Infection or osteomyelitis well controlled. Bood pressure &lt; 160/90 mmHg. No use of immunosuppressor or its dosage maintained in recent three weeks. No severe heart, lung, liver or renal dysfunctions, blood or psychological disease. The patient accepts to participate and sign the information consent form</P>
<P>
<B>Exclusion criteria</B>: Diabetic acute complications. Severe infection or uncontrolled osteomyelitis. Pregnant and lactating women. Allergic history to several drugs. Myocardial infarction, arrhythmia or cerebral infarction in recent 3 to 6 months, cardiac dysfunction, COPD, or hepatocirrhosis. Ulcer caused by malignant tumour. The patient received radiotherapy, chemotherapy, immunosuppressant or overdose of glucocorticoid therapy in recent 3 weeks. Anaemia (Hb &lt; 90 g/L), thrombocytopenia, platelet count &lt; 100×10^9/L, leukaemia; psychological disease. Poor compliance. The patient took part in other new drug clinical trials in recent 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 02:57:59 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental: PRP gel</P>
<P>
<BR/>Comparator: Standard treatment consists of daily topical washing, cleaning, debridement and dressing changing of the wounds<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 02:58:04 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcome: Variation of ulcer area and volume</P>
<P>Secondary outcomes: Blood and urine routine examination, blood glucose levels, lipid profiles, bacterial culture on ulcer, and HbA1c</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-01 18:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>January 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-01-03 22:28:17 +0000" MODIFIED_BY="[Empty name]">
<P>Wang Chun; Department of Endocrinology and Metabolism, West China Hospital, Guoxue Lane 37#, Chengdu, Sichuan; snoopywc@163.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-20 04:46:40 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-IRCT2014060415574N3">
<CHAR_STUDY_NAME MODIFIED="2015-03-25 15:46:49 +0000" MODIFIED_BY="[Empty name]">
<P>Effect of platelet dressing on the healing of diabetic foot ulcers compared with routine dressing in patients with diabetic foot ulcers Shahid Beheshti Hospital</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-05-19 02:58:21 +0100" MODIFIED_BY="Clare Dooley">
<P>Open-label, parallel-group, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-20 04:46:40 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: Iran</P>
<P>Number randomised (patients): 60</P>
<P>Wound aetiology: diabetic foot ulcers</P>
<P>Age: 18 year and older</P>
<P>Sex: male and female<BR/>
</P>
<P>
<B>Inclusion criteria</B>: Diabetic patients with foot ulcers who entered is stage 1 or 2 foot ulcer. Platelet count equal to or greater than 100,000. Haemoglobin equal or greater 10 g/dL</P>
<P>
<B>Exclusion criteria</B>: Use of medications that suppress the immune system. Clotting problems. Signs of sepsis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 03:00:29 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental: After preparing the PRP, 5 cc of it will be used for wound dressing using a 5 cc syringe we pour the PRP on the sterile gauze ant put it on the wound covering with sterile gauze. This PRP dressing will remain for 3 days on the wound</P>
<P>
<BR/>Comparator: After debridement, the wound will be irrigated with normal saline and sterile gauze dressing. Dressing change daily</P>
<P>Wounds will be evaluated on days 7, 14 and 21 by a digital camera that gets pictures from the wounds from 30 cm distance<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 03:00:32 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcome: Platelet dressing</P>
<P>Secondary outcomes: Depth of wound. Duration of wound healing. Wound area. Wound healing</P>
<P>Timepoint of all measures: Days 1, 7, 14 and 21. Method of measurement: by checklist</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-25 15:46:53 +0000" MODIFIED_BY="[Empty name]">
<P>19/11/2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-25 15:46:53 +0000" MODIFIED_BY="[Empty name]">
<P>Mohammad Afshar; afshar_m_1343@yahoo.com; mohammad.afshar@modares.ac.ir</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-25 15:46:54 +0000" MODIFIED_BY="[Empty name]">
<P>Founding: Vice chancellor for research, Kashan University of Medical Sciences</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-20 04:36:45 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-ISRCTN84928077">
<CHAR_STUDY_NAME MODIFIED="2015-03-25 15:46:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial of platelet rich plasma biotherapies in the management of adult patients with recalcitrant and slow healing wounds following major trauma</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-03-25 15:46:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised multicentre controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 03:03:01 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: UK</P>
<P>Number randomised (patients): 100</P>
<P>Wound aetiology: recalcitrant and slow healing wounds following major trauma</P>
<P>Age: 18 years and older</P>
<P>Sex: Male and female<BR/>
</P>
<P>
<B>Inclusion criteria</B>: Adults (male and female patients) over 18 years of age. Patients with slow healing wounds and patients with wounds that have not healed within 28 days of the initial injury</P>
<P>
<B>Exclusion criteria</B>: Patients do not consent to participation or refuse to donate blood for the PRP gel treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-20 04:36:45 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental:</P>
<P>1. Autologel autologous PRP gel plus bovine thrombin until &gt; 90% wound closure is achieved</P>
<P>2. Angel autologous PRP gel plus autologous thrombin until &gt; 90% wound closure is achieved</P>
<P>Total anticipated duration of the PRP treatments will be 10 weeks. However the Standard Advanced Wound Care may very well exceed this</P>
<P>Comparator: Standard Advanced Wound Care</P>
<P>Follow-up for all treatment will be the same and is as per the standard care pathway for complex wounds involving a multicentre approach<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 03:04:32 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcome: Time to 90% wound closure as measured by 3D photography. The wounds will be monitored on a weekly basis</P>
<P>Secondary outcomes:</P>
<P>1. Quality of life using the SF-36 health survey (this is the key secondary outcome)</P>
<P>2. Number of treatment 'deferrals' (i.e. temporary rejections) of donors due to low haemoglobin and other factors</P>
<P>3. Markers of platelet concentration, leucocyte levels within the PRP Biotherapies</P>
<P>4. Cognitive ability (reasoning, attention and memory)</P>
<P>5. Levels of physical activity</P>
<P>6. Cost-effectiveness</P>
<P>7. Donor attitudes, beliefs and values</P>
<P>The wounds will be monitored on a weekly basis using 3D photographic measurement. Secondary outcomes regarding wound infection and antibiotic usage will be monitored on a monthly basis</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-25 15:47:04 +0000" MODIFIED_BY="[Empty name]">
<P>31/10/2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-05-19 03:04:49 +0100" MODIFIED_BY="Clare Dooley">
<P>Steven Jeffery. The Queen Elizabeth Hospital Mindelsohn Way Edgbaston, B15 2TH, Birmingham, United Kingdom</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-25 15:47:04 +0000" MODIFIED_BY="[Empty name]">
<P>Founding: National Institute for Health Research (NIHR) (UK) - Efficacy and Mechanism Evaluation (EME) Programme, Ref 13/55/99</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-23 10:47:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-JPRN_x002d_UMIN000004840">
<CHAR_STUDY_NAME MODIFIED="2016-05-19 03:05:03 +0100" MODIFIED_BY="Clare Dooley">
<P>Clinical study for the treatment of chronic wounds using platelet-rich plasma</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-03-25 15:47:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised parallel controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-23 10:47:53 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Japan</P>
<P>Number randomised (patients): 20</P>
<P>Wound aetiology: Pressure ulcer, foot ulcer</P>
<P>Age: 20 years and older</P>
<P>Sex: Male and female<BR/>
</P>
<P>
<B>Inclusion criteria</B>: Chronic or unstable skin ulcer. Written informed consent by patient themselves</P>
<P>
<B>Exclusion criteria</B>: presence of anaemia, thrombocytopenia or local infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 03:06:07 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental: Local injection of PRP together with standard therapy using ointment and dressing materials</P>
<P>
<BR/>Comparator: Standard therapy using ointment and dressing materials<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 03:06:23 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcome: Period for complete wound closure</P>
<P>Secondary outcomes: If complete wound closure is unsuccessful, other evaluation will be: wound condition, wound area, formation of granulation tissue, epithelialisation of wound margin, etc</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-25 15:47:10 +0000" MODIFIED_BY="[Empty name]">
<P>1/1/2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-25 15:47:10 +0000" MODIFIED_BY="[Empty name]">
<P>Jiro Maegawa; Kazunori Yasumura, burngdy@hotmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-25 15:47:10 +0000" MODIFIED_BY="[Empty name]">
<P>Funding: Yokohama City University Hospital (Japan)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-19 03:07:36 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT00658983">
<CHAR_STUDY_NAME MODIFIED="2016-05-19 03:06:49 +0100" MODIFIED_BY="Clare Dooley">
<P>Autologous platelet enriched gel versus metalloproteinase inhibitor in the healing of chronic lower leg ulcers</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-05-19 03:06:52 +0100" MODIFIED_BY="Clare Dooley">
<P>Randomised, open-label, parallel assignment, efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 03:07:27 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: Belgium. Number randomised (patients): 20</P>
<P>Wound aetiology: Mixed. Age: 18 years and older. Sex: male and female<BR/>
<B>Inclusion criteria</B>: 18 years or older. A non-healing chronic lower leg ulcer. Platelet ranges of 150,000 per mL circulating blood</P>
<P>
<B>Exclusion Criteria</B>: Presence of a tumour or metastatic disease. Hypersensitive to collagen regenerated cellulose. Hemodynamic unstable patient. Hypercoagulability. Heart decompensation or angina pectoris</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 03:07:36 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental: Autologous Platelet Enriched Gel Active</P>
<P>
<BR/>Comparator: Metalloproteinase Inhibitor (Promogran)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-11 15:28:03 +0000" MODIFIED_BY="[Empty name]">
<P>Wound healing (time frame: 6 weeks)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-09 15:54:02 +0100" MODIFIED_BY="[Empty name]">
<P>April 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-08 22:19:20 +0000" MODIFIED_BY="[Empty name]">
<P>Wim Bongaerts, MD; University Hospital Ghent <A HREF="mailto:Willem.bongaerts%40ugent.be">Willem.bongaerts@ugent.be</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-05-09 15:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Colaborators:  Medtronic and Johnson &amp; Johnson</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-20 22:54:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02209662">
<CHAR_STUDY_NAME MODIFIED="2016-05-19 03:08:02 +0100" MODIFIED_BY="Clare Dooley">
<P>Safety and efficacy study of APIC-PRP in non-healing diabetic foot ulcers</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-05-19 03:01:36 +0100" MODIFIED_BY="Clare Dooley">
<P>Multicentre, randomised, double-blind (subject, caregiver, investigator, outcomes assessor)</P>
<P>controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 03:10:15 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: USA</P>
<P>Number randomised (patients): 274</P>
<P>Wound aetiology: Diabetic food ulcer</P>
<P>Age: 18 year and older.</P>
<P>Sex: Male and female.<BR/>
</P>
<P>
<B>Inclusion criteria</B>: Age &gt; 18 years old at the time the informed consent is signed. Diabetes type I or II). Subjects will have only one diabetic foot ulcer on the target limb (referred to as the index ulcer). Debrided ulcer size between 1 cm<SUP>2</SUP> and 4 cm<SUP>2</SUP>. Ulcer duration &#8805; 1 month at first visit and free of clinical signs of infection. Subject has adequate circulation to the study foot as evidenced by a Doppler measured ABI of &#8805; 0.7 after 10 minutes of rest</P>
<P>
<B>Exclusion criteria</B>: Hemoglobin of less than 12 g/dL. Ulcer has increased in size by &gt; 50% or ulcer healed by 25% or more during the run-in screening period. History of bleeding disorder. Any malignancy other than non-melanoma skin cancer requiring treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or corticosteroids less than 30 days before enrolment. Subject has gangrene present on any part of the affected limb. Ulcer is over a Charcot deformity of the mid-foot or over the tarsal bones-talus, distal calcaneus, navicular, and cuboid. Severe malnutrition or with Acquired Immunodeficiency Syndrome (AIDS), liver disease, aplastic anaemia, scleroderma, malignancy, cellulitis, suspected osteomyelitis or other evidence of systemic infection, or is Human Immunodeficiency Virus (HIV)-positive. Subject is on dialysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 03:12:18 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental: Cytonics Autologous Platelet Integrated Concentration (APIC-PRP) plus standard of care</P>
<P>
<BR/>Comparator: Placebo (saline) plus standard of care<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-20 22:54:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Complete wound closure within 12 weeks</P>
<P>Secondary outcomes: Improvement in wound healing trajectory of diabetic food ulcer over the 12-week treatment period between the APIC-PRP + standard of care groups and standard of care alone groups</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-25 15:47:21 +0000" MODIFIED_BY="[Empty name]">
<P>October 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-25 15:47:21 +0000" MODIFIED_BY="[Empty name]">
<P>Gaetano J Scuderi. Cytonics Corporation</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-25 15:47:21 +0000" MODIFIED_BY="[Empty name]">
<P>Funding: Cytonics Corporation</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-19 03:14:55 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT02213952">
<CHAR_STUDY_NAME MODIFIED="2016-05-19 03:13:04 +0100" MODIFIED_BY="Clare Dooley">
<P>Feasibility, potential efficacy and safety of autologous platelet-rich plasma in the treatment of vascular venous ulcers in primary care (phase I and II pilot study) - PRP in vascular ulcers in primary care</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-05-19 03:13:12 +0100" MODIFIED_BY="Clare Dooley">
<P>Phase III, open-label, parallel-group, multicentre, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 03:13:54 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: Spain</P>
<P>Number randomised (patients): 150</P>
<P>Wound aetiology: Vascular venous ulcer</P>
<P>Age: 18 years and older</P>
<P>Sex: Male and female<BR/>
</P>
<P>
<B>Inclusion criteria</B>: Between 40 and 100 years of age with an at least 2-month history of a vascular venous ulcer</P>
<P>
<B>Exclusion criteria</B>: ABI below 0.8 or above 1.5. Chronic use of immunosuppressants or antiretroviral drugs. Patients with syphilis, Hepatitis B, Hepatitis C and HIV. Active infection or fever at the beginning of the study. Clotting disorders. Chronic infectious diseases. History of cancer. Treatment with radiotherapy or chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 03:14:15 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental: Autologous PRP; one heal per week during the two months of treatment</P>
<P>
<BR/>Comparator: Current treatment<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 03:14:35 +0100" MODIFIED_BY="Clare Dooley">
<P>Primaries outcomes: Reduction of the ulcer at baseline and 5 and 9 weeks after starting the treatment. The area of the wound will be compared between baseline, after a month and two months of treatment, measuring the area in cm<SUP>2</SUP> by image processing of photographs of the ulcer using ImageJ software</P>
<P>Secondary outcomes: Reduction in pain, percentage of infected ulcers and wound edge. Quality of live using the CIVIQ</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-25 15:46:36 +0000" MODIFIED_BY="[Empty name]">
<P>17 December 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-25 15:46:40 +0000" MODIFIED_BY="[Empty name]">
<P>Natalia Burgos Alonso. Unidad de investigacion de atencion Primaria de Bizakaia. Spain</P>
<P>natalia.burgosalonso@osakidetza.net</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-05-19 03:14:55 +0100" MODIFIED_BY="Clare Dooley">
<P>Founding. Spanish Carlos III Health Institute and Department of Health and Consumer Affairs of the Government of the Basque Country</P>
<P>This clinical trial is also registered in clinicaltrial.gov (<LINK REF="STD-NCT02213952" TYPE="STUDY">NCT02213952</LINK> Title: PRP ULCERAS: Clinical Trial Phase III (PRPULCERAS))</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-20 04:31:43 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT02307448">
<CHAR_STUDY_NAME MODIFIED="2016-05-19 03:15:30 +0100" MODIFIED_BY="Clare Dooley">
<P>Effectiveness of autologous platelet rich plasma in the treatment of chronic non-healing wounds</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-05-19 03:15:39 +0100" MODIFIED_BY="Clare Dooley">
<P>Randomised single-blind (outcomes assessor) multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-20 04:31:43 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: USA</P>
<P>Number randomised (patients): 1500</P>
<P>Wound aetiology: Diabetic foot ulcers, venous ulcers, or pressure ulcers</P>
<P>Age: 18 years and older</P>
<P>Sex: Male and female<BR/>
</P>
<P>
<B>Inclusion criteria</B>: Medicare eligible. Written informed consent. Male or female &#8805; 18 years of age. Duration of diabetic foot ulcers, venous ulcers, or pressure ulcers is greater than 30 days at first visit/patient screening. Classified as Wagner 1-3 on the Wagner classification system. The ulcer must be clinically non-infected</P>
<P>
<B>Exclusion Criteria</B>: Patients with known sensitivity to components of the PRP kit. Presence of non-treated osteomyelitis. Received systemic corticosteroids or immunosuppressive agents, electrostimulation, growth factors, or any cell or tissue-derived products for wounds during the 30 days preceding the screening visit</P>
<P>Received radiation therapy or chemotherapy within previous 3 months. Charcot foot. Patients with thrombocytopenia &lt; 50,000 platelets/µL. Wounds smaller than 2 cm will be excluded. Minimum Hgb/HCT level: Hgb 9 g/dL Hct 27%. Min/max ABIs: Min = 0.7, No maximum</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 03:17:44 +0100" MODIFIED_BY="Clare Dooley">
<P>Experimental: PRPa. Patients will receive weekly PRP treatments with standard of care</P>
<P>
<BR/>Comparator: Standard of care. Patients will receive weekly standard of care<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 03:17:48 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcome: The primary objective of this trial is to evaluate increasing the proportion of wounds with complete closure within 20 weeks of initial treatment</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-25 15:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>January 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-25 15:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>Study Director: Todd Shaffett, APRN, FNP-C</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-25 15:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>Sponsor:ACR Biologics, LLC</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-05-19 03:22:23 +0100" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-NCT02312518">
<CHAR_STUDY_NAME MODIFIED="2016-05-19 03:18:23 +0100" MODIFIED_BY="Clare Dooley">
<P>Clinical Trial of ECLIPSE PRP&#8482; Wound Biomatrix in chronic non-healing venous leg ulcers</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-05-19 03:18:31 +0100" MODIFIED_BY="Clare Dooley">
<P>Randomised single-blinded (outcomes assessor) multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 03:21:09 +0100" MODIFIED_BY="Clare Dooley">
<P>Country: USA</P>
<P>Number randomised (patients): 250</P>
<P>Wound aetiology: Venous leg ulcers</P>
<P>Age: 18 years and older</P>
<P>Sex: Male and female<BR/>
</P>
<P>
<B>Inclusion criteria</B>: subjects &#8805; 18 years of age with chronic non-healing venous leg ulcers (greater than 4 weeks duration). Three or fewer ulcers that are separated by &gt; 3.0 cm distance. Post-debridement, the ulcer size must be between 2 cm2 and 200 cm<SUP>2</SUP>. Demonstrated adequate compression regimen. Able and willing to attend scheduled follow-up visits and study related exams. Able and willing to provide a voluntary written informed consent</P>
<P>
<B>Exclusion criteria</B>: No venous ulcers. Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator. Gross clinical infection at the study ulcer site. Known allergy tor sensitivity to Eclipse PRP kit components. Plasma platelet count of less than 100 x 109/L, or Hemoglobin of less than 10.5 g/dL, known renal failure, rheumatoid arthritis, vasculitis, sickle cell disease, HIV severe liver disease, presence of additional abnormal lab values, radiation therapy, chemotherapy, immunosuppressive therapy or chronic steroid use within 30 days of enrolment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-25 15:47:38 +0000" MODIFIED_BY="[Empty name]">
<P>Experimental: Eclipse PRP&#8482; Wound Biomatrix<BR/>Comparator: usual and customary practice<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 03:22:23 +0100" MODIFIED_BY="Clare Dooley">
<P>Primary outcomes:</P>
<UL>
<LI>Time to complete wound closure at 12 weeks. Complete wound closure is defined as full epithelialisation of the wound with the absence of drainage, durability confirmed at 2 weeks</LI>
<LI>Percent of wounds healed at 12 weeks</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>Wound trajectory at 12 weeks. Mean and median of percent (%) wound size changes at 4 weeks, 8 weeks and 12 weeks</LI>
<LI>Ulcer recurrence at 3 months. Ulcer recurrence out to 3 months for subjects whose wounds heal by conclusion of 12-week visit</LI>
<LI>Quality of life at 3 months. Changes in quality of life scores and ability to return to previous function/resumption of normal activities</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-25 15:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>January 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-25 15:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>Damon Keeky: <A HREF="mailto:dk%40hemoconcepts.com">dk@hemoconcepts.com</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-25 15:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>Sponsor:PRP Concepts, LLC</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ABI: ankle-brachial index<BR/>COPD: Chronic obstructive pulmonary disease<BR/>Hb: haemoglobin<BR/>PRP: platelet-rich plasma</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-05-19 02:45:01 +0100" MODIFIED_BY="Clare Dooley">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-05-19 02:44:16 +0100" MODIFIED_BY="Clare Dooley" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:06:50 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Anitua-2008">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned according to a computer generated randomisation table to wound care with PRGF (experimental group) or standard wound care (control group)"</P>
<P>Comments: randomisation sequence was generated by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:18:20 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Driver-2006">
<DESCRIPTION>
<P>Quote:"The randomization schedule was electronically generated, blocked per investigational center, ...". "Each eligible study participant was assigned to one of two treatment groups, PRP or control, and received the next available consecutive randomization number"</P>
<P>Comments: The randomisation schedule was electronically generated and blocked per investigational centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:22:37 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Kakagia-2007">
<DESCRIPTION>
<P>Quote: "At enrolment, patients were randomly assigned by the use of a random number generator to receive treatment for 8 weeks"</P>
<P>Comments: The random sequence was generated by a computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:26:41 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Knighton-1990">
<DESCRIPTION>
<P>Quote: "All patients were randomised by the laboratory personnel who prepared the PDWHF, using a blinded card selection process"</P>
<P>Comments: How randomisation was generated was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:31:32 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Krupski-1991">
<DESCRIPTION>
<P>Quote:&#8220;... patients were randomized to control (placebo) or treatment (PDWHF) groups by use of a blinded card process by means of computer-generated random numbers&#8221;</P>
<P>Comments: The random sequence was generated by a computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 15:10:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2012">
<DESCRIPTION>
<P>Comment: The random sequence was generated using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:38:28 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<DESCRIPTION>
<P>Quote: "In a small randomised study..."</P>
<P>Comments: The paper states this was randomised but gives no further detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:40:17 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Senet-2003">
<DESCRIPTION>
<P>Quote: "Immediately after collection and preparation of platelets, patients were randomized to receive either placebo or platelets"</P>
<P>Comments: The paper states this was randomised but gives no further detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:41:41 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Stacey-2000">
<DESCRIPTION>
<P>Quote: "Randomisation was by a sealed envelope system which was opened after all entry criteria were fulfilled and the patient had given informed consent"</P>
<P>Comments: How the randomisation sequence was generated was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:44:16 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Weed-2004">
<DESCRIPTION>
<P>Quote: "The patients were randomly assigned to receive either platelet lysate product mixed with collagen (the treatment group) or platelet-poor plasma mixed with collagen (the placebo group) for the first 12 weeks of therapy"</P>
<P>Comments: How the allocation sequence was generated is not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-05-19 02:44:19 +0100" MODIFIED_BY="Clare Dooley" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:06:54 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Anitua-2008">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:18:30 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Driver-2006">
<DESCRIPTION>
<P>Quote:"The randomization schedule was electronically generated, blocked per investigational center, and provided to the site by the contract research organization (CRO)"</P>
<P>Comments: The randomisation schedule was provided to the site by a contact with a contract research organisation and this was judged to be an adequate form of concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:22:39 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Kakagia-2007">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:26:46 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Knighton-1990">
<DESCRIPTION>
<P>Quote: "All patients were randomised by the laboratory personnel who prepared the PDWHF, using a blinded card selection process"</P>
<P>Comments: The allocation was centralised using a blinded card selection process and this was judged to be adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:31:37 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Krupski-1991">
<DESCRIPTION>
<P>Quote:&#8220;...patients were randomized to control (placebo) or treatment (PDWHF) groups by use of a blinded card process by means of computer-generated random numbers&#8221;</P>
<P>Comments: Patients were allocated to PRP or control by a "blinded card process" and this was judged to be adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-02 12:01:44 +0000" MODIFIED_BY="Nicky Cullum" RESULT="UNKNOWN" STUDY_ID="STD-Li-2012">
<DESCRIPTION>
<P>Comment: Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:38:28 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:40:19 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Senet-2003">
<DESCRIPTION>
<P>Not  specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:41:44 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Stacey-2000">
<DESCRIPTION>
<P>Quote: "Randomisation was by a sealed envelope system which was opened after all entry criteria were fulfilled and the patient had given informed consent"</P>
<P>Comments: The allocation concealment was by sealed envelope, although this was not described as an opaque and sequentially sealed envelope we have judged this to be adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:44:19 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Weed-2004">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-05-19 02:44:32 +0100" MODIFIED_BY="Clare Dooley" NO="9">
<NAME>Blinding of participants (performance bias and detection bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:06:56 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Anitua-2008">
<DESCRIPTION>
<P>Quote: "...open-label, standard care-controlled pilot clinical trial"</P>
<P>Comments: The clinical trial was open. No masking of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:18:40 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Driver-2006">
<DESCRIPTION>
<P>Quote: "A strategically placed drape prohibited the patient from seeing which treatment was applied to the wound. Blood was drawn from both the treatment and control patients to maintain blinding"</P>
<P>Comments: The participants were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:22:40 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Kakagia-2007">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:26:58 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Knighton-1990">
<DESCRIPTION>
<P>Quote: "Patients randomised to the treatment group received PDWHF added to microcrystalline collagen (Avitene®). Those randomised to the non-treatment group received an equivalent amount of platelet buffer solution added to the same amount of microcrystalline collagen. Both preparations were identical in colour, consistency and smell"</P>
<P>Comments: Participants were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:31:47 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Krupski-1991">
<DESCRIPTION>
<P>Quote: "Neither patients nor care-providers knew whether the topical solution was placebo or PDWHF until the study was terminated and participants were told which solution was used". "Placebo solution consisted of physiologic saline. The two solutions were identical in colour, consistency, and smell"</P>
<P>Comment: Patients did not know whether the topical solution was placebo or PDWHF until the study was terminated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-02 12:01:46 +0000" MODIFIED_BY="Nicky Cullum" RESULT="UNKNOWN" STUDY_ID="STD-Li-2012">
<DESCRIPTION>
<P>Comment: Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:38:32 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<DESCRIPTION>
<P>There was no information in the abstract to allow a judgement to be made for this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:40:25 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Senet-2003">
<DESCRIPTION>
<P>Quote: "After the wound was cleansed with normal saline solution, the appropriate volume of either FAP or placebo was applied to the wound surface with a syringe. FAP and placebo appeared identical"</P>
<P>Comments: The treatments (experimental and control) were of similar appearance and therefore it was judged that the participant was properly blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:41:47 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Stacey-2000">
<DESCRIPTION>
<P>Quote: "The aim of this study was to undertake a double blind placebo-controlled trial...."</P>
<P>Comment: The process of intervention concealment to participants was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:44:32 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Weed-2004">
<DESCRIPTION>
<P>Quote: "Plasma and platelet lysate products were indistinguishable in physical appearance (straw-coloured material)." "The placebo product was composed of platelet-poor plasma added to collagen. This placebo product looked, smelled, and behaved like the autologous platelet lysate product. Both products were packaged and prepared identically (i.e. freezing technique)"</P>
<P>Comments: It was judged that the participants were likely blinded to the intervention because both products were similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-05-19 02:44:45 +0100" MODIFIED_BY="Clare Dooley" NO="10">
<NAME>Blinding of personnel (performance and detection bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:07:00 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Anitua-2008">
<DESCRIPTION>
<P>Quote: "...open-label, standard care-controlled pilot clinical trial"</P>
<P>Comments: The clinical trial was open. No masking of care provider</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:18:54 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Driver-2006">
<DESCRIPTION>
<P>Quote: "Each site had one designated &#8220;unblinded&#8221; person to treat the patient (also blinded) and maintain documents in a secure private area to maintain blinding of the investigator, investigative site staff, patient, sponsor, and CRO staff and monitor. This person did not participate in any other aspect of the patient&#8217;s care"</P>
<P>Comments: No masking of care provider.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:22:41 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Kakagia-2007">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:27:03 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Knighton-1990">
<DESCRIPTION>
<P>Quote: "Patients randomised to the treatment group received PDWHF added to microcrystalline collagen (Avitene®). Those randomised to the non-treatment group received an equivalent amount of platelet buffer solution added to the same amount of microcrystalline collagen. Both preparations were identical in colour, consistency and smell"</P>
<P>Comments: Personnel was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:31:54 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Krupski-1991">
<DESCRIPTION>
<P>Quote: "Neither patients nor care-providers knew whether the topical solution was placebo or PDWHF until the study was terminated and participants were told which solution was used" "Placebo solution consisted of physiologic saline. The two solutions were identical in colour, consistency, and smell"</P>
<P>Comment: Care-providers did not know whether the topical solution was placebo or PDWHF until the study was terminated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-02 12:01:47 +0000" MODIFIED_BY="Nicky Cullum" RESULT="UNKNOWN" STUDY_ID="STD-Li-2012">
<DESCRIPTION>
<P>Comment: Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:38:32 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<DESCRIPTION>
<P>There was no information in the abstract to allow a judgement to be made for this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:40:28 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Senet-2003">
<DESCRIPTION>
<P>Quote: "After the wound was cleansed with normal saline solution, the appropriate volume of either FAP or placebo was applied to the wound surface with a syringe. FAP and placebo appeared identical"</P>
<P>Comments: The treatments (experimental and control) were of similar appearance and therefore it was judged that the care giver was properly blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:41:51 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Stacey-2000">
<DESCRIPTION>
<P>Quote: "The patients were attended twice weekly for application of either platelet lysate or placebo and for replacement of dressings and bandages"</P>
<P>Comment: The process of intervention concealment was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:44:45 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Weed-2004">
<DESCRIPTION>
<P>Quote: "Plasma and platelet lysate products were indistinguishable in physical appearance (straw-coloured material)." "The placebo product was composed of platelet-poor plasma added to collagen. This placebo product looked, smelled, and behaved like the autologous platelet lysate product. Both products were packaged and prepared identically (i.e. freezing technique)"</P>
<P>Comments: It was judged that the personnel were likely blinded to the intervention because both products were similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-05-19 02:44:58 +0100" MODIFIED_BY="Clare Dooley" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:07:02 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Anitua-2008">
<DESCRIPTION>
<P>Quote: "...open-label, standard care-controlled pilot clinical trial"</P>
<P>Comments: The clinical trial was open. No masking of outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:19:00 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Driver-2006">
<DESCRIPTION>
<P>Quote: "The blinded investigators and staff measured the wounds; performed all tests, assessments, and debridement; and determined wound closure"</P>
<P>Comments: The outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:22:44 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Kakagia-2007">
<DESCRIPTION>
<P>Quote: "Wound dimensions were calculated in a blinded fashion and analyzed"</P>
<P>Comments: The outcome assessor was blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:27:09 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Knighton-1990">
<DESCRIPTION>
<P>Quote: "Patients randomised to the treatment group received PDWHF added to microcrystalline collagen (Avitene®). Those randomised to the non-treatment group received an equivalent amount of platelet buffer solution added to the same amount of microcrystalline collagen. Both preparations were identical in colour, consistency and smell"</P>
<P>Comments: Personnel that assessed outcomes was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:32:05 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Krupski-1991">
<DESCRIPTION>
<P>Quote: "Placebo solution consisted of physiologic saline. The two solutions were identical in colour, consistency, and smell."</P>
<P>Comment: The outcome assessors did not know whether the topical solution was placebo or PDWHF until the study was terminated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-25 15:45:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2012">
<DESCRIPTION>
<P>Quote: &#8220;after the following-up of the study, a researcher who is responsible for collecting the data (the photos) of the study did the analysis and measurements of the ulcers, using software Image J 1.46 h&#8221;</P>
<P>Comment: The assessor was blinded to the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:38:34 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<DESCRIPTION>
<P>There was no information in the abstract to allow a judgement to be made for this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:40:32 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Senet-2003">
<DESCRIPTION>
<P>Quote: "After the wound was cleansed with normal saline solution, the appropriate volume of either FAP or placebo was applied to the wound surface with a syringe. FAP and placebo appeared identical"</P>
<P>Comments: The treatments (experimental and control) were of similar appearance. The outcome assessor was judged to be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:41:55 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Stacey-2000">
<DESCRIPTION>
<P>Quote: "All patients had their leg ulcers treated at the leg ulcer clinic at Fremantle Hospital. They attended twice weekly for application of either platelet lysate or placebo and for replacement of dressings and bandages"</P>
<P>Comment: It is unknown if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-19 02:44:58 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Weed-2004">
<DESCRIPTION>
<P>Quote: "Plasma and platelet lysate products were indistinguishable in physical appearance (straw-coloured material)." "The placebo product was composed of platelet-poor plasma added to collagen. This placebo product looked, smelled, and behaved like the autologous platelet lysate product. Both products were packaged and prepared identically (i.e. freezing technique)"</P>
<P>Comments: It was judged that the outcome assessors were likely blinded to the intervention because both products were similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-05-19 02:45:00 +0100" MODIFIED_BY="Clare Dooley" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:07:08 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Anitua-2008">
<DESCRIPTION>
<P>40% of patients were lost to follow-up; Group 1: 3/8 (37.5%) Group 2: 3/7 (42.8%)</P>
<P>Comments: this represents a high level of loss (over 30%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:19:07 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Driver-2006">
<DESCRIPTION>
<P>Total losses were 44.4%, 21 (52.5%) patients in experimental group and 11 (34.4%) patients in control group</P>
<P>Comments: this represents a high level of loss (over 30%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:22:47 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Kakagia-2007">
<DESCRIPTION>
<P>Three patients were selected but finally did not participate. Loss to follow-up: none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:27:14 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Knighton-1990">
<DESCRIPTION>
<P>There were 25% of participants lost, 3 (18.7%) patients in the experimental group and 5 (31.2%) patients in the control group. Analysis was per protocol</P>
<P>Comments: this represents a high level of loss (over 30%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:32:10 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Krupski-1991">
<DESCRIPTION>
<P>There were no losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-26 15:18:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2012">
<DESCRIPTION>
<P>Comment: The data of all included patients were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:38:36 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<DESCRIPTION>
<P>There was no information in the abstract to allow a judgement to be made for this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:40:35 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Senet-2003">
<DESCRIPTION>
<P>The percentage of total losses was low (13.3%), 1(12.5%) patient in experimental group and 1(14.3%) patient in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:41:59 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Stacey-2000">
<DESCRIPTION>
<P>Losses in both groups were 12.8%, 5 (11.9%) patients in the experimental group and 6 (13.6%) in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-19 02:45:00 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Weed-2004">
<DESCRIPTION>
<P>There were no exclusions after randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-05-19 02:45:01 +0100" MODIFIED_BY="Clare Dooley" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:07:15 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Anitua-2008">
<DESCRIPTION>
<P>The results of all outcomes prespecified in the methods of the trial report were presented. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:19:20 +0100" MODIFIED_BY="Clare Dooley" RESULT="NO" STUDY_ID="STD-Driver-2006">
<DESCRIPTION>
<P>The results of prespecified outcomes in methods were not reported as "percent change in wound area at the end-of-study visit (EOSV) from baseline", "percent change in wound volume at the EOSV from baseline"; and "volume closure rate per day at the EOSV". The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:22:47 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Kakagia-2007">
<DESCRIPTION>
<P>The results of all outcomes were presented. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:27:18 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Knighton-1990">
<DESCRIPTION>
<P>The results of all outcomes specified in methods were presented. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:32:11 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Krupski-1991">
<DESCRIPTION>
<P>The results of all outcomes were reported. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 15:52:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2012">
<DESCRIPTION>
<P>Comment: There were results of all variables listed in methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:38:37 +0100" MODIFIED_BY="Clare Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Planinsek-Rucigaj-2007">
<DESCRIPTION>
<P>Outcome results were incomplete because the SD was not reported. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:40:36 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Senet-2003">
<DESCRIPTION>
<P>The results of all outcomes were reported. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:42:00 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Stacey-2000">
<DESCRIPTION>
<P>Results of all outcomes specified in methods are given. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 02:45:01 +0100" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Weed-2004">
<DESCRIPTION>
<P>The results of all outcomes were presented. The trial protocol was not sought</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-01-26 15:57:11 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-01-26 15:57:11 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-01-26 15:57:11 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-05-23 09:58:31 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-05-23 09:58:31 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-05-21 17:08:27 +0100" MODIFIED_BY="[Empty name]">Autologous platelet-rich plasma compared with standard care with/without placebo for chronic wounds</TITLE>
<TABLE COLS="6" ROWS="15">
<TR>
<TD COLSPAN="6">
<P>
<B>Autologous platelet-rich plasma compared with standard care with/without placebo for chronic wounds</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>adults with chronic wounds</P>
<P>
<B>Settings: </B>hospital</P>
<P>
<B>Intervention: </B>autologous platelet-rich plasma</P>
<P>
<B>Comparison: </B>standard treatment with/without placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>Standard care with/without placebo</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Autologous platelet-rich plasma</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Chronic wounds (all) completely healed</B>
</P>
<P>Follow-up: 8-36 weeks</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.19</B>
</P>
<P>(0.95 to 1.50)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>391<BR/>(8 studies)<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>
<B>low<SUP>1</SUP>
</B>
</P>
<P/>
<P>
<BR/>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>514 per 1000</B>
</P>
<P/>
<P/>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>611 per 1000</B>
<BR/>(488 to 771)</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Chronic wounds (diabetic foot ulcers) completely healed </B>
</P>
<P>Follow-up: 12-24 weeks</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.22</B>
</P>
<P>(1.01 to 1.49)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>189<BR/>(2 studies)<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<BR/>&#8853;&#8853;&#8861;&#8861;</P>
<P>
<B>low<SUP>2</SUP>
</B>
</P>
<P/>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>544 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>664 per 1000</B>
<BR/>(550 to 811)</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Chronic wounds (venous leg ulcers) completely healed</B>
</P>
<P>Follow-up: 16-36 weeks</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.02 </B>
</P>
<P>(0.81 to 1.27)</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>101<BR/>(2 studies)<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>
<B>low<SUP>3,4</SUP>
</B>
</P>
<P/>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>686 per 1000</B>
</P>
<P/>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>700 per 1000</B>
<BR/>(556 to 872)</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: 8-24 weeks</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.05 </B>
</P>
<P>(0.29 to 3.88)</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>102<BR/>(3 studies)<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;</P>
<P>
<B>very low<SUP>3,4,5</SUP>
</B>
</P>
<P/>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>87 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>91 per 1000</B>
<BR/>(25 to 337)</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded two levels due to limitations in the trial execution: three clinical trials presented incomplete outcome data, and one selective reporting.<BR/>
<SUP>2</SUP> Downgraded two levels due to limitations in the trial execution: one of the trials providing data for this outcome presented incomplete outcome data and selective reporting.<BR/>
<SUP>3</SUP> Downgraded one level due to limitations in the trial design: the randomisation was unclear.<BR/>
<SUP>4</SUP> Downgraded one level due to imprecision: the confidence interval was wide.<BR/>
<SUP>5</SUP> Downgraded one level due to limitations in the trial execution: two clinical trials presented incomplete outcome data, and one selective reporting.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-05-20 22:56:51 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-05-20 22:56:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-03-04 18:01:35 +0000" MODIFIED_BY="[Empty name]">Characteristics of skin ulcer at baseline</TITLE>
<TABLE COLS="5" ROWS="11">
<TR>
<TH VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Ulcer size PRP (cm<SUP>2</SUP>)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Ulcer size control (cm<SUP>2</SUP>)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Time of ulcer PRP (weeks)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Time of ulcer control (weeks)</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Anitua-2008" TYPE="STUDY">Anitua 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>5.5</P>
</TD>
<TD ALIGN="LEFT">
<P>27.6</P>
</TD>
<TD ALIGN="LEFT">
<P>68.0</P>
</TD>
<TD ALIGN="LEFT">
<P>110.0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Driver-2006" TYPE="STUDY">Driver 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>4.0</P>
</TD>
<TD ALIGN="LEFT">
<P>22.0</P>
</TD>
<TD ALIGN="LEFT">
<P> -</P>
</TD>
<TD ALIGN="LEFT">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Kakagia-2007" TYPE="STUDY">Kakagia 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>28.4</P>
</TD>
<TD ALIGN="LEFT">
<P>28.9</P>
</TD>
<TD ALIGN="LEFT">
<P>20.0</P>
</TD>
<TD ALIGN="LEFT">
<P>19.0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Knighton-1990" TYPE="STUDY">Knighton 1990</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>11.6</P>
</TD>
<TD ALIGN="LEFT">
<P>109.7</P>
</TD>
<TD ALIGN="LEFT">
<P>119.0</P>
</TD>
<TD ALIGN="LEFT">
<P>47.0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Krupski-1991" TYPE="STUDY">Krupski 1991</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>13.0</P>
</TD>
<TD ALIGN="LEFT">
<P>10.8</P>
</TD>
<TD ALIGN="LEFT">
<P>22.0</P>
</TD>
<TD ALIGN="LEFT">
<P>24.8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>-</P>
</TD>
<TD ALIGN="LEFT">
<P>-</P>
</TD>
<TD ALIGN="LEFT">
<P>6 (2-13)</P>
</TD>
<TD ALIGN="LEFT">
<P>3 (2-9)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Planinsek-Rucigaj-2007" TYPE="STUDY">Planinsek Rucigaj 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>148.7</P>
</TD>
<TD ALIGN="LEFT">
<P>4.8</P>
</TD>
<TD ALIGN="LEFT">
<P> -</P>
</TD>
<TD ALIGN="LEFT">
<P> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Senet-2003" TYPE="STUDY">Senet 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>13.7</P>
</TD>
<TD ALIGN="LEFT">
<P>5.7</P>
</TD>
<TD ALIGN="LEFT">
<P>202.4</P>
</TD>
<TD ALIGN="LEFT">
<P>280.0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Stacey-2000" TYPE="STUDY">Stacey 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>5.1</P>
</TD>
<TD ALIGN="LEFT">
<P>8.9</P>
</TD>
<TD ALIGN="LEFT">
<P>24.0</P>
</TD>
<TD ALIGN="LEFT">
<P>24.0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Weed-2004" TYPE="STUDY">Weed 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>6.7</P>
</TD>
<TD ALIGN="LEFT">
<P>3.2</P>
</TD>
<TD ALIGN="LEFT">
<P>51.3</P>
</TD>
<TD ALIGN="LEFT">
<P>54.4</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PRP: platelet-rich plasma</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-05-21 17:18:49 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-05-21 17:18:49 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>PRP versus standard care (with/without placebo)</NAME>
<DICH_OUTCOME CHI2="9.650062195519896" CI_END="1.5037329834366575" CI_START="0.9459490146587998" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.192667067538902" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="93" I2="27.46160741585898" I2_Q="24.193721229522396" ID="CMP-001.01" LOG_CI_END="0.17717072580667093" LOG_CI_START="-0.02413227083822799" LOG_EFFECT_SIZE="0.0765192274842215" METHOD="MH" MODIFIED="2016-05-21 17:12:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20928652870749131" P_Q="0.26736210200030064" P_Z="0.136213270952197" Q="2.6383038878026164" RANDOM="YES" SCALE="1000.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.024226821804693408" TOTALS="YES" TOTAL_1="210" TOTAL_2="181" WEIGHT="100.0" Z="1.4900417032386188">
<NAME>Chronic wounds completely healed</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care (with or without placebo)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PRP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03176345902120696" CI_END="1.4877847820715473" CI_START="1.0055057657866198" DF="1" EFFECT_SIZE="1.2231010492279575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="49" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.17254011217841667" LOG_CI_START="0.0023845652779953576" LOG_EFFECT_SIZE="0.08746233872820602" MODIFIED="2015-03-20 19:09:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.858547843447812" P_Z="0.043915339655277996" STUDIES="2" TAU2="0.0" TOTAL_1="99" TOTAL_2="90" WEIGHT="48.870100034219014" Z="2.014897980507765">
<NAME>Diabetic foot ulcers</NAME>
<DICH_DATA CI_END="2.3539367910863125" CI_START="0.567266141993167" EFFECT_SIZE="1.1555555555555554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.37179479680351396" LOG_CI_START="-0.24621313708460318" LOG_EFFECT_SIZE="0.06279082985945544" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.36302091955449073" STUDY_ID="STD-Driver-2006" TOTAL_1="40" TOTAL_2="32" VAR="0.13178418803418804" WEIGHT="8.962319784971365"/>
<DICH_DATA CI_END="1.5065523283486417" CI_START="1.002277010337108" EFFECT_SIZE="1.228813559322034" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="40" LOG_CI_END="0.17798422098672645" LOG_CI_START="9.87768870972537E-4" LOG_EFFECT_SIZE="0.08948599492884952" MODIFIED="2015-03-20 19:09:38 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.10396859211936213" STUDY_ID="STD-Li-2012" TOTAL_1="59" TOTAL_2="58" VAR="0.01080946814728229" WEIGHT="39.90778024924765"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.013716289932104992" CI_END="1.2708385253123586" CI_START="0.8117109521357695" DF="1" EFFECT_SIZE="1.015654246971927" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.10409037193805308" LOG_CI_START="-0.09059859420778542" LOG_EFFECT_SIZE="0.006745888865133875" MODIFIED="2012-09-04 14:47:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9067676849287645" P_Z="0.8919605626144567" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="38.17684424955645" Z="0.13582381663548362">
<NAME>Venous leg ulcers</NAME>
<DICH_DATA CI_END="1.2733637572668295" CI_START="0.8119407399538928" EFFECT_SIZE="1.0168067226890756" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" LOG_CI_END="0.10495248472758684" LOG_CI_START="-0.09047566687974821" LOG_EFFECT_SIZE="0.007238408923919297" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.11479546363910083" STUDY_ID="STD-Stacey-2000" TOTAL_1="42" TOTAL_2="44" VAR="0.01317799847211612" WEIGHT="37.38075867775917"/>
<DICH_DATA CI_END="11.54202607332288" CI_START="0.0663336744464294" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0622820510406965" LOG_CI_START="-1.17826594499607" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="1.3161089837634485" STUDY_ID="STD-Senet-2003" TOTAL_1="8" TOTAL_2="7" VAR="1.7321428571428572" WEIGHT="0.7960855717972821"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.206934967484861" CI_END="4.50645629965559" CI_START="0.7570373819745643" DF="3" EFFECT_SIZE="1.8470397610972131" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="9" I2="42.384531039205406" ID="CMP-001.01.03" LOG_CI_END="0.6538351639500494" LOG_CI_START="-0.12088267481374737" LOG_EFFECT_SIZE="0.26647624456815094" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.15725656539253097" P_Z="0.1775554291274073" STUDIES="4" TAU2="0.33867812943985864" TOTAL_1="61" TOTAL_2="40" WEIGHT="12.953055716224537" Z="1.3483201649840981">
<NAME>Mixed chronic wounds</NAME>
<DICH_DATA CI_END="19.14630891541413" CI_START="1.4461085865519223" EFFECT_SIZE="5.261904761904762" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.2820850617419626" LOG_CI_START="0.1602009048324577" LOG_EFFECT_SIZE="0.7211429832872103" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.6590003071847843" STUDY_ID="STD-Knighton-1990" TOTAL_1="21" TOTAL_2="13" VAR="0.4342814048696401" WEIGHT="3.0494993956683993"/>
<DICH_DATA CI_END="2.488981208133303" CI_START="0.200190300579837" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.3960216176874121" LOG_CI_START="-0.6985569683487102" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.6429608796890036" STUDY_ID="STD-Krupski-1991" TOTAL_1="17" TOTAL_2="9" VAR="0.41339869281045744" WEIGHT="3.1950160890001325"/>
<DICH_DATA CI_END="3.994869587530726" CI_START="0.6814990928609531" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.6015026063433191" LOG_CI_START="-0.16653471791550659" LOG_EFFECT_SIZE="0.21748394421390627" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.4511489261157047" STUDY_ID="STD-Weed-2004" TOTAL_1="15" TOTAL_2="11" VAR="0.20353535353535354" WEIGHT="6.1389497973701666"/>
<DICH_DATA CI_END="56.62553149101196" CI_START="0.1255813574525096" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7530122913569661" LOG_CI_START="-0.9010748268124038" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="1.5590239111558089" STUDY_ID="STD-Anitua-2008" TOTAL_1="8" TOTAL_2="7" VAR="2.4305555555555554" WEIGHT="0.5695904341858388"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.768378515954428" CI_END="3.1132439570761026" CI_START="-8.670606164012243" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.7786811034680703" ESTIMABLE="YES" I2="46.92677522885584" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2016-05-21 17:12:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15195230974643148" P_Q="1.0" P_Z="0.3553117298068692" Q="0.0" RANDOM="YES" SCALE="94.21" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="12.294662421990573" TOTALS="SUB" TOTAL_1="31" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="0.9243353965565264">
<NAME>Total area epithelialised (cm<SUP>2</SUP>)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care (with or without placebo)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PRP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.768378515954428" CI_END="3.1132439570761026" CI_START="-8.670606164012243" DF="2" EFFECT_SIZE="-2.7786811034680703" ESTIMABLE="YES" I2="46.92677522885584" ID="CMP-001.02.01" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15195230974643148" P_Z="0.3553117298068692" STUDIES="3" TAU2="12.294662421990573" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="0.9243353965565264">
<NAME>Mixed chronic wounds</NAME>
<CONT_DATA CI_END="92.22861486091227" CI_START="-22.628614860912286" EFFECT_SIZE="34.8" ESTIMABLE="YES" MEAN_1="43.5" MEAN_2="8.7" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="87.4" SD_2="12.9" SE="29.300852114580607" STUDY_ID="STD-Krupski-1991" TOTAL_1="9" TOTAL_2="17" WEIGHT="1.037725699214828"/>
<CONT_DATA CI_END="2.0342812339723086" CI_START="-4.13428123397231" EFFECT_SIZE="-1.0500000000000003" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.74" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="2.65" SD_2="4.7" SE="1.573641790512849" STUDY_ID="STD-Weed-2004" TOTAL_1="15" TOTAL_2="11" WEIGHT="61.17979648358039"/>
<CONT_DATA CI_END="0.07215508667212589" CI_START="-13.292155086672127" EFFECT_SIZE="-6.61" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="8.74" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="1.89" SD_2="8.82" SE="3.409325446477646" STUDY_ID="STD-Anitua-2008" TOTAL_1="7" TOTAL_2="7" WEIGHT="37.78247781720478"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.436443286777959E-4" CI_END="70.86284951809449" CI_START="32.69508561187669" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="51.77896756498559" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2016-05-21 17:12:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9782445106466169" P_Q="1.0" P_Z="1.0500994709443313E-7" Q="0.0" RANDOM="YES" SCALE="409.66" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="5.3178337527657344">
<NAME>Percentage of wound area healed</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care (with or without placebo)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PRP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.436443286777959E-4" CI_END="70.86284951809449" CI_START="32.69508561187669" DF="1" EFFECT_SIZE="51.77896756498559" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9782445106466169" P_Z="1.0500994709443313E-7" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="5.3178337527657344">
<NAME>Mixed chronic wounds</NAME>
<CONT_DATA CI_END="76.83077873115552" CI_START="27.169221268844478" EFFECT_SIZE="52.0" ESTIMABLE="YES" MEAN_1="93.0" MEAN_2="41.0" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="17.0" SD_2="39.0" SE="12.668997454554031" STUDY_ID="STD-Knighton-1990" TOTAL_1="13" TOTAL_2="11" WEIGHT="59.06806758992495"/>
<CONT_DATA CI_END="81.28878730032164" CI_START="21.63121269967834" EFFECT_SIZE="51.459999999999994" ESTIMABLE="YES" MEAN_1="72.94" MEAN_2="21.48" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="22.25" SD_2="33.56" SE="15.219048684367326" STUDY_ID="STD-Anitua-2008" TOTAL_1="7" TOTAL_2="7" WEIGHT="40.931932410075056"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.2715317352827717" CI_END="3.7557541353446964" CI_START="0.26456244826106357" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9968106686394396" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5746971541057787" LOG_CI_START="-0.5774717991143474" LOG_EFFECT_SIZE="-0.0013873225042844337" METHOD="MH" MODIFIED="2016-05-21 17:12:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.735904090609741" P_Q="0.7194053572362317" P_Z="0.996234021827961" Q="0.1290632498396368" RANDOM="YES" SCALE="1000.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="53" WEIGHT="199.99999999999997" Z="0.004719971208632177">
<NAME>Wound complications</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care (with or without placebo)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard care</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9022496048089627" CI_END="4.728681209309398" CI_START="0.13657228228411702" DF="1" EFFECT_SIZE="0.8036210456113024" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.674740036429346" LOG_CI_START="-0.8646374329569263" LOG_EFFECT_SIZE="-0.09494869826379015" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3421793471512069" P_Z="0.8089499457512925" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="99.99999999999997" Z="0.2417808921812832">
<NAME>Infection</NAME>
<DICH_DATA CI_END="56.62553149101196" CI_START="0.1255813574525096" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7530122913569661" LOG_CI_START="-0.9010748268124038" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="1.5590239111558089" STUDY_ID="STD-Senet-2003" TOTAL_1="8" TOTAL_2="7" VAR="2.4305555555555554" WEIGHT="33.64030335861322"/>
<DICH_DATA CI_END="3.8532590105421765" CI_START="0.04967386035465806" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.585828202646153" LOG_CI_START="-1.303872087929489" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="1.1100193048514324" STUDY_ID="STD-Anitua-2008" TOTAL_1="8" TOTAL_2="7" VAR="1.2321428571428572" WEIGHT="66.35969664138676"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24140032779134019" CI_END="9.6931075274047" CI_START="0.17746416832902773" DF="1" EFFECT_SIZE="1.3115560475537116" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.986463030471702" LOG_CI_START="-0.7508893218645525" LOG_EFFECT_SIZE="0.11778685430357479" MODIFIED="2015-03-25 16:11:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6231965766134069" P_Z="0.7904252822303804" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="39" WEIGHT="100.0" Z="0.2657584018311929">
<NAME>Dermatitis</NAME>
<DICH_DATA CI_END="11.54202607332288" CI_START="0.0663336744464294" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0622820510406965" LOG_CI_START="-1.17826594499607" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.3161089837634485" STUDY_ID="STD-Senet-2003" TOTAL_1="8" TOTAL_2="7" VAR="1.7321428571428572" WEIGHT="60.12669188351638"/>
<DICH_DATA CI_END="57.34945419100586" CI_START="0.10166544987960083" EFFECT_SIZE="2.4146341463414633" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.758529288968545" LOG_CI_START="-0.9928266132129161" LOG_EFFECT_SIZE="0.3828513378778144" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.6161600763727575" STUDY_ID="STD-Driver-2006" TOTAL_1="40" TOTAL_2="32" VAR="2.611973392461197" WEIGHT="39.873308116483614"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4486695752012193" CI_END="3.8784293332648865" CI_START="0.2866735904938393" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0544397860682573" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.588655882810575" LOG_CI_START="-0.5426123141378796" LOG_EFFECT_SIZE="0.023021784336347714" METHOD="MH" MODIFIED="2016-05-21 17:13:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.48464693382996393" P_Q="0.4847994597162173" P_Z="0.9364184466601849" Q="1.4480402420086698" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="46" WEIGHT="99.99999999999997" Z="0.07977218537709112">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care (with or without placebo)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard care</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.297642301998604" CI_START="0.0520424959746949" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="1.0898218566930638" LOG_CI_START="-1.2836418827091765" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-09-04 14:46:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8728392319412981" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="32" WEIGHT="22.717783365307323" Z="0.160053117377673">
<NAME>Diabetic foot ulcers</NAME>
<DICH_DATA CI_END="12.297642301998604" CI_START="0.0520424959746949" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0898218566930638" LOG_CI_START="-1.2836418827091765" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="1.3941843493598687" STUDY_ID="STD-Driver-2006" TOTAL_1="40" TOTAL_2="32" VAR="1.94375" WEIGHT="22.717783365307323"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.849783103828482" CI_START="0.3471385538047006" DF="0" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.2977557656419514" LOG_CI_START="-0.45949715015799997" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2012-09-04 14:46:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3498102419264698" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="7" WEIGHT="41.44409026782741" Z="0.9349574448314597">
<NAME>Venous leg ulcers</NAME>
<DICH_DATA CI_END="19.849783103828482" CI_START="0.3471385538047006" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2977557656419514" LOG_CI_START="-0.45949715015799997" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="1.0322190612831128" STUDY_ID="STD-Senet-2003" TOTAL_1="8" TOTAL_2="7" VAR="1.0654761904761905" WEIGHT="41.44409026782741"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8532590105421765" CI_START="0.04967386035465806" DF="0" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.585828202646153" LOG_CI_START="-1.303872087929489" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.45642739573659685" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="7" WEIGHT="35.83812636686525" Z="0.7447425189556613">
<NAME>Mixed chronic wounds</NAME>
<DICH_DATA CI_END="3.8532590105421765" CI_START="0.04967386035465806" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.585828202646153" LOG_CI_START="-1.303872087929489" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="1.1100193048514324" STUDY_ID="STD-Anitua-2008" TOTAL_1="8" TOTAL_2="7" VAR="1.2321428571428572" WEIGHT="35.83812636686525"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-05-21 17:18:14 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Subgroup analysis: PRP releasate/lysate versus standard care (with/without placebo)</NAME>
<DICH_OUTCOME CHI2="9.67826848696556" CI_END="1.5610946492508053" CI_START="0.9357115705139436" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2086084254097291" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="92" I2="38.005439629199756" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.19342923515799537" LOG_CI_START="-0.028858000234329786" LOG_EFFECT_SIZE="0.08228561746183277" METHOD="MH" MODIFIED="2016-05-21 17:13:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13887118716953328" P_Q="0.6756209992936049" P_Z="0.14676117751697887" Q="0.17509747857724073" RANDOM="YES" SCALE="1000.0" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.033879143836094285" TOTALS="YES" TOTAL_1="202" TOTAL_2="174" WEIGHT="100.0" Z="1.451067096913481">
<NAME>Chronic wounds completely healed</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care (with or without placebo)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PRP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.275800803373259" CI_END="1.4919402709541691" CI_START="1.0091239215222259" DF="2" EFFECT_SIZE="1.2270096238017874" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="49" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.17375143673299465" LOG_CI_START="0.003944501349571776" LOG_EFFECT_SIZE="0.08884796904128325" MODIFIED="2015-03-23 16:17:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8711854645147031" P_Z="0.04026487395427115" STUDIES="3" TAU2="0.0" TOTAL_1="107" TOTAL_2="97" WEIGHT="49.13441916693236" Z="2.0510212851700156">
<NAME>PRP releasate</NAME>
<DICH_DATA CI_END="56.62553149101196" CI_START="0.1255813574525096" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7530122913569661" LOG_CI_START="-0.9010748268124038" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.5590239111558089" STUDY_ID="STD-Anitua-2008" TOTAL_1="8" TOTAL_2="7" VAR="2.4305555555555554" WEIGHT="0.6918101634819265"/>
<DICH_DATA CI_END="2.3539367910863125" CI_START="0.567266141993167" EFFECT_SIZE="1.1555555555555554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.37179479680351396" LOG_CI_START="-0.24621313708460318" LOG_EFFECT_SIZE="0.06279082985945544" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.36302091955449073" STUDY_ID="STD-Driver-2006" TOTAL_1="40" TOTAL_2="32" VAR="0.13178418803418804" WEIGHT="10.291480637439168"/>
<DICH_DATA CI_END="1.5065523283486417" CI_START="1.002277010337108" EFFECT_SIZE="1.228813559322034" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="40" LOG_CI_END="0.17798422098672645" LOG_CI_START="9.87768870972537E-4" LOG_EFFECT_SIZE="0.08948599492884952" MODIFIED="2015-03-23 16:17:50 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.10396859211936213" STUDY_ID="STD-Li-2012" TOTAL_1="59" TOTAL_2="58" VAR="0.01080946814728229" WEIGHT="38.15112836601127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.084131500615209" CI_END="3.130487649083526" CI_START="0.6744617349359047" DF="3" EFFECT_SIZE="1.4530637050715625" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="43" I2="70.25028878474089" ID="CMP-002.01.02" LOG_CI_END="0.495611994674257" LOG_CI_START="-0.1710426846541833" LOG_EFFECT_SIZE="0.1622846550100369" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01786440364296582" P_Z="0.33996552569934335" STUDIES="4" TAU2="0.39862568484997946" TOTAL_1="95" TOTAL_2="77" WEIGHT="50.86558083306764" Z="0.9542333952672238">
<NAME>PRP lysate</NAME>
<DICH_DATA CI_END="19.14630891541413" CI_START="1.4461085865519223" EFFECT_SIZE="5.261904761904762" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.2820850617419626" LOG_CI_START="0.1602009048324577" LOG_EFFECT_SIZE="0.7211429832872103" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.6590003071847843" STUDY_ID="STD-Knighton-1990" TOTAL_1="21" TOTAL_2="13" VAR="0.4342814048696401" WEIGHT="3.6417442199904575"/>
<DICH_DATA CI_END="2.488981208133303" CI_START="0.200190300579837" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.3960216176874121" LOG_CI_START="-0.6985569683487102" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.6429608796890036" STUDY_ID="STD-Krupski-1991" TOTAL_1="17" TOTAL_2="9" VAR="0.41339869281045744" WEIGHT="3.8117716385395894"/>
<DICH_DATA CI_END="1.2733637572668295" CI_START="0.8119407399538928" EFFECT_SIZE="1.0168067226890756" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" LOG_CI_END="0.10495248472758684" LOG_CI_START="-0.09047566687974821" LOG_EFFECT_SIZE="0.007238408923919297" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.11479546363910083" STUDY_ID="STD-Stacey-2000" TOTAL_1="42" TOTAL_2="44" VAR="0.01317799847211612" WEIGHT="36.230865042971374"/>
<DICH_DATA CI_END="3.994869587530726" CI_START="0.6814990928609531" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.6015026063433191" LOG_CI_START="-0.16653471791550659" LOG_EFFECT_SIZE="0.21748394421390627" MODIFIED="2012-08-24 13:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.4511489261157047" STUDY_ID="STD-Weed-2004" TOTAL_1="15" TOTAL_2="11" VAR="0.20353535353535354" WEIGHT="7.18119993156622"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-05-21 17:17:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>PRP plus protease-modulating matrix (PMM) versus PMM</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-05-21 17:15:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Chronic wounds completely healed</NAME>
<GROUP_LABEL_1>PRP + PMM</GROUP_LABEL_1>
<GROUP_LABEL_2>PMM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP + PMM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PMM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-05 18:45:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Diabetic foot ulcers</NAME>
<DICH_DATA CI_END="6.303251334775796" CI_START="0.15864828274939313" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7995646244554626" LOG_CI_START="-0.7995646244554625" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-05 18:45:13 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.9393364366277243" STUDY_ID="STD-Kakagia-2007" TOTAL_1="17" TOTAL_2="17" VAR="0.8823529411764706" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-05-23 10:16:59 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-05-23 10:16:59 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAARZCAYAAADglYYqAAByCElEQVR42uydD6RVTd/+H5IkSSRJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-05-19 02:45:02 +0100" MODIFIED_BY="Clare Dooley" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAnMAAAEACAMAAADvMADOAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-05-19 02:45:02 +0100" MODIFIED_BY="Clare Dooley" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAW4AAAKWCAIAAADm6eQxAAAmFUlEQVR42u3dzW4Ux9vG4ZGQEAsW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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-08-22 14:01:06 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2016-05-23 15:42:58 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-05-20 23:05:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-01-04 14:25:34 +0000" MODIFIED_BY="[Empty name]">Glossary of terms</TITLE>
<APPENDIX_BODY MODIFIED="2016-05-20 23:05:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Granulation</B> is fibrous connective tissue that replaces a fibrin clot in healing wounds.<BR/>
<B>Fibrin</B> is a fibrous non-globular protein involved in the clotting of blood.<BR/>
<B>Haemostasis</B> is a process which causes bleeding to stop.<BR/>
<B>Lysate</B> refers to the breaking down of a cell.<BR/>
<B>Platelet lysate </B>is to break the plaquetar membrane by physical methods such as freezing or sonication.<BR/>
<B>Platelet releasate </B>is to activate the platelet by chemical methods with thrombin or calcium to liberate the contents.<BR/>
<B>Sonication </B>is the process that disrupts cell membranes and releases cellular content using ultrasound.<BR/>
<B>Synonyms of autologous platelet-rich plasma (PRP): </B>Autologous platelet gel, plasma-rich growth factors (PRGFs), autologous platelet concentrate.<BR/>
<B>Thromboangitis</B> is a thrombotic episode secondary to vasculitis.<BR/>
<B>Protease-modulating matrix </B>is a natural or synthetic substance used in medicine and introduced into the body in order to support or replace a natural function.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-03-01 15:36:28 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-03-01 15:35:35 +0000" MODIFIED_BY="[Empty name]">Cochrane Central Register of Controlled Trials (CENTRAL) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-01 15:36:28 +0000" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor Platelet-Derived Growth Factor explode all trees<BR/>#2 (platelet-derived NEXT growth NEXT factor*) or PDGF<BR/>#3 MeSH descriptor Blood Platelets explode all trees<BR/>#4 (platelet NEXT rich NEXT plasma) or (platelet-rich NEXT plasma) or PRP or (platelet gel*)<BR/>#5 MeSH descriptor Platelet Activation explode all trees<BR/>#6 platelet* NEXT activat*<BR/>#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)<BR/>#8 MeSH descriptor Wound Healing explode all trees<BR/>#9 MeSH descriptor Skin Ulcer explode all trees<BR/>#10 MeSH descriptor Diabetic Foot explode all trees<BR/>#11 (skin NEXT ulcer*) or (foot NEXT ulcer*) or (diabetic NEXT foot) or (leg NEXT ulcer*) or (varicose NEXT ulcer*) or (venous NEXT ulcer*) or (stasis NEXT ulcer*) or (arterial NEXT ulcer*)<BR/>#12 ((ischaemic or ischemic) NEXT (wound* or ulcer*))<BR/>#13 (bed NEXT sore*) or (pressure NEXT sore*) or (pressure NEXT ulcer*) or (decubitus NEXT ulcer*)<BR/>#14 chronic NEXT wound*<BR/>#15 chronic NEXT ulcer*<BR/>#16 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)<BR/>#17 (#7 AND #16)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-03-01 15:35:51 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-05-10 17:25:49 +0100" MODIFIED_BY="[Empty name]">Ovid MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-09-02 11:31:42 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp Platelet-Derived Growth Factor/<BR/>2 (platelet-derived growth factors or PDGF).mp.<BR/>3 exp Blood Platelets/<BR/>4 (platelet rich plasma or platelet-rich plasma or PRP or platelet gel$).mp.<BR/>5 exp Platelet Activation/<BR/>6 (platelet$ adj activat$).mp.<BR/>7 or/1-6<BR/>8 exp Wound Healing/<BR/>9 exp Skin Ulcer/<BR/>10 exp Diabetic Foot/<BR/>11 (skin ulcer$ or foot ulcer$ or diabetic foot or diabetic feet or leg ulcer$ or varicose ulcer$ or venous ulcer$ or stasis ulcer$ or arterial ulcer$ or neuropathic ulcer$).mp.<BR/>12 ((ischaemic or ischemic) adj (wound$ or ulcer$)).mp.<BR/>13 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).mp.<BR/>14 (chronic adj wound$).mp.<BR/>15 (chronic adj ulcer$).mp.<BR/>16 or/8-15<BR/>17 7 and 16</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-03-01 15:35:46 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-05-10 17:26:02 +0100" MODIFIED_BY="[Empty name]">Ovid EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-05-10 17:27:35 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp Platelet Derived Growth Factor/ <BR/>2 (platelet-derived growth factors or PDGF).mp. <BR/>3 exp Thrombocyte/ <BR/>4 exp Thrombocyte Rich Plasma/ <BR/>5 (platelet rich plasma or platelet-rich plasma or PRP or platelet gel$).mp. <BR/>6 exp Thrombocyte Activation/ <BR/>7 (platelet$ adj activat$).mp. <BR/>8 or/1-7 <BR/>9 exp Wound Healing/ <BR/>10 exp Skin Ulcer/ <BR/>11 exp Diabetic Foot/ <BR/>12 (skin ulcer$ or foot ulcer$ or diabetic foot or diabetic feet or leg ulcer$ or varicose ulcer$ or venous ulcer$ or stasis ulcer$ or arterial ulcer$ or neuropathic ulcer$).mp. <BR/>13 ((ischaemic or ischemic) adj (wound$ or ulcer$)).mp. <BR/>14 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).mp. <BR/>15 (chronic adj wound$).mp. <BR/>16 (chronic adj ulcer$).mp. <BR/>17 or/9-16 <BR/>18 8 and 17</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-05-23 15:36:17 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-05-10 17:26:27 +0100" MODIFIED_BY="[Empty name]">EBSCO CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-05-23 15:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>S17 S7 and S16<BR/>S16 (S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15<BR/>S15 TI ( chronic wound* or chronic ulcer* ) or AB ( chronic wound* or chronic ulcer*)<BR/>S14 TI ( bed sore* or pressure sore* or pressure ulcer* or decubitus ulcer* ) or AB ( bed sore* or pressure sore* or pressure ulcer* or decubitus ulcer* )<BR/>S13 TI ( bed sore* or pressure sore* or pressure ulcer* or decubitus ulcer* ) or AB ( bed sore* or pressure sore* or pressure ulcer* or decubitus ulcer* )<BR/>S12 TI ( ischaemic ulcer* or ischemic ulcer* or ischaemic wound* or ischemic wound* ) or AB ( ischaemic ulcer* or ischemic ulcer* or ischaemic wound* or ischemic wound* )<BR/>S11 TI ( skin ulcer* or foot ulcer* or diabetic foot or diabetic feet or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or arterial ulcer* or neuropathic ulcer* ) or AB ( skin ulcer* or foot ulcer* or diabetic foot or diabetic feet or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or arterial ulcer* or neuropathic ulcer* )<BR/>S10 (MH "Diabetic Foot")<BR/>S9 (MH "Skin Ulcer+")<BR/>S8 (MH "Wound Healing+")<BR/>S7 S1 or S2 or S3 or S4 or S5 or S6<BR/>S6 TI platelet* activat* or AB platelet* activat*<BR/>S5 (MH "Platelet Activation+")<BR/>S4 TI ( platelet rich plasma or platelet-rich plasma or PRP or platelet gel* ) or TI (platelet rich plasma or platelet-rich plasma or PRP or platelet gel* )<BR/>S3 (MH "Blood Platelets")<BR/>S2 TI ( platelet-derived growth factor* or PDGF ) or AB ( platelet-derived growth factor* or PDGF )<BR/>S1 (MH "Platelet-Derived Growth Factor")</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;19 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;(9 ongoing studies)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;66 full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;301 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 duplicate records removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;297 records identified through database searching:&lt;/p&gt;&lt;p&gt;-Cochrane Wounds Group Specialised Register&lt;br&gt;-The Cochrane Central Register of Controlled Trials&lt;br&gt;-Ovid MEDLINE&lt;br&gt;-Ovid EMBASE&lt;br&gt;-EBSCO CINAHL&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;20 additional records identified through other sources:&lt;/p&gt;&lt;p&gt;-International Clinical Trials Registry Platform (ICTRP)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;235 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;45 full-text articles excluded, with reasons (11 ongoing studies)&lt;/p&gt;&lt;p&gt;2 clinical trials awaiting assessment&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>